<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28928747</article-id>
<article-id pub-id-type="pmc">5591889</article-id>
<article-id pub-id-type="doi">10.3389/fimmu.2017.01081</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Modulation of Multiple Sclerosis and Its Animal Model Experimental Autoimmune Encephalomyelitis by Food and Gut Microbiota</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>van den Hoogen</surname>
<given-names>Ward J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://frontiersin.org/people/u/406981" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Laman</surname>
<given-names>Jon D.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>’t Hart</surname>
<given-names>Bert A.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://frontiersin.org/people/u/82036" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Utrecht University</institution>, <addr-line>Utrecht</addr-line>, <country>Netherlands</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neuroscience, University Medical Center Groningen, University of Groningen</institution>, <addr-line>Groningen</addr-line>, <country>Netherlands</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Immunobiology, Biomedical Primate Research Center</institution>, <addr-line>Rijswijk</addr-line>, <country>Netherlands</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Jia Sun, Jiangnan University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Lothar Rink, RWTH Aachen University, Germany; Gurumoorthy Krishnamoorthy, Max Planck Institute of Neurobiology (MPG), Germany</p>
</fn>
<corresp content-type="corresp" id="cor1">*Correspondence: Jon D. Laman, <email>j.d.laman@umcg.nl</email></corresp>
<fn fn-type="other" id="fn001">
<p>Specialty section: This article was submitted to Nutritional Immunology, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>1081</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>3</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>8</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 van den Hoogen, Laman and ’t Hart.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>van den Hoogen, Laman and ’t Hart</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Multiple sclerosis (MS) is an autoimmune neurological disease characterized by chronic inflammation of the central nervous system (CNS), leading to demyelination, axonal damage, and symptoms such as fatigue and disability. Although the cause of MS is not known, the infiltration of peripherally activated immune cells into the CNS has a key pathogenic role. Accumulating evidence supports an important role of diet and gut microbiota in immune-mediated diseases. Preclinical as well as clinical studies suggest a role for gut microbiota and dietary components in MS. Here, we review these recent studies on gut microbiota and dietary interventions in MS and its animal model experimental autoimmune encephalomyelitis. We also propose directions for future research.</p>
</abstract>
<kwd-group>
<kwd>prebiotic</kwd>
<kwd>probiotic</kwd>
<kwd>autoimmunity</kwd>
<kwd>immunomodulation</kwd>
<kwd>fecal transplant</kwd>
<kwd>Food</kwd>
<kwd>gut microbiome</kwd>
</kwd-group>
<counts>
<fig-count count="5"></fig-count>
<table-count count="4"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="155"></ref-count>
<page-count count="24"></page-count>
<word-count count="41692"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Approach</title>
<p>PubMed was used as search engine for this review. Combinations of the following keywords were used: microbiota, microbiome, experimental autoimmune encephalomyelitis, multiple sclerosis, probiotic, prebiotic, synbiotic, fecal microbiota transplantation, and diet (see Box <xref ref-type="boxed-text" rid="BX1">1</xref>). In addition, preliminary reports acquired from conference abstracts have been used in the case of multiple sclerosis microbiota studies, to increase the amount of studies that our findings are based on. The studies of which only abstracts were available are noted in Table <xref ref-type="table" rid="T3">3</xref> as author, abstract. Since this article is not a systematic review, the 155 cited articles are a balanced selection out of approximately 200 papers. PubMed was last checked for new articles on July 10, 2017.</p>
<boxed-text id="BX1" position="float">
<label>Box 1</label>
<caption>
<title>List of definitions used in this article.</title>
</caption>
<p>Microbiota: “’The population of microbes in a given anatomical niche in the human body (<xref ref-type="bibr" rid="B11">11</xref>).”</p>
<p>Microbiome: The collective genome of the microbiota (<xref ref-type="bibr" rid="B11">11</xref>).</p>
<p>Probiotic: “A live microbial feed supplement which beneficially affects the host animal by improving its microbial balance (<xref ref-type="bibr" rid="B154">154</xref>).”</p>
<p>Prebiotic: “Non-digestable food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacterial species already resident in the colon, and thus attempt to improve host health (<xref ref-type="bibr" rid="B155">155</xref>).”</p>
<p>Synbiotic: “A mixture of probiotics and prebiotics that beneficially affects the host by improving the survival and implantation of live microbial dietary supplements in the gastrointestinal tract, by selectively stimulating the growth and/or by activating the metabolism of one or a limited number of health-promoting bacteria, and thus improving host welfare (<xref ref-type="bibr" rid="B155">155</xref>).”</p>
</boxed-text>
</sec>
<sec id="S2" sec-type="introduction">
<title>Introduction</title>
<p>Roughly 2.5 million people worldwide are affected by multiple sclerosis (MS), an autoimmune neurological disease of the central nervous system (CNS). Frequently observed symptoms are fatigue, numbness, loss of coordination, vision loss, dizziness, pain, cognitive defects, depression, and bladder and bowel dysfunction (<xref ref-type="bibr" rid="B1">1</xref>). MS can lead to serious motoric disability, as approximately 50% of patients require permanent use of a wheelchair 25 years after diagnosis (<xref ref-type="bibr" rid="B2">2</xref>). Although the cause of MS is not known, several lines of evidence point to a crucial pathogenic role of the immune system. Genome-wide association studies, neuropathological analyses, and successful therapy trials support the concept that peripheral interactions of environmental risk factors with MS-predisposing genetic factors elicit an autoimmune attack on the CNS causing the formation of lesions. Classically, lesions are defined as usually sharply edged demyelinated areas within the white matter with a variable degree of inflammation, axonal damage, and gliosis. The presence of immune cells (T and B cells, macrophages) and immune molecules (antibodies, complement) supports the characterization of MS as an autoimmune-mediated inflammatory disease.</p>
<p>A growing body of evidence indicates that gut microbiota can modify the incidence and/or course of immune-mediated, extraintestinal diseases (<xref ref-type="bibr" rid="B3">3</xref>). Since the gut microbiota are greatly impacted by diet, studies have also started to assess the contribution of gut microbiota and diet in MS and animal models of autoimmune demyelinating diseases such as experimental autoimmune encephalomyelitis (EAE). The aim of this review is to determine whether MS can be treated <italic>via</italic> modification of gut microbiota and dietary components. We describe key players of the immune system that are involved in the pathogenesis of MS, and we discuss how the cross talk of gut microbiota with the immune system can affect the expression of MS/EAE. We then review recent studies on gut emicrobiota and dietary components in the animal model of EAE and MS patients. We also review how gut microbiota can be modulated and propose future research topics.</p>
</sec>
<sec id="S3">
<title>Key Players in MS Immunopathology</title>
<p>Multiple sclerosis presents itself in several forms of symptoms and disease courses. 85% of patients are diagnosed with relapsing remitting (RR) MS, which is characterized by alternating episodes of neurological symptoms (relapses) and recovery (remissions). During relapses, inflammatory active lesions can be detected in the CNS with imaging techniques, such as magnetic resonance imaging (MRI). As the disease progresses, recovery declines and 80% of RR MS patients develop secondary progressive (SP) MS within 10–20 years after initial diagnosis. SP MS does not come with periods of relapses and recovery, but increased disability gradually occurs along with axonal loss and decreased brain volume (atrophy). 10% of MS patients are diagnosed with primary progressive MS, which presents itself as SP MS directly from the start of the disease (<xref ref-type="bibr" rid="B2">2</xref>). The cause of MS is unknown, but various concepts have been proposed to explain disease etiology. An inside-out concept suggests that MS starts as a primary lesion in the CNS, for instance caused by an infection or by primary neurodegeneration inducing the release of self-antigens against which autoreactive T and B cells react. An outside-in concept, supported by animal research in EAE models, postulates that autoreactive T cells that have escaped thymic selection are activated by a peripheral infection. This activation can occur through antigens that closely resemble CNS antigens, bystander activation, novel autoantigen presentation, or recognition of sequestered CNS antigens. In both concepts, activated CD4<sup>+</sup> T<sub>h1</sub> and Th17 cells infiltrate into the CNS where they can be reactivated by resident antigen-presenting cells (APC), microglia for example. CD4<sup>+</sup> T<sub>h1</sub> and T<sub>h17</sub> produce IFNγ and IL-17A, and the inflammatory reaction that follows increases the permeability of the blood–brain barrier and recruits other immune cells such as B cells and monocytes to the CNS. The inflammatory milieu also activates microglia, which in turn produce pro-inflammatory mediators which elicit demyelination and axonal loss (<xref ref-type="bibr" rid="B4">4</xref>). Naïve CD4<sup>+</sup> T cells infiltrating the CNS can broaden the pattern of autoimmune reactions by epitope spreading, adding to the inflammatory milieu (<xref ref-type="bibr" rid="B2">2</xref>). CD8<sup>+</sup> T cells likely also contribute to MS pathogenesis. They are found in high frequency in demyelinating lesions and correlate with axonal damage. Myelin-specific CD8<sup>+</sup> T cells can be activated by epitope spreading, and up to a quarter of CD8<sup>+</sup> T cells in active lesions are thought to be mucosa-associated invariant T (MAIT) cells. MAIT cells are able to produce IL-17 and are associated with the gut and liver (<xref ref-type="bibr" rid="B5">5</xref>). MS patients have increased serum levels of IL-18 (<xref ref-type="bibr" rid="B6">6</xref>), which activates MAIT cells and is inversely correlated with MAIT cell blood frequency (<xref ref-type="bibr" rid="B7">7</xref>). When costimulated by IL-18 and T-cell receptor stimulation, MAIT cells upregulate integrin very late antigen-4, which is involved in cell migration into the CNS (<xref ref-type="bibr" rid="B7">7</xref>). In addition, MAIT cells are depleted after efficacious autologous hematopoietic stem cell transplantation, a treatment which can be beneficial in MS patients (<xref ref-type="bibr" rid="B8">8</xref>). Therefore, MAIT cells are likely involved in the immunopathogenesis of MS. The relative significance of the different T cell subsets in human MS is not yet completely understood, as EAE is usually induced <italic>via</italic> complete Freund’s adjuvant (CFA), and interspecies immunological differences exist. Additionally, a more predominant CD4<sup>+</sup> driven disease course is seen in EAE, while a more CD8<sup>+</sup> T cell-driven immune response is seen in MS (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>In addition to T cells, autoreactive B cells may be activated in the periphery. B cells infiltrating the CNS locally produce autoantibodies, which bind myelin and cause damage to myelin <italic>via</italic> complement- and/or macrophage-mediated cytopathic reactions (CDC and ADCC). These B cells are also able to migrate out of the CNS and mature in the lymph nodes before migrating back to the CNS (<xref ref-type="bibr" rid="B9">9</xref>). Protective T<sub>reg</sub> cells and their anti-inflammatory effects could also be defective. Protective cells include CD4<sup>+</sup> Foxp3 expressing T<sub>reg</sub>, IL-10 producing T<sub>r1</sub>, and CD39<sup>+</sup> T<sub>reg</sub> cells. In MS patients, these cells are found in reduced frequency in the periphery and they have reduced immunosuppressive capacity compared to healthy individuals. Other regulatory cell types could also play a role, as they may increase after treatments. These include the CD8<sup>+</sup> T<sub>reg</sub> and IL-10 producing B<sub>reg</sub> cells. In addition to defective regulatory cells, effector cells may escape their regulation when they are less sensitive to the suppression by T<sub>reg</sub> cells (<xref ref-type="bibr" rid="B2">2</xref>). A clear imbalance of effector cells and regulatory cells is seen in early MS, which leads to a pro-inflammatory milieu in the CNS and promotes demyelination and axonal damage (see Figure <xref ref-type="fig" rid="F1">1</xref>) (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B10">10</xref>). In later stages of the disease immune cell migration from the periphery into the CNS subsides, but chronic CNS inflammation and neurodegeneration may continue to take place. This is associated with the formation of tertiary lymphoid-like structures within the CNS and associated meninges and with dysfunction of astrocytes and microglia. Microglial activation can promote dysfunction of astrocytes, after which astrocytes inhibit the maturation of myelin producing oligodendrocyte progenitors, resulting in reduced remyelination. Astrocytes can also produce CCL2 and GM-CSF, which further recruits and activates microglia and creates a self-sustaining feedback loop. Pro-inflammatory mediators such as reactive oxygen species (ROS) produced by astrocytes and microglia are neurotoxic, and the continuous CNS inflammation promotes gradual neurodegeneration (<xref ref-type="bibr" rid="B2">2</xref>) (see Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Immune cells involved in the pathology of early MS. Immune cells infiltrate the CNS and are reactivated by APC. The infiltrating T cells produce pro-inflammatory cytokines, which increases immune cell infiltration. The inflammatory milieu also activates microglia, which produce pro-inflammatory mediators and elicit demyelination and axonal loss. Autoantibodies produced by B cells cause damage to myelin through complement-mediated cytotoxicity and macrophage-mediated cytopathic reactions. As the disease progresses, immune cells accumulate in perivascular spaces. ODC, oligodendrocyte; MAIT, mucosa-associated invariant T cells; APC, antigen-presenting cells; CNS, central nervous system; MS, multiple sclerosis. The figure has been inspired by: Fugger et al., Grigoriadis et al., and Goverman (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B10">10</xref>).</p>
</caption>
<graphic xlink:href="fimmu-08-01081-g001"></graphic>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Immune cells involved in the pathology of late MS. Immune cell migration from the periphery into the CNS subsides, but chronic inflammation of the CNS still takes place. Chronic CNS inflammation is associated with tertiary lymphoid-like structures in perivascular spaces and dysfunctional astrocytes and microglia. Microglia activation promotes astrocyte production of CCL2 and GM-CSF, which recruits and activates more microglia. Astrocytes inhibit remyelination, and both microglia and astrocytes produce pro-inflammatory mediators that are neurotoxic and contribute to gradual neurodegeneration. FDC, follicular dendritic cells; ODC, oligodendrocyte; CNS, central nervous system; MS, multiple sclerosis. The figure has been inspired by: Fugger et al. and Goverman (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B10">10</xref>).</p>
</caption>
<graphic xlink:href="fimmu-08-01081-g002"></graphic>
</fig>
</sec>
<sec id="S4">
<title>Key Players of the Human Gut Microbiota</title>
<p>The human gut serves as a host to many microbes (bacteria, archaea, viruses, and fungi). Newborn humans have a sterile gut, and colonization occurs through exposure to new flora depending on the mode of delivery, diet, and hygiene (<xref ref-type="bibr" rid="B11">11</xref>). Over the years, the gut microbiota increase in diversity and reach a maximum at adolescence, after which they remain fairly stable (<xref ref-type="bibr" rid="B11">11</xref>). The diversity of gut microbiota can be expressed as α-diversity, which shows the richness and distribution of taxa within one population. β-Diversity is used to measure differences between multiple populations, and it measures how many taxa are shared between populations (<xref ref-type="bibr" rid="B12">12</xref>). Gut microbiota display a low diversity at the phylum level, as bacteria from only 8 out of 55 phyla have been detected in the human gut (<xref ref-type="bibr" rid="B13">13</xref>). Yet, large interindividual variation exists in the relative abundance of microbiota members. This variation is not only greatly impacted by short-term dietary alteration but also influenced by long-term dietary habits, host genotype, and stochastic processes such as history of colonization and ecological processes, such as selection and evolution (<xref ref-type="bibr" rid="B14">14</xref>) (see Figure <xref ref-type="fig" rid="F3">3</xref>). Additionally, the use of antibiotics can reduce the number and diversity of gut microbiota, but these are largely restored to the pretreatment composition after a recovery period (<xref ref-type="bibr" rid="B15">15</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Factors that determine gut microbiota composition. The composition of gut microbiota is influenced by multiple factors, such as diet and host genotype. Within the gut, ecological processes such as selection and evolution take place. The use of antibiotics reduces the numbers and diversity of gut microbiota. The figure has been modified after: Walter and Donaldson et al. (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>).</p>
</caption>
<graphic xlink:href="fimmu-08-01081-g003"></graphic>
</fig>
<p>Studies investigating the human gut microbiota often use the sequencing of specific genes such as the 16s ribosomal RNA gene in stool samples to determine which species are present. This has to be interpreted with care, as the microbiota composition differs from the small intestine to the large intestine. The abundance of microbiota is increased along the gastrointestinal tract and while the jejunum is host to mainly aerobic species, the colon is dominated by anaerobic species. Sequencing of stool samples is therefore most informative of microbiota in the large intestine (<xref ref-type="bibr" rid="B16">16</xref>).</p>
<sec id="S4-1">
<title>Bacteria</title>
<p>The gut bacterial flora of healthy adults comprises mainly bacteria from the phyla Firmicutes and Bacteroidetes (<xref ref-type="bibr" rid="B16">16</xref>). These bacteria serve many functions. They aid in metabolism and nutrient availability by fermenting complex carbohydrates into short-chain fatty acids (SCFA), which can be used as an energy source by mucosa. Bacteria can also produce vitamins, such as vitamin K and components of certain vitamin B species (<xref ref-type="bibr" rid="B17">17</xref>), and play a role in the metabolism of medications. Gut microbiota also aid in the protection against pathogens by competitive exclusion (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). The tremendous contribution of bacteria to host physiology is best seen in germfree (GF) mice, which have impaired development of the epithelium, musculature, and vasculature of the intestines as well as systemic defects, such as in immune functions and brain development. The gut-associated lymphoid tissue (GALT) is strongly underdeveloped in GF mice, with a reduced number of immune cells and lymph node size. These defects can be restored by colonization with bacteria, indicating the strong influence of bacteria on the host immune system. Conversely, the immune system promotes optimal growth and nutritional benefit and influences the species composition in the gut by the production of secretory IgA antibodies and bactericidal products, such as antimicrobial peptides (defensins and cathelicidins) (<xref ref-type="bibr" rid="B18">18</xref>). In addition, epithelial cells are covered by a mucus layer that is continuously consumed by bacteria and renewed by goblet cells (<xref ref-type="bibr" rid="B19">19</xref>). This mucus layer also contains peptides which aggregate bacteria but are not bactericidal and functions to keep bacteria at a safe distance from epithelial cells (<xref ref-type="bibr" rid="B20">20</xref>). A fiber-deprived diet increases the number and activity of mucus-degrading bacteria, thus reducing the mucus layer and increasing susceptibility to pathogens (<xref ref-type="bibr" rid="B21">21</xref>), indicating the importance and interplay of dietary components with microbiota and the immune system.</p>
</sec>
<sec id="S4-2">
<title>Archaea</title>
<p>The majority of archaea found thus far in the human body are methanoarchaea, which all produce methane in the absence of oxygen. Because methods to efficiently detect archaea have only recently been developed, insight into the functional role of archaea in the gut is limited. Archaea seem to have a nutritional role as they form syntrophic interactions with bacteria and can favor the growth of fermenting bacteria (<xref ref-type="bibr" rid="B22">22</xref>). Archaea may also have immunogenic roles as lipids from <italic>Methanobrevibacter</italic> have powerful adjuvant properties (<xref ref-type="bibr" rid="B23">23</xref>) and exposure of monocyte-derived dendritic cells (DC) to archaea strains activates these cells (<xref ref-type="bibr" rid="B24">24</xref>).</p>
</sec>
<sec id="S4-3">
<title>Viruses</title>
<p>Most studies on viruses in the human gut microbiota focus on DNA viruses, as over 95% of RNA viruses in the human gut are of plant origin and may have little influence on the gut microbiota of human hosts. Among DNA viruses, double-stranded DNA viruses from the order Caudovirales (Podoviridae, Siphoviridae, and Myoviridae) or single-stranded DNA viruses from the family Microviridae (<xref ref-type="bibr" rid="B25">25</xref>) have been identified in the human gut. Viruses can prevent infection of the host epithelium by binding to mucin glycoproteins, thereby limiting bacterial–epithelium adhesion. Additionally, viruses (phages) infect bacteria and exert effects on the host through the modulation of bacteria in the gut. Phages use distinct surface molecules for infecting bacteria, and therefore, have a tropism for specific strains of bacteria. After infection, phages can display a lysogenic phase, in which the phage integrates into the viral genome and stays there in a latent phase, the phage is then called a called prophage. Alternatively, phages can kill bacteria after viral replication which is called the lytic phase. Most gut bacteria are believed to have at least one prophage latently incorporated in their genome, and prophages can enter the lytic phase from a lysogenic phase after exposure to a range of stimuli (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B25">25</xref>).</p>
<p>Bacteria protect themselves from virus infections by clustered regularly interspaced short palindromic repeats (CRISPR) in their genome. These are short DNA regions that contain foreign virus DNA in between them. When phages infect bacteria, bacteria transcribe the foreign DNA in the CRISPR region, which guides the bacteria to cleave the intruding phage and fight off the infection. During the battle between bacteria and phages, phages may incorporate whole gene segments from previously infected bacteria into bacterial chromosomes. This may disrupt host bacteria genes. Alternatively, the incorporated gene segment may increase bacterial fitness, thereby promoting colonization. Viruses can also introduce toxin-encoding genes into bacteria, which may promote dysbiosis of gut microbiota. Bacteria may use their prophages to their advantage, by producing them for lysis of competitor bacterial species. Finally, viruses can protect the host from overgrowth of dominant bacterial species, by killing bacteria when a high density is reached (<xref ref-type="bibr" rid="B13">13</xref>).</p>
</sec>
</sec>
<sec id="S5">
<title>The Influence of Gut Microbiota on Extraintestinal Tissues</title>
<p>In addition, gut microbiota may influence distant host tissues such as the CNS. Accumulating evidence indicates that gut microbiota affect various behaviors such as social interaction (<xref ref-type="bibr" rid="B26">26</xref>), nociceptive responses (<xref ref-type="bibr" rid="B27">27</xref>), depression (<xref ref-type="bibr" rid="B28">28</xref>), stress responsiveness, and anxiety (<xref ref-type="bibr" rid="B29">29</xref>). Gut microbiota also influence hippocampal neurogenesis (<xref ref-type="bibr" rid="B30">30</xref>), blood–brain barrier integrity (<xref ref-type="bibr" rid="B31">31</xref>), and microglia maturation (<xref ref-type="bibr" rid="B32">32</xref>).</p>
<p>Gut microbiota affect the CNS through multiple mechanisms. The gut enteric nervous system controls the motility and homeostasis of the gut, which influences the gut microbiota composition (<xref ref-type="bibr" rid="B33">33</xref>). Conversely, gut microbiota influence the enteric nervous system, and the vagus nerve provides a direct communicatory link between the gut and the CNS. Gut microbiota can produce neurotransmitters or precursors such as tryptophan, and microbiota metabolites can also directly influence the brain. For instance, fermenting bacteria produce SCFA, which can translocate into the brain and inhibit deacetylases, resulting in epigenetic changes (<xref ref-type="bibr" rid="B32">32</xref>). In addition, bacterial RNA, DNA, and proteins are detected in the human brain (<xref ref-type="bibr" rid="B34">34</xref>). Fragments of bacterial cell walls, such as peptidoglycan (PGN) may translocate to the brain and possibly influence brain development and social interaction (<xref ref-type="bibr" rid="B35">35</xref>). Bacteria also produce microbial-associated molecular patterns, which can be recognized by the host immune system with pattern recognition receptors, such as Toll- or Nod-like receptors and influence gut physiology (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B35">35</xref>). The GALT is located along the small and large intestines and functions as immune surveillance of the gut. Gut microbiota can elicit an immune response in the GALT (<xref ref-type="bibr" rid="B36">36</xref>), which can be pro-inflammatory or anti-inflammatory, depending on the involved microbiota (<xref ref-type="bibr" rid="B37">37</xref>). The pro-inflammatory response of segmented filamentous bacteria (SFB) is best characterized. Studies in mice show that SFB enhance antigen presentation by DC resulting in greatly increased numbers of pro-inflammatory intraepithelial lymphocytes (IEL), such as γδ T cells and CD8<sup>+</sup> T cells. SFB also increase IgA<sup>+</sup> B cells and Th17 cells (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Th17 cells produce the cytokines IL-17A, IL-17F, IL-21, and IL-22. IL-17A and IL-17F control bacterial and fungal infections through the recruitment of neutrophils and more Th17 cells and increased production of β-defensin by epithelial cells. IL-22 induces epithelial cell proliferation, survival, tissue repair, and increased expression of antimicrobial molecules (<xref ref-type="bibr" rid="B13">13</xref>). In addition, gut bacteria such as <italic>Helicobacter hepaticus</italic> elicit a pro-inflammatory response, marked by increased numbers of T<sub>h17</sub> and Th1 cells and pro-inflammatory cytokines excretion (<xref ref-type="bibr" rid="B38">38</xref>). Th1 cells are instrumental in fighting intracellular bacteria and viruses, <italic>via</italic> the production of IFNγ (<xref ref-type="bibr" rid="B13">13</xref>).</p>
<p>Gut microbiota are potent activators of innate lymphoid cells (ILC). ILC arise from common lymphoid precursors and respond rapidly to cytokines produced by the epithelium. ILC can be divided into three groups based on molecular markers: type 1 which expresses T box transcription factor (TBX21 or T-bet) in T cells, type 2 which expresses GATA binding protein and type 3 which expresses retinoid-related orphan receptor (ROR)γt. Type 3 ILC produce IL-17 and IL-22, and IL-22 production can be induced by bacterial metabolites acting on the aryl hydrocarbon receptor (AHR) (<xref ref-type="bibr" rid="B17">17</xref>). The pro-inflammatory reactions caused by gut microbiota may contribute to MS pathogenesis <italic>via</italic> the activation of autoreactive T-cells (<xref ref-type="bibr" rid="B36">36</xref>). Conversely, gut microbiota may also elicit an anti-inflammatory response, characterized by the induction of CD4<sup>+</sup> T<sub>reg</sub> cells. T<sub>reg</sub> cells produce TGF-β and IL-10, which decrease pro-inflammatory cytokine production and cell proliferation. Clostridia species promote production of TGF-β, which helps maintain an anti-inflammatory milieu and is involved in the induction of T<sub>reg</sub> cells (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Additionally, Bacteroides species increase the production of anti-inflammatory cytokines and suppress IL-17 production (<xref ref-type="bibr" rid="B36">36</xref>).</p>
<p>Gut microbiota also affect invariant natural killer T cells (iNKT cells); GF mice have increased iNKT cell numbers in their colon. These are a pro-inflammatory subset of T cells that express the invariant T-cell receptor α, with which they detect lipid antigens presented by CD1d molecules. They can promote T<sub>h1</sub> and T<sub>h17</sub> responses by producing IFNγ, IL-2, IL17A and tumor necrosis factor (TNF) (<xref ref-type="bibr" rid="B13">13</xref>).</p>
</sec>
<sec id="S6">
<title>The Influence of phages on the Immune System</title>
<p>The influence of phages on the immune system is likely mostly indirect, through modulation of bacteria by mechanisms mentioned earlier. Phages may also directly communicate with the immune system. Humans are constantly sensitized with phage antigens present in food. This induces a constant low level of phage-neutralizing antibodies in human serum. After systemic phage administration in animals, these neutralizing antibodies are produced at higher titers. In humans, administration of enterobacteria PhiX174 phages induced IgM antibodies, followed by IgG antibodies after a second exposure (<xref ref-type="bibr" rid="B39">39</xref>). The function of antibodies is clearance of phages as illustrated by the lower clearance in B cell-deficient mice. A reduction of macrophages, natural killer, or T cells does not influence phage clearance (<xref ref-type="bibr" rid="B40">40</xref>). Conversely, phages can influence T cell functions <italic>in vitro</italic>. Mycobacteriophages were found to suppress phytohemagglutinin-induced activation of T lymphocytes from guinea pigs in a dose-dependent matter (<xref ref-type="bibr" rid="B41">41</xref>). Moreover, purified T4 phages can inhibit human T cell proliferation <italic>via</italic> the CD3 T-cell receptor complex, while phage lysates of <italic>Staphylococcus aureus</italic> can induce T-cell proliferation (<xref ref-type="bibr" rid="B41">41</xref>). In addition, phages can affect host phagocytes. Phagocytosis and ROS production may limit bacterial densities in the gut. Excessive phagocyte activity may also lead to pathology. Preincubation of monocytes and neutrophils with T4 and F8 phages from <italic>Pseudomonas aeruginosa</italic> reduced <italic>in vivo</italic> phagocytosis of <italic>Escherichia coli</italic>. T4 phages also reduced the ROS production by phagocytes exposed to LPS and bacterial cells, although this effect may be phage strain-dependent, because staphylococcal A3/R-purified phage (lysates) did not affect ROS production (<xref ref-type="bibr" rid="B41">41</xref>). The effect of phages depends also on the type of preparation, as T4 lysates promote IL-6 production by monocytes but purified T4 phages do not (<xref ref-type="bibr" rid="B41">41</xref>). Most effects of phages are anti-inflammatory, as reflected by mitigated phagocytosis, ROS production, and lymphocyte proliferation. However, phage lysates of <italic>S. aureus</italic> are likely more pro-inflammatory. Overall, effects of phages on the host immune system are complex and depend on phage identity, phage tropism, and preparation.</p>
<p>Collectively, variable exposure to the environment and food greatly influences gut microbiota composition. Elements of the gut microbiota constantly interact with each other and with the host and are essential for the normal development of the immune system and CNS. Pro- and anti-inflammatory effects have been attributed to different microbial species and an imbalance may contribute to autoimmune disease may contribute to autoimmune disease (see Figure <xref ref-type="fig" rid="F4">4</xref>).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Interactions between members of the gut microbiota and the immune system. Bacteriophages can infect and lyse bacteria or undergo a lysogenic cycle in which they stay dormant inside bacteria. During this process, gene segments may be transmitted which influences the fitness of the bacteria. Bacteria protect themselves from phage infection by CRISPR. Bacteria may cause a pro- and anti-inflammatory effect dependent on the bacterial species. Anti-inflammatory effects include the induction of T<sub>reg</sub> cells and the reduction of iNKT cells. Pro-inflammatory effects include induction of T<sub>h1</sub>, T<sub>h17</sub>, IgA producing B cells and stimulation of IL-22 production by ILC, which increases AMP production. These immune cells and the mucus layer protect the epithelial cells from being infected by bacteria. In addition, phages limit bacteria–epithelial adhesion by binding to the mucus layer. The effects of the gut immune system on phages remain largely unknown. SFB, segmented filamentous bacteria; AMP, antimicrobial peptides; iNKT, invariant natural killer T; ILC, innate lymphoid cells; IEL, intraepithelial lymphocytes; DC, dendritic cell; CRISPR, clustered regularly interspaced short palindromic repeats. The figure has been inspired by: Glenn and Mowry (<xref ref-type="bibr" rid="B13">13</xref>).</p>
</caption>
<graphic xlink:href="fimmu-08-01081-g004"></graphic>
</fig>
</sec>
<sec id="S7">
<title>EAE Models</title>
<p>Due to the inaccessibility of the CNS of MS patients, animal models are used for translational research into the pathogenesis of MS and for therapy development. As in none of the available models the immunological and pathological complexity of MS is fully replicated, multiple models are being used. Depending on the research question models of MS-like demyelination are induced chemically (cuprizone, lysolecithin), with neurotropic viruses (Theiler’s murine encephalitis virus, Semliki Forest virus), through specific cytokine overexpression in the CNS, diphtheria toxin-based depletion of oligodendrocytes, and active immunization with myelin components in suitable adjuvants (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>). The active immunization model, known as EAE, is the most widely used preclinical MS model. EAE can be induced in a wide variety of laboratory animal species including mice, rats, rabbits, guinea pigs, and non-human primates by inoculation of myelin antigens formulated with a strong adjuvant, such as CFA. For synchronous EAE induction at high incidence in mice, the immunization is usually supplemented with injection of <italic>Bordetella pertussis</italic> toxin. Different myelin antigens and dosages are used to model the heterogeneity of MS. For example, SJL mice develop a RR type of EAE after sensitization against residues 79–87 of myelin basic protein (MBP<sub>79–87</sub>) or residues 131–151 of proteolipid protein (PLP<sub>131–151</sub>). C57Bl/6 mice can develop RR EAE after immunization with a low dose of myelin oligodendrocyte glycoprotein residues 35–55 (MOG<sub>35–55</sub>) and develop chronic EAE without remission upon immunization with a high dose of MOG<sub>35–55</sub> (<xref ref-type="bibr" rid="B44">44</xref>). It is increasingly felt that the usage of strong adjuvants precludes a role of subtle regulatory mechanisms. For such studies, passive EAE models induced by the transfer of activated T cells from a donor with actively induced EAE or spontaneous EAE models established in mice expressing transgenic T and/or B cell receptors specific for myelin antigens may be more useful (<xref ref-type="bibr" rid="B43">43</xref>).</p>
<p>Although EAE models have proven their relevance as a preclinical test system for new therapeutics they also have their limitations. The highly artificial way by which the autoimmune process is activated in CFA-based EAE models does not necessarily reflect the natural immune response toward self-antigens. As an illustration, the EAE model is dominated by CD4<sup>+</sup> T cells, whereas CD8<sup>+</sup> T cells are likely more immunodominant in MS patients (<xref ref-type="bibr" rid="B44">44</xref>). Another difference between EAE and MS is that mice with EAE mostly show lesions in the spinal cord, whereas MS patients mostly show lesions in the brain (<xref ref-type="bibr" rid="B43">43</xref>). A noticeable exception is formed by the atypical EAE models in marmosets, a small-bodied Neotropical primate, which more closely approximate MS with respect to clinical, pathological, and immunological presentation (<xref ref-type="bibr" rid="B45">45</xref>).</p>
</sec>
<sec id="S8">
<title>Gut Microbiota-Based Interventions in EAE Models</title>
<p>The first evidence that gut microbiota are involved in the pathogenesis of EAE stems from decades ago. Already in 1993, it was discovered that transgenic mice expressing T-cell receptors specific for MBP fail to develop EAE when they were housed in a sterile, specific pathogen-free (SPF) environment, while mice housed in a non-sterile environment did develop EAE (<xref ref-type="bibr" rid="B46">46</xref>). To determine the role of gut microbiota in EAE, GF models, antibiotic treatments, probiotic mixtures, bacterial products, and diet-based interventions have been used. These studies are summarized in Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>The role of gut microbiota in EAE.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Reference</th>
<th align="left" colspan="1" rowspan="1" valign="top">Animal model</th>
<th align="left" colspan="1" rowspan="1" valign="top">Intervention</th>
<th align="left" colspan="1" rowspan="1" valign="top">Clinical score</th>
<th align="left" colspan="1" rowspan="1" valign="top">Immune response</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Berer et al. (<xref ref-type="bibr" rid="B47">47</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL anti-MOG<sub>92–106</sub> TCR<sup>tg</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">Germfree housing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Protected</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T<sub>h17</sub>, impaired B-cell recruitment to brain-draining lymph nodes<break></break>Reduced anti-MOG B cell response</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lee et al. (<xref ref-type="bibr" rid="B48">48</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Germfree housing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T<sub>h1</sub> and T<sub>h17</sub>, increased T<sub>reg</sub><break></break>Reduced DC capacity to induce T<sub>h1</sub> and T<sub>h17</sub> responses</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yokote et al. (<xref ref-type="bibr" rid="B49">49</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Broad spectrum antibiotics</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased pro-inflammatory cytokines, decreased T<sub>h17</sub></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ochoa-Repáraz et al. (<xref ref-type="bibr" rid="B50">50</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL PLP<sub>139–151</sub>; C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Broad spectrum antibiotics</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced pro-inflammatory cytokines, increased T<sub>reg</sub><break></break>Increased CD11c<sup>high</sup>CD103<sup>+</sup> cells</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ochoa-Repáraz et al. (<xref ref-type="bibr" rid="B51">51</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Broad spectrum antibiotics</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased IL-10 producing CD5<sup>+</sup> B-cells<break></break>Shift from T<sub>h1</sub> and T<sub>h17</sub> toward T<sub>h2</sub> response</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ochoa-Repáraz et al. (<xref ref-type="bibr" rid="B52">52</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL PLP<sub>139–151</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral administration of <italic>Bacteroides fragilis</italic></td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased T<sub>reg</sub>, reduced T<sub>h17</sub></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ochoa-Repáraz et al. (<xref ref-type="bibr" rid="B52">52</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL PLP<sub>139–151</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral administration of PSA<sup>−/−</sup>
<italic>B. fragilis</italic></td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ezendam et al. (<xref ref-type="bibr" rid="B53">53</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lewis rats MBP</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral administration of <italic>Bifidobacterium animalis</italic></td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased duration</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not investigated</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lavasani et al. (<xref ref-type="bibr" rid="B54">54</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral administration of three <italic>Lactobacilli</italic> strains</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T<sub>h1</sub> and T<sub>h17</sub>, increased T<sub>reg</sub>, IL-10 dependent</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Takata et al. (<xref ref-type="bibr" rid="B55">55</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub>; SJL PLP<sub>139–151</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral treatment with heat-killed <italic>Pediococcus acidilactici</italic></td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T<sub>h1</sub> and T<sub>h17</sub>, increased T<sub>reg</sub></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Maassen and Claassen (<xref ref-type="bibr" rid="B56">56</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lewis rats MBP; SJL PLP<sub>139–151</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral treatment with commercially available probiotic drinks containing <italic>Lactobacillus casei</italic></td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased in Lewis rats, no effect in SJL model</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not investigated</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kwon et al. (<xref ref-type="bibr" rid="B57">57</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral administration of <italic>Bifidobacterium bifidum, Streptococcus thermophilus</italic> and three <italic>Lactobacillus</italic> strains</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T<sub>h1</sub> and T<sub>h17</sub> response, increased T<sub>reg</sub></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rezende et al. (<xref ref-type="bibr" rid="B58">58</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral administration of recombinant HSP65-producing <italic>Lactococcus lactis</italic><sup>tg</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased IL-17, increased IL-10, dependent on increased CD4<sup>+</sup>LAP<sup>+</sup> T<sub>reg</sub></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Wang et al.; Ochoa-Repáraz et al. (<xref ref-type="bibr" rid="B59">59</xref>–<xref ref-type="bibr" rid="B61">61</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL PLP<sub>139–151</sub>; C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral treatment with <italic>B. fragilis</italic>-produced PSA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T<sub>h1</sub> and T<sub>h17</sub>, increased T<sub>reg</sub> and CD103<sup>+</sup> DC, increased CD39<sup>+</sup> T<sub>reg</sub></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kadowaki et al. (<xref ref-type="bibr" rid="B62">62</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">2D2 anti-MOG TCR<sup>tg</sup>; C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Adoptive transfer of CD4<sup>+</sup> induced IEL</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T<sub>h17</sub><break></break>CD4<sup>+</sup> induced IEL are dependent on gut microbiota and diet</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Maassen et al. (<xref ref-type="bibr" rid="B63">63</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lewis rats, MBP<sub>72–85</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral administration of live/intranasal administration of soluble cell extracts from myelin proteins producing <italic>L. casei</italic></td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased, extracts from guinea pig MBP producing bacteria increased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not investigated</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Germfree housing, antibiotics, probiotics, and bacterial products affect the EAE clinical score</italic>.</p>
<p><italic>DC, dendritic cells; EAE, experimental autoimmune encephalomyelitis; IEL, intraepithelial lymphocytes; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; PLP, proteolipid protein; PSA, polysaccharide A</italic>.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Dietary interventions in EAE.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Reference</th>
<th align="left" colspan="1" rowspan="1" valign="top">Animal model</th>
<th align="left" colspan="1" rowspan="1" valign="top">Intervention</th>
<th align="left" colspan="1" rowspan="1" valign="top">Clinical score</th>
<th align="left" colspan="1" rowspan="1" valign="top">Immune response</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Haghikia et al. (<xref ref-type="bibr" rid="B64">64</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral administration of propionic acid (short-chain fatty acid) and lauric acid (long-chain fatty acid)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased T<sub>reg</sub>, reduced T<sub>h17</sub> on PA treatment<break></break>Increased T<sub>h1</sub> and T<sub>h17</sub>, decreased <italic>Prevotellaceae</italic> and <italic>Bacteroidetes</italic> on lauric acid treatment</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lemire and Archer (<xref ref-type="bibr" rid="B65">65</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL spinal cord homogenate</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal vitamin D administration</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced antibodies against MBP</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantorna et al. (<xref ref-type="bibr" rid="B66">66</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B10.PL MBP<sub>79–87</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Dietary vitamin D supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not investigated</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Spach et al. (<xref ref-type="bibr" rid="B67">67</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Dietary vitamin D supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced inflammatory cells, IFNγ in the spinal cord, IL-10 dependent</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Piccio et al. (<xref ref-type="bibr" rid="B68">68</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL PLP<sub>139–151</sub>; C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">40% caloric restriction</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased plasma levels of corticosterone, adiponectin, reduced plasma levels of IL-6 and leptin</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Esquifino et al. (<xref ref-type="bibr" rid="B69">69</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lewis rats spinal cord homogenate</td>
<td align="left" colspan="1" rowspan="1" valign="top">33 and 66% caloric restriction</td>
<td align="left" colspan="1" rowspan="1" valign="top">66% caloric restriction protected from EAE signs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced splenic CD8<sup>+</sup> T cells and B cells, reduced lymphoid and thymic CD4<sup>+</sup> T cells and B cells and IFNγ production</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kafami et al. (<xref ref-type="bibr" rid="B70">70</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Intermittent feeding</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not investigated</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Harbige et al. (<xref ref-type="bibr" rid="B71">71</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL MOG<sub>92–106</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral γ-linolenic acid treatment</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased TGF-β, prostaglandin E<sub>2</sub> production by spleen mononuclear cells</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Harbige et al. (<xref ref-type="bibr" rid="B72">72</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lewis rats, guinea pig spinal cord homogenate</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral γ-linolenic acid treatment</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not investigated</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kong et al. (<xref ref-type="bibr" rid="B73">73</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">DHA-rich diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T<sub>h1</sub> and Th17 cell differentiation, reduced amounts of T<sub>h1</sub>, T<sub>h17</sub> found in the spleen and spinal cord of mice on a DHA-rich diet. <italic>In vitro</italic>, DHA reduced the expression of costimulatory molecules on DC and reduced their production of pro-inflammatory cytokines</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Unoda et al. (<xref ref-type="bibr" rid="B74">74</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">EPA supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased expression of PPAR α, β, and γ on CD4<sup>+</sup> T cells in the spinal cord, reduced IFNγ and IL-17 cytokine production. CD4<sup>+</sup> T cells from the spleen of EPA-treated mice expressed increased mRNA levels of Foxp3, but also of IL-17 and RORγt</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Salvati et al. (<xref ref-type="bibr" rid="B75">75</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dark agouti rats, guinea pig spinal cord homogenate</td>
<td align="left" colspan="1" rowspan="1" valign="top">EPA supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Delayed time before EAE symptoms appeared</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased myelination of axons in the spinal cord</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kim et al. (<xref ref-type="bibr" rid="B76">76</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Ketogenic diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T<sub>h1</sub>, T<sub>h17</sub>, and pro-inflammatory cytokines</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Choi et al. (<xref ref-type="bibr" rid="B77">77</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Cycles of fasting<break></break>Ketogenic diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fasting increased T<sub>reg</sub>, corticosterone, reduced CD11<sup>+</sup> DC, T<sub>h1</sub>, T<sub>h17</sub>, pro-inflammatory cytokines<break></break>Ketogenic diet: not investigated</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Jörg et al. (<xref ref-type="bibr" rid="B78">78</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">High-salt diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased T<sub>h17</sub></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Krementsov et al. (<xref ref-type="bibr" rid="B79">79</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub>, SJL PLP<sub>135–151</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">High-salt diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased in C57Bl/6 mice, in SJL only increased in females</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in T<sub>reg</sub>, T<sub>h1</sub>, and Th17 cells</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Wu et al. (<xref ref-type="bibr" rid="B80">80</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">High-salt diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased T<sub>h17</sub> in CNS and mesenteric lymph nodes, SGK-1 signaling dependent</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kleinewietfeld et al. (<xref ref-type="bibr" rid="B81">81</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">High-salt diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased inflammatory cell infiltration into the CNS, increased T<sub>h17</sub></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Veldhoen et al. (<xref ref-type="bibr" rid="B82">82</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">FICZ administration</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased IL-17- and IL-22-producing CD4<sup>+</sup> T cells in the spinal cords</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Quintana et al. (<xref ref-type="bibr" rid="B83">83</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">FICZ, ITE, TCDD administration</td>
<td align="left" colspan="1" rowspan="1" valign="top">FICZ increased, ITE and TCDD reduced</td>
<td align="left" colspan="1" rowspan="1" valign="top">FICZ: increased IL-17<sup>+</sup>CD4<sup>+</sup> and IFNγ<sup>+</sup>CD4<sup>+</sup> T cells in the spleen<break></break>TCDD: increased Foxp3<sup>+</sup> T<sub>reg</sub></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rothhammer et al. (<xref ref-type="bibr" rid="B84">84</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Tryptophan-deficient diet, supplementation with tryptophan metabolites and tryptophanase</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased, supplementation reduced EAE scores</td>
<td align="left" colspan="1" rowspan="1" valign="top">IFN-1 signaling induces AHR expression in astrocytes, supplementation does not reduce EAE scores in astrocyte-specific AHR knockout mice</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Stoye et al. (<xref ref-type="bibr" rid="B85">85</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL PLP<sub>139–151</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal injection of ZnAsp</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased, but increased on high doses</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced proliferation of stimulated human T-cells, reduced pro-inflammatory cytokine production</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Schubert et al. (<xref ref-type="bibr" rid="B86">86</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL PLP<sub>139–151</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral ZnAsp supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased, but increased on high doses</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced proliferation of stimulated human T-cells, reduced pro-inflammatory cytokine production</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kitabayashi et al. (<xref ref-type="bibr" rid="B87">87</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral Zink supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not investigated</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rosenkranz et al. (<xref ref-type="bibr" rid="B88">88</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal injection of ZnAsp</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced systemic Th17 cells and increased Foxp3<sup>+</sup> T-cells in the spinal cord</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Scelsi et al. (<xref ref-type="bibr" rid="B89">89</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Guinea pigs, spinal cord homogenate</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral selenium supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased on high doses, normal on normal doses</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not investigated</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chanaday et al. (<xref ref-type="bibr" rid="B90">90</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Wistar rats, whole MBP</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal and oral diphenyl diselenide</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diphenyl diselenide was toxic when intraperitoneally administered, reduced when orally administered</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced number of macrophages in the CNS, reduced MBP-specific T-cell proliferation</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Xue et al. (<xref ref-type="bibr" rid="B91">91</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal tocopherol administration</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced MOG-specific splenocyte proliferation. Splenocytes incubated with tocopherol produced less IFNγ</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Blanchard et al. (<xref ref-type="bibr" rid="B92">92</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal TFA-12 administration</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced inflammation of the CNS, astrogliosis and demyelination. Induces oligodendrocyte maturation</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Racke et al. (<xref ref-type="bibr" rid="B93">93</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SJL, MOG-incubated lymph node cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dietary 13-cis-retinoic acid and 4-HPR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not investigated</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zhan et al. (<xref ref-type="bibr" rid="B94">94</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal all-trans retinoic acid administration</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced DC maturation, reduced pro-inflammatory monocytes in the subarachnoid space. Reduced numbers of T<sub>h1</sub> and Th17 cells in the draining lymph nodes</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Xiao et al. (<xref ref-type="bibr" rid="B95">95</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">C57Bl/6 MOG<sub>35–55</sub></td>
<td align="left" colspan="1" rowspan="1" valign="top">Intraperitoneal all-trans retinoic acid administration</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibits T<sub>h17</sub> differentiation by reducing expression of the IL-6 and IL-23 receptor</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Dietary interventions affect the microbiota and EAE clinical scores</italic>.</p>
<p><italic>AHR, aryl hydrocarbon receptor; CNS, central nervous system; DC, dendritic cells; DHA, docosahexaenoic acid; EAE, experimental autoimmune encephalomyelitis; EPA, eicosapentaenoic acid; FICZ, 6-formylindolo[3-2b]carbazole; ITE, 2-(1′H-indole-3′carbonyl)-thiazole-4-carboxylic acid methyl ester; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; PLP, proteolipid protein; SGK-1, serum/glucocorticoid kinase 1; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin</italic>.</p>
</table-wrap-foot>
</table-wrap>
<sec id="S8-1">
<title>GF Models</title>
<p>Germfree mice, which are bred and raised in a sterile environment, display significantly attenuated disease in both spontaneous and actively induced EAE models (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). In the actively induced EAE model, GF mice develop EAE at a reduced incidence, while in mice developing overt disease, symptoms are milder and of shorter duration compared to conventionally colonized mice. This has been attributed to reduced mesenteric lymph node DC capacity to induce T<sub>h1</sub> and T<sub>h17</sub> responses. GF mice have reduced IL-17 and IFNγ producing CD4<sup>+</sup> T cells in their spinal cord. This is accompanied by increased CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T<sub>reg</sub> cells in draining lymph nodes and spleen. Compared to GF mice, monocolonization with SFB significantly increases EAE clinical scores, with increased IL-17 and IFNγ production in the small intestines and spinal cord (<xref ref-type="bibr" rid="B48">48</xref>). SPF-bred MOG TCR transgenic mice develop spontaneous EAE at high incidence, but appear completely EAE resistant under GF conditions (<xref ref-type="bibr" rid="B47">47</xref>). Upon colonization with conventional microbiota, EAE quickly developed (<xref ref-type="bibr" rid="B47">47</xref>).</p>
<p>Compared to conventionally colonized mice, GF mice have reduced IL-17 producing CD4<sup>+</sup> cells in Peyer’s patches and lamina propria, but no difference is seen in mesenteric lymph nodes or other remote organs. Additionally, MOG-immunized GF mice had reduced autoreactive anti-MOG antibodies which could be increased by colonization. It is thought that MOG-specific B cells are activated and recruited into deep cervical lymph nodes by helper T cells. Once there, B cells encounter MOG imported from the lymphatic vessels and undergo proliferation, immunoglobulin class switching, and somatic hypermutation (<xref ref-type="bibr" rid="B47">47</xref>).</p>
<p>Germfree mice also have reduced gut luminal extracellular adenosine 5′-triphosphate (ATP). ATP can be derived from bacteria, and ATP activates lamina propria CD70<sup>high</sup>CD11c<sup>low</sup> DC, leading to the production of IL-6 and IL-23 which are important for the differentiation of Th17 cells. Systemic and rectal administration of ATP increases the number of Th17 cells in GF mice. Although investigated in a colitis model, administration of ATP increases T<sub>h17</sub> response (<xref ref-type="bibr" rid="B96">96</xref>). This may be relevant for EAE due to the role of Th17 cells in EAE. Administration of alkaline phosphatase, which can neutralize ATP and LPS, reduced the clinical signs of EAE when given presymptomatically but not in the acute or chronic phase (<xref ref-type="bibr" rid="B97">97</xref>). Besides reduced gut luminal ATP, GF animals have reduced tight junctions and increased permeability at the blood–brain barrier, potentially affecting EAE (<xref ref-type="bibr" rid="B32">32</xref>).</p>
<p>A general caveat in the usage of GF mice for the modeling of human autoimmune disease is that the immunocompetence of such mice is seriously disturbed. Even the frequently used SPF-bred mice are immunologically incomparable to adult humans. SPF-bred mice have reduced cervix mucosal memory T cells, and a relatively lower number of differentiated effector memory CD8<sup>+</sup> T-cells in their blood, a signature which is comparable to neonatal humans. Feral and pet store mice are immunologically more comparable to adult humans, and SPF-bred mice could be immunologically normalized by cohousing them with pet store mice (<xref ref-type="bibr" rid="B98">98</xref>). This indicates that exposure to pathogens affects the immune system and that studies using GF and SPF animals may not always translate well into the clinic.</p>
</sec>
<sec id="S8-2">
<title>Antibiotics</title>
<p>Antibiotic treatments modulate gut microbiota and this also affects EAE. An oral cocktail of non-absorbing antibiotics [kanamycin, colistin, and vancomycin (KCV)] administered 1 week before active EAE induction reduces disease scores. The impairment of normal EAE development is accompanied by a reduction of IFNγ, TNFα, IL-6, and IL-17 production by MOG-reactive T cells from draining lymph nodes. KCV also reduced the number of Th17 cells in mesenteric lymph nodes while this effect was not seen in iNKT cell-deficient mice, indicating that iNKT cells are mechanistically important in KCV treatment. Since no differences were found in mesenteric lymph node iNKT cells, Foxp3<sup>+</sup> T<sub>reg</sub> cells and T<sub>h17</sub> promoting cytokines, KCV treatment likely exerts its effect upstream of the mesenteric lymph nodes. In the KCV-treated group, reduced expression of IL-21 and IL-23 cytokines were found in lamina propria lymphocytes, and it is therefore speculated that KCV alters iNKT cells in the lamina propria, ultimately leading to Th17 cells in the mesenteric lymph nodes (<xref ref-type="bibr" rid="B49">49</xref>).</p>
<p>With a different antibiotics mixture (ampicillin, vancomycin, neomycin sulfate, and metronidazole) orally administered before EAE induction, normal EAE development was also impaired. This has been attributed to an increase in Foxp3<sup>+</sup> Treg cells in the mesenteric and cervical lymph nodes (deep or superficial lymph nodes not specified) of antibiotic-treated mice. The increase in Foxp3<sup>+</sup> Treg cells is likely a result of increased CD11c<sup>high</sup>CD103<sup>+</sup> DC in Peyer’s patches and mesenteric lymph nodes. CD11c<sup>high</sup>CD103<sup>+</sup> DC enhance the conversion of naive CD4<sup>+</sup> T cells into Foxp3<sup>+</sup> Treg cells (<xref ref-type="bibr" rid="B50">50</xref>). In addition, this antibiotics mixture increases IL-10 producing CD5<sup>+</sup> B cells in cervical lymph nodes (deep/superficial lymph nodes not specified). Adoptive transfer of splenic CD5<sup>+</sup> B cells obtained from mice treated with antibiotics into naïve recipient mice which were MOG<sub>35–55-</sub>immunized 1 day post transfer reduced EAE disease score. The reduced disease score was associated with a shift from a T<sub>h1</sub>/T<sub>h17</sub> cytokine profile toward a Th2 cytokine profile (<xref ref-type="bibr" rid="B51">51</xref>). Thus, this antibiotic treatment induced both regulatory T and B cells which protected against EAE.</p>
</sec>
<sec id="S8-3">
<title>Probiotics</title>
<p>The finding that gut microbiota can elicit pro- and anti-inflammatory reactions, has raised the interest for treatment of EAE with bacteria. Prophylactic treatment with <italic>Bifidobacterium animalis</italic> decreases the duration of EAE symptoms (<xref ref-type="bibr" rid="B53">53</xref>) and three commercially available probiotic drinks containing strains of <italic>Lactobacillus casei</italic> could reduce the EAE disease score in Lewis rats. However, no significant effects of these drinks have been observed in an SJL mouse model (<xref ref-type="bibr" rid="B56">56</xref>).</p>
<p>Prophylactic use of <italic>Lactobacilli</italic> monostrains reduces autoreactive T cells and prevents EAE. However, using these monostrains, established EAE could not be reversed. When three <italic>Lactobacilli</italic> strains are combined in a mixture, <italic>Lactobacilli</italic> therapeutically suppress disease progression and reduce clinical signs in MOG<sub>35–55</sub>-immunized mice. The beneficial effect was IL-10 dependent, and treatment induced CD4<sup>+</sup>CD25<sup>+</sup> T<sub>reg</sub> cells in the mesenteric lymph nodes. The treatment also reduced T<sub>h1</sub> and T<sub>h17</sub> cytokines and increased IL-10 production in cultures of splenocytes cultured with autoantigen. In addition, reduced IL-17 and increased IL-10 levels were found in the CNS of treated animals (<xref ref-type="bibr" rid="B54">54</xref>).</p>
<p>Prophylactic treatment with heat-killed <italic>Pediococcus acidilactici</italic> resulted in reduced EAE scores and decreased MOG<sub>35–55</sub>-induced IL-17 and IFNγ production from draining lymph node cells and splenocytes. Treatment also increased CD4<sup>+</sup> IL-10<sup>+</sup> cells in mesenteric lymph nodes and the spleen but not in the lamina propria. It is therefore thought that the treatment with heat-killed <italic>P. acidilactici</italic> activates inhibitory DC, which then migrate to the mesenteric lymph nodes to locally induce IL-10<sup>+</sup> T<sub>reg</sub> cells. Treatment with heat-killed <italic>P. acidilactici</italic> also reduced the disease score in established EAE (<xref ref-type="bibr" rid="B55">55</xref>).</p>
<p>Prophylactic treatment with a cocktail of <italic>Bifidobacterium bifidum, Streptococcus thermophilus</italic>, and three <italic>Lactobacillus</italic> subspecies suppressed the EAE incidence and severity in MOG<sub>35–55</sub>-immunized C57Bl/6 mice. The beneficial effect was associated with reduced T<sub>h1</sub> and Th17 cell frequency and concomitant cytokine production along with increased IL-10 production in lymph nodes and spinal cord. IL-10 production by CD4<sup>+</sup> T cells and CD11c<sup>+</sup> DC is also increased in the spinal cord. When given after EAE immunization, this cocktail delays disease onset but cannot halt disease progression (<xref ref-type="bibr" rid="B57">57</xref>).</p>
<p>Intraepithelial lymphocytes are located in the epithelial layers of mucosal linings, e.g., of gastrointestinal and reproductive tracts. They comprise CD2<sup>−</sup>CD5<sup>−</sup> natural, and CD2<sup>+</sup>CD5<sup>+</sup> induced T cells, which release cytokines upon antigenic stimulation without the need of antecedent priming. Natural IEL acquire their activated phenotype in the presence of self-antigens in the thymus, while induced IEL acquire their phenotype in post-thymic cognate interaction with antigen. Adoptive transfer of CD4<sup>+</sup> IEL prior to EAE induction results in reduced disease severity. IEL cells transferred to the CNS upregulate LAG-3, CTLA-4, and TGF-β, but it is still unclear where and how they acquire their phenotype. It is evident, however, that IEL are affected by gut microbiota and can be induced by dietary components, such as aryl hydrocarbon ligands. It has not been tested whether CD4<sup>+</sup> IEL can reduce established EAE (<xref ref-type="bibr" rid="B62">62</xref>).</p>
<p>A series of observations shows the therapeutic value of polysaccharide A (PSA), produced by the bacterium <italic>Bacteroides fragilis</italic>. First, mice treated with antibiotics and recolonized with <italic>B. fragilis</italic> have reduced EAE disease scores compared to those not recolonized. Second, mice recolonized with PSA-deficient <italic>B. fragilis</italic> develop a normal EAE disease course (<xref ref-type="bibr" rid="B52">52</xref>), while mice colonized with wild-type <italic>B. fragilis</italic> have a milder disease course. The clinical effect is mirrored by reduced Th17 cells in the periphery and reduced IL-17 but increased IL-10 levels in the brains. Wild-type <italic>B. fragilis</italic> recolonized mice also have increased CD103<sup>+</sup> DC in their cervical lymph nodes (deep/superficial lymph nodes not specified). CD103<sup>+</sup> DC are known to convert naïve CD4<sup>+</sup> T cells into IL-10 producing Foxp3<sup>+</sup> T cells (<xref ref-type="bibr" rid="B52">52</xref>).</p>
</sec>
<sec id="S8-4">
<title>Bacterial Products</title>
<p>Oral treatment with purified PSA protects against EAE both in a prophylactic and therapeutic mode. PSA treatment led to increased CD103<sup>+</sup> DC in the cervical lymph nodes (deep/superficial lymph nodes not specified) (<xref ref-type="bibr" rid="B59">59</xref>). Additionally, PSA is also recognized by DC near mesenteric lymph nodes in a toll-like receptor 2-dependent mechanism. PSA-exposed DC migrate to the mesenteric lymph nodes where they induce IL-10 producing T<sub>reg</sub> cells (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B99">99</xref>). A type of T<sub>reg</sub> cell specifically induced by PSA has surface expression of ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase-1; CD39). The NTPDase-1 converts extracellular pro-inflammatory ATP into 5′AMP, which can be further degraded to adenosine which, in contrast to ATP, has anti-inflammatory properties exerted <italic>via</italic> adenosine receptors (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B99">99</xref>). CD39<sup>+</sup> T<sub>reg</sub> cells have increased migratory capacity and are more abundant in the CNS of PSA-treated mice. Upon adoptive transfer, CD39<sup>+</sup> T<sub>reg</sub> cells are protective against EAE in MOG-induced C57Bl/6 mice. PSA does not protect against EAE in CD39-deficient mice (<xref ref-type="bibr" rid="B61">61</xref>). Multiple bacteria species present in the large intestine are able to produce SCFA (acetate, propionate, and butyrate) by fermentation of dietary fibers. Through its effect on histone deacetylases butyrate can induce epigenetic modifications, such as acetylation of the Foxp3 locus. Butyrate can also stimulate DC and macrophages to secrete IL-10 and retinoic acid through G-protein-coupled receptors, such as Gpr41, 43, and 109a. SCFA may also act on epithelial cells, e.g., by stimulating TGF-β production. The acetylation of the Foxp3 locus as well as production of IL-10, retinoic acid, and TGF-β facilitates differentiation of naïve CD4<sup>+</sup> T cells into anti-inflammatory Foxp3<sup>+</sup> T cells (<xref ref-type="bibr" rid="B100">100</xref>).</p>
</sec>
<sec id="S8-5">
<title>Modified Probiotics</title>
<p>Bacteria can also be used as vector to deliver proteins into the gut and induce tolerance against these proteins. Oral pretreatment with recombinant <italic>L. casei</italic> which produce myelin antigens can reduce EAE scores in Lewis rats. In addition, intranasal pretreatment with soluble cell extracts of bacteria producing MBP<sub>72–85</sub> could also reduce the EAE disease score, while extracts of bacteria producing guinea pig MBP exacerbated the EAE disease score (<xref ref-type="bibr" rid="B63">63</xref>). Effects of <italic>Lactobacilli</italic> on the immune system are strain dependent, as different <italic>Lactobacilli</italic> induce distinct cytokine profiles in the mucosa (<xref ref-type="bibr" rid="B101">101</xref>). In addition, the growth phase (log vs stationary) of the bacterial culture is of importance, since this influences the IgG1/IgG2a antibody subclass ratio, which is indicative of the T<sub>h2</sub>/T<sub>h1</sub> pathway ratio (<xref ref-type="bibr" rid="B102">102</xref>). The differential effect of <italic>Lactobacilli</italic> strains and the influence of the phase of the bacterial culture should be taken into account when designing probiotic preparations.</p>
<p>Pretreatment with <italic>Lactococcus lactis</italic>, expressing heat shock protein 65 as a transgene, suppressed EAE development in MOG<sub>35–55</sub>-immunized C57Bl/6 mice. The clinical effect was associated with reduced MOG-induced IL-17 production by splenocytes and increased IL-10 production by MOG-stimulated mesenteric lymph node cells. The treatment also caused increased T<sub>reg</sub> cells in the spleen, inguinal and mesenteric lymph nodes, and spinal cord. <italic>In vivo</italic> depletion of CD4<sup>+</sup>LAP<sup>+</sup> T<sub>reg</sub> cells abrogated the protective effect of transgenic <italic>L. lactis</italic>, indicating that the increased T<sub>reg</sub> cells are mechanistically important. The efficacy of this treatment during established EAE has not yet been investigated (<xref ref-type="bibr" rid="B58">58</xref>).</p>
</sec>
</sec>
<sec id="S9">
<title>Diet-Based Interventions in EAE Models</title>
<p>The notions that SCFA (&lt;6 carbons) produced by gut microbiota modify immune functions and that SCFA are consumed through the diet underlie the hypothesis that the diet influences microbiota, the immune system, and ultimately EAE. Prophylactic oral treatment with propionic acid, a SCFA that is ingested with food, increases T<sub>reg</sub> cells and reduces the EAE disease score. In contrast, long-chain fatty acids (LCFA; 13–21 carbons) increase EAE scores, which is associated with increased T<sub>h1</sub> and Th17 cells (<xref ref-type="bibr" rid="B64">64</xref>). Of note, SCFA can migrate into the CNS and serve as fuel for CNS neurons and glial cells. The microbiota composition of these mice also differs, as those fed with lauric acid, a saturated LCFA, have reduced <italic>Prevotellaceae</italic> and <italic>Bacteroidetes</italic> in their gut microbiota. This illustrates the impact that dietary components can have on the immune system and EAE expression, possibly through the modification of gut microbiota. Fatty acids can also have beneficial effects on EAE, regardless of their length, when they are unsaturated. These lipids have one or more double bonds between the carbon atoms of their hydrocarbon chain. Fatty acids with a double bond at the third carbon atom counted from the methyl (–CH3) tail of the chain are Ω-3 fatty acids and with a double bond at the sixth carbon atom are Ω-6 fatty acids. Oral treatment with the Ω-6 fatty acid γ-linolenic acid reduced the EAE clinical scores in MOG<sub>92–106</sub>-immunized SJL mice. This was associated with increased TGF-β, prostaglandin E<sub>2</sub> production by spleen mononuclear cells (<xref ref-type="bibr" rid="B71">71</xref>). Oral treatment with oils containing γ-linolenic acid also reduced the EAE clinical scores in Lewis rats, where EAE was induced with guinea pig CNS matter homogenate (<xref ref-type="bibr" rid="B72">72</xref>). Ω-3 fatty acids can also reduce the EAE clinical scores. A diet rich in docosahexaenoic acid (DHA) starting 5 weeks before induction of EAE with MOG<sub>35–55</sub> reduced the EAE clinical scores in C57Bl/6 mice. This was found associated with reduced T<sub>h1</sub> and Th17 cell differentiation, and reduced amounts of these cells were found in the spleen and spinal cord of mice on a DHA-rich diet. <italic>In vitro</italic>, DHA reduced the expression of costimulatory molecules on DC and reduced their production of pro-inflammatory cytokines (<xref ref-type="bibr" rid="B73">73</xref>). A diet with the triglyceride form of DHA, starting before EAE induction also reduced the EAE clinical scores in the same mouse model. <italic>In vitro</italic>, pretreatment of microglia cells with the triglyceride form of DHA reduced microglial oxidative stress and production of nitric oxide and inflammatory cytokines (<xref ref-type="bibr" rid="B103">103</xref>). Eicosapentaenoic acid (EPA) supplementation starting 7 days after EAE induction reduced the EAE clinical scores in MOG<sub>35–55</sub>-immunized C57Bl/6 mice. EPA is a ligand for PPAR α, β, and γ and increased their expression on CD4<sup>+</sup> T cells in the spinal cord, while reducing IFNγ and IL-17 cytokine production. CD4<sup>+</sup> T cells from the spleen of EPA-treated mice expressed increased mRNA levels of Foxp3, but also of IL-17 and RORγt (<xref ref-type="bibr" rid="B74">74</xref>). When an EPA rich diet was given at the time point of EAE induction, it delayed the time before EAE symptoms appeared in guinea pig spinal cord homogenate-immunized dark agouti rats. This was associated with increased myelination of axons in the spinal cord (<xref ref-type="bibr" rid="B75">75</xref>). A ketogenic diet, characterized by a high fat to protein and carbohydrate diet, also reduced the EAE clinical score when given before EAE induction. This was associated with reduced T<sub>h1</sub> and Th17 cells in the CNS and lymph nodes (the authors did not specify which lymph nodes). Additionally, mice on a ketogenic diet had reduced levels of pro-inflammatory cytokines in their lymph nodes and CNS (<xref ref-type="bibr" rid="B76">76</xref>). Another study confirmed the beneficial effect of the same ketogenic diet but did not investigate effects on the immune system (<xref ref-type="bibr" rid="B77">77</xref>). The proportion and types of lipids in the diet influence the gut microbiota composition. In healthy C57Bl/6 mice, mice were subjected to a high fat diet containing palm oil (high in saturated fatty acids), olive oil (high in monounsaturated fatty acids), safflower oil (high in Ω-6 polyunsaturated acids), or flaxseed/fish oil (high in Ω-3 polyunsaturated fatty acids). These diets were also compared to two low-fat diets, of which one contained a high percentage of calories from maize and one diet in which most calories came from sucrose. The cecum contents were tested for microbiota composition. In the palm oil group, the relative abundance of Bacteroidetes and <italic>Bacteroidaceae</italic> was reduced, while <italic>Lachnospiraceae</italic> was increased. Mice that received an olive oil-based diet had an increased proportion of <italic>Bacteroidaceae</italic>. In the flaxseed/fish oil group, the proportion of <italic>Bifidobacteriaceae</italic> and <italic>Bifidobacterium</italic> was increased. Within the low-fat diets, the relative abundance of <italic>Ruminococcaceae</italic> was increased and <italic>Erysipelotrichaceae</italic> was reduced in the high sucrose diet. Interestingly, cecal concentrations of SCFA were increased in the palm oil supplemented group (<xref ref-type="bibr" rid="B104">104</xref>). This indicates that dietary fats greatly influence the gut microbiota composition, which influences SCFA production or absorption. In this way, shifts in gut microbiota composition as a result from dietary fats may influence EAE/MS.</p>
<p>Other dietary components can also modify EAE disease scores. Potentially relevant for MS is the beneficial effect of vitamin D3 on EAE, as vitamin D3 deficiency is an established MS risk factor. Intraperitoneal administration of vitamin D prevents EAE development in SJL/J mice immunized with rat spinal cord homogenate when given prophylactically (<xref ref-type="bibr" rid="B65">65</xref>). Additionally, dietary vitamin D supplementation reduces EAE scores when given to MBP<sub>79–87</sub>-immunized B10.PL mice (<xref ref-type="bibr" rid="B66">66</xref>) and MOG<sub>35–55</sub>-immunized C57Bl/6 mice with established EAE, in which the effect was IL-10 dependent (<xref ref-type="bibr" rid="B67">67</xref>). DC isolated from MOG<sub>35–55</sub>-immunized C57Bl/6 mice were also able to reduce EAE severity when incubated with 1,25-dihydroxyvitamin D3 prior to adoptive transfer into mice with EAE. Even though the proportions of T<sub>h1</sub> and Th17 cells in lymph nodes and the spleen were increased during this treatment, their proportions in the spinal cord were reduced. Therefore, DC that were exposed to 1,25-dihydroxyvitamin D3 may reduce migration of pathogenic T cells from the periphery into the CNS (<xref ref-type="bibr" rid="B105">105</xref>). <italic>In vitro</italic> culture with high concentrations of vitamin D inhibits CD4<sup>+</sup> T cell proliferation, reduces IL-6, IL-17 producing T-cells while enhancing IL-10 producing and CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cells (<xref ref-type="bibr" rid="B106">106</xref>). In other models, vitamin D reduced demyelination and increased remyelination (<xref ref-type="bibr" rid="B107">107</xref>) and exerted additional anti-inflammatory effects, such as inhibition of the T<sub>h1</sub> and B-cell response and modulation of DC (<xref ref-type="bibr" rid="B108">108</xref>). Vitamin D may also inhibit the bacteria-induced pro-inflammatory NF-κB pathway and affect tight junction expression, contributing to proper intestinal barrier function (<xref ref-type="bibr" rid="B108">108</xref>).</p>
<p>Excess calorie intake and/or fasting may have a negative effect on MS/EAE. A prophylactic diet of 66% caloric restriction protected Lewis rats from developing EAE (<xref ref-type="bibr" rid="B69">69</xref>), while a prophylactic caloric restriction of 40% reduced the EAE score in several mouse models, which was associated with reduced spinal cord inflammation, demyelination, and axonal injury (<xref ref-type="bibr" rid="B68">68</xref>). Additionally, increased plasma levels of corticosterone, adiponectin and reduced plasma levels of IL-6 and leptin were found in animals with reduced food intake (<xref ref-type="bibr" rid="B68">68</xref>). These altered plasma concentrations are interesting, as corticosterone has broad inhibitory effects on the immune system, and adiponectin reduces IL-6 and TNFα production as well as induces production of IL-10R and IL-1R antagonists. Leptin induces T cell proliferation, T<sub>h1</sub> differentiation, and pro-inflammatory cytokine production (<xref ref-type="bibr" rid="B68">68</xref>). Intermittent feeding (<italic>ad libitum</italic> access to food on alternating days) also had a positive effect on the EAE clinical score, but its effect on the immune system was not investigated (<xref ref-type="bibr" rid="B70">70</xref>). The beneficial effect of fasting on EAE disease score was confirmed in another study, in which mice were fed in cycles of 4 days <italic>ad libitum</italic>, followed by 3 days of fasting (first day of fasting 50%, then 2 days of 10% of normal caloric intake). This intervention was able to reduce the clinical EAE score, even in mice with established EAE. The suppression of EAE was associated with reduced immune cell infiltration into the spinal cord, reduced splenic CD11<sup>+</sup> DC, reduced pro-inflammatory cytokines, increased corticosterone in serum, increased T<sub>reg</sub>, and reduced T<sub>h1</sub> and Th17 cells in the lymph nodes and spleen. In addition, fasting protects oligodendrocytes from apoptosis and stimulates maturation of oligodendrocyte precursors (<xref ref-type="bibr" rid="B77">77</xref>). The effect on oligodendrocytes is seen in EAE and also in a cuprizone model, which demonstrates that fasting affects oligodendrocytes also in an autoimmunity-independent way (<xref ref-type="bibr" rid="B77">77</xref>).</p>
<p>Increased salt intake increased the EAE disease score in MOG<sub>35–55</sub>-immunized C57Bl/6 mice (<xref ref-type="bibr" rid="B78">78</xref>–<xref ref-type="bibr" rid="B81">81</xref>). This effect was associated with increased activity of Th17 cells in the spinal cord and spleen. It is thought that the effect of high sodium is DC independent, as DC function is not altered by exposure to salt (<xref ref-type="bibr" rid="B78">78</xref>). Instead, sodium directly influences T<sub>h17</sub> differentiation. Two studies found that high sodium induces the expression of serum/glucocorticoid kinase 1 (SGK-1) in naïve T cells (<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B81">81</xref>). SGK-1 promotes IL-23R expression and induces T<sub>h17</sub> differentiation (<xref ref-type="bibr" rid="B80">80</xref>). The importance of SGK-1 signaling is shown by the observation that a high-salt diet increases the severity of EAE in mice, while SGK-1-deficient mice develop less severe EAE. This effect was associated with reduced Th17 cells in the CNS and mesenteric lymph nodes in SGK-1-deficient mice (<xref ref-type="bibr" rid="B80">80</xref>). Dietary tryptophan can be metabolized into a variety of AHR ligands. AHR ligands have shown different effects on EAE when given prophylactically. The tryptophan-derived AHR ligand 6-formylindolo[3-2b]carbazole (FICZ) accelerates EAE onset and increases pathology in MOG<sub>35–55</sub>-immunized C57Bl/6 mice. This is associated with increased IL-17 and IL-22 producing CD4<sup>+</sup> T cells in the spinal cords (<xref ref-type="bibr" rid="B82">82</xref>). Another study verified that FICZ increases EAE severity and shows that FICZ-treated mice have increased IL-17<sup>+</sup>CD4<sup>+</sup> and IFNγ<sup>+</sup>CD4<sup>+</sup> T cells in the spleen (<xref ref-type="bibr" rid="B83">83</xref>). In addition, they show that tryptophan-derived 2-(1′H-indole-3′carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) reduces EAE severity. Stimulation with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a less natural AHR ligand, induces T<sub>reg</sub> cells, which are protective of EAE also after adoptive transfer (<xref ref-type="bibr" rid="B83">83</xref>). Even though in these studies the AHR ligands were injected rather than supplemented through diet, it shows the immunomodulatory effects of different AHR ligands which may also be taken through the diet. AHR signaling may also have protective effects through astrocytes. Mice fed a tryptophan-deficient diet develop increased EAE severity. This effect could be reversed by tryptophan supplementation in control mice, but not in astrocyte-specific AHR knockout mice. Gut microbiota mediate the conversion of tryptophan into AHR ligands. Depletion of these microbiota by ampicillin treatment increased EAE disease scores, which can be reduced by supplementation with multiple tryptophan metabolites and the bacterial enzyme tryptophanase. This shows a protective effect of the interplay between dietary tryptophan, gut microbiota, AHR ligands, and astrocytes (<xref ref-type="bibr" rid="B84">84</xref>).</p>
<p>Zinc can also influence EAE. <italic>In vitro</italic>, salt composed of zinc with the amino acid aspartate (zinc aspartate = ZnAsp) reduces the proliferation of stimulated human T-cells (<xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>) and also reduces their production of IL-2, IL-10, IL-17 (<xref ref-type="bibr" rid="B85">85</xref>), IFNγ, TNFα, GM-CSF, and IL-5 (<xref ref-type="bibr" rid="B86">86</xref>). The same effects of ZnAsp were seen in mouse splenocyte cultures (<xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>). In PLP<sub>139–151</sub>-immunized SJL mice, intraperitoneal injection of 30 µg ZnAsp per day reduced the EAE clinical score prophylactically as well as therapeutically, while 120 µg increased the EAE severity (<xref ref-type="bibr" rid="B85">85</xref>). An oral dose of 6 or 12 µg ZnAsp per day reduced the clinical disease score in the same EAE model, while an oral dose of 30 µg increased the disease score (<xref ref-type="bibr" rid="B86">86</xref>). Zinc supplementation also affected EAE in the MOG<sub>35–55</sub>-immunized C57Bl/6 model. Zinc supplementation in drinking water (<xref ref-type="bibr" rid="B87">87</xref>) and daily intraperitoneal injections of 6 and 30 µg ZnAsp both reduced the EAE clinical score when given before EAE induction (<xref ref-type="bibr" rid="B88">88</xref>). The mechanisms underlying the effect of ZnAsp injections include reduced systemic Th17 cells and increased Foxp3<sup>+</sup> T-cells in the spinal cord (<xref ref-type="bibr" rid="B88">88</xref>). Lower plasma or serum concentrations of zinc have been found in MS patients compared to healthy individuals, while others have found no differences. Mice with EAE had reduced zinc plasma levels on day 21 after EAE induction compared to naïve mice (<xref ref-type="bibr" rid="B86">86</xref>). Given the beneficial effects of zinc supplementation in EAE, normalizing zinc levels in MS patients with zinc deficiency may be tested in clinical trials, but a high dosage or long-term supplementation may also have detrimental effects, thus patient serum concentrations in these trials must be tightly monitored (<xref ref-type="bibr" rid="B86">86</xref>). A zinc-deficient diet of 10 days did not alter the microbiota composition at phylum level and total bacterial abundance in healthy C57Bl/6 mice compared to those that were fed a normal diet. The relative abundance of several bacterial genera did differ between these diet groups, which included the genera <italic>Enterococcus, Enterobacteriaceae, Paenibacillus, Granulicatella, Clostridium, Akkermansia</italic>, and <italic>Burkholderia</italic> (<xref ref-type="bibr" rid="B109">109</xref>).</p>
<p>High dietary selenium (10× normal intake) increased EAE incidence and severity in guinea pigs, while those on normal and half amounts of selenium developed EAE in a normal fashion (<xref ref-type="bibr" rid="B89">89</xref>).</p>
<p>Intraperitoneal injection of diphenyl diselenide was toxic for whole MBP-immunized Wistar rats, while oral administration 1 week after immunization resulted in reduced EAE incidence and symptoms. This was associated with reduced macrophage numbers in the CNS and reduced MBP-specific T-cell proliferation. The EAE-reducing mechanism of diphenyl diselenide is thought to be based on reduced NF-κB signaling in macrophages and T-cells. In addition, diphenyl diselenide may increase ROS clearance as it mimics glutathione peroxidase activity, which protects against oxidative damage (<xref ref-type="bibr" rid="B90">90</xref>). The different effects of dietary selenium on EAE may be explained by differences in formulation.</p>
<p>Vitamin E has potent antioxidant properties. Multiple compounds are considered part of the vitamin E group, of which tocopherol is best studied. Intraperitoneal administration of tocopherol reduced the EAE clinical scores in MOG<sub>35–55</sub>-immunized C57Bl/6 mice, which was associated with reduced MOG-specific splenocyte proliferation. In addition, splenocytes incubated with tocopherol produced less IFNγ (<xref ref-type="bibr" rid="B91">91</xref>). Vitamin E also increases remyelination and reduces demyelination in an animal model where demyelination is chemically induced (<xref ref-type="bibr" rid="B107">107</xref>). TFA-12, a synthetic tocopherol derivative, reduced the EAE clinical scores in MOG<sub>35–55</sub>-immunized C57Bl/6 mice when injected intraperitoneally at the onset of EAE symptoms. This was associated with reduced inflammation of the CNS, astrogliosis, and demyelination. TFA-12 also accelerated remyelination in a chemically induced demyelination model. The mechanism behind this is believed to be due to the induction of oligodendrocyte maturation (<xref ref-type="bibr" rid="B92">92</xref>).</p>
<p>Vitamin A and its metabolites all-trans retinoic acid and 9-cis-retinoic acid can also reduce EAE severity. Prophylactic dietary 13-cis-retinoic acid and 4-HPR (a synthetic retinoid derivative) reduced EAE incidence in SJL mice which received MOG-incubated lymph node cells to induce EAE. Dietary 4-HPR can also reduce EAE severity in a therapeutic manner (<xref ref-type="bibr" rid="B93">93</xref>). In MOG<sub>35–55</sub>-immunized C57Bl/6 mice, intraperitoneal injection with all-trans retinoic acid reduced the EAE clinical score when given prophylactically (<xref ref-type="bibr" rid="B94">94</xref>) as well as therapeutically (<xref ref-type="bibr" rid="B95">95</xref>). This was associated with reduced DC maturation and reduced pro-inflammatory monocytes in the subarachnoid space. Reduced T<sub>h1</sub> and Th17 cells were also found in the draining lymph nodes. In addition, bone mesenchymal DC pretreated with all-trans retinoic acid were able to reduce T<sub>h1</sub> and T<sub>h17</sub> differentiation and lymphocyte proliferation <italic>in vitro</italic> (<xref ref-type="bibr" rid="B94">94</xref>). All-trans retinoic acid also directly affected naïve CD4<sup>+</sup> T cells, as it inhibited T<sub>h17</sub> differentiation by reducing expression of the IL-6 and IL-23 receptor (<xref ref-type="bibr" rid="B95">95</xref>). Even though all-trans retinoic acid can induce Foxp3<sup>+</sup> T cells <italic>in vitro</italic>, the frequency of these cells was not increased in EAE-affected mice treated with the metabolite (<xref ref-type="bibr" rid="B95">95</xref>). <italic>In vitro</italic>, 9-cis-retinoic acid reduced pro-inflammatory cytokine production in LPS-stimulated microglia and reduced TNF-α and nitric oxide production in astrocytes (<xref ref-type="bibr" rid="B110">110</xref>). Mechanisms underlying gut microbiota and dietary interventions are summarized in Box <xref ref-type="boxed-text" rid="BX2">2</xref>.</p>
<boxed-text id="BX2" position="float">
<label>Box 2</label>
<caption>
<title>Mechanisms underlying microbiota and dietary interventions in experimental autoimmune encephalomyelitis (EAE).</title>
</caption>
<p>Most interventions are mediated by the induction of anti-inflammatory IL-10 producing T<sub>regs</sub>. These cells suppress pro-inflammatory cytokine production and T cell proliferation. In addition, multiple other mechanisms have been unraveled.</p>
<p><italic>Germfree</italic> mice are resistant against EAE. The EAE resistance is attributed to reduced recruitment and activation of autoantibody producing B cells (<xref ref-type="bibr" rid="B47">47</xref>) as well as dendritic cells (DC) and the reduced capacity of these professional antigen-presenting cells (APC) to stimulate pro-inflammatory T cell responses (<xref ref-type="bibr" rid="B48">48</xref>).</p>
<p><italic>Antibiotic</italic> treatments reduce EAE <italic>via</italic> invariant natural killer T (iNKT) cells and CD1<sup>high</sup>CD5<sup>+</sup> B cells. Antibiotic treatments likely suppress pro-inflammatory cytokine production by iNKT cells located in the lamina propria, which reduces T<sub>h17</sub> development (<xref ref-type="bibr" rid="B49">49</xref>). Antibiotic treatment also induces IL-10 producing CD1<sup>high</sup>CD5<sup>+</sup> B cells in distant lymph nodes, and adoptive transfer of CD1<sup>high</sup>CD5<sup>+</sup> B cells protect against EAE (<xref ref-type="bibr" rid="B51">51</xref>). Antibiotic treatments increase CD11c<sup>high</sup>CD103<sup>+</sup> DC in mesenteric lymph nodes, which are able to induce Foxp3<sup>+</sup> T cells (<xref ref-type="bibr" rid="B50">50</xref>).</p>
<p><italic>Polysaccharide A (PSA)</italic> is captured by DC in the gut <italic>via</italic> a TLR-2 dependent mechanism. DC then migrate to the mesenteric lymph nodes and induce IL-10 producing CD4<sup>+</sup> T<sub>regs</sub>. A type of IL-10 producing T<sub>reg</sub> specifically induced by PSA expresses the ectonucleosidase CD39 on its surface. CD39<sup>+</sup> T<sub>reg</sub> cells have increased migratory capacity, are more abundant in the central nervous system (CNS) of PSA-treated mice, and are protective against EAE. The EAE modulatory capacity relies on the conversion of ATP into adenosine, which increases the anti-inflammatory effects of T<sub>regs</sub> and suppresses effector cells, thus protecting against CNS inflammatory tissue damage (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B99">99</xref>). Additionally, PSA treatment causes accumulation of CD103<sup>+</sup> DC in the cervical lymph nodes, which converses naïve CD4<sup>+</sup> T cells into protective IL-10 producing Foxp3<sup>+</sup> T cells. The mechanism causing the accumulation of CD103<sup>+</sup> DC in the cervical lymph nodes is unknown (<xref ref-type="bibr" rid="B59">59</xref>).</p>
<p><italic>Short-chain fatty acids (SCFA)</italic>, such as butyrate and propionic acid, are produced by bacterial fermentation of dietary fibers in the colon or consumed with the diet. SCFA induce T<sub>regs</sub> through multiple known mechanisms. Oral administration of propionic acid can induce CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T<sub>reg</sub> cells, while simultaneously reducing T<sub>h17</sub> responses (<xref ref-type="bibr" rid="B64">64</xref>). Butyrate can stimulate DC, macrophages, and epithelial cells to produce cytokines that facilitate the differentiation of naïve CD4<sup>+</sup> T cells into anti-inflammatory Foxp3<sup>+</sup> T cells (<xref ref-type="bibr" rid="B100">100</xref>). <italic>Dietary components</italic> influencing EAE also include: (1) Different types and ratios of lipids, such as Ω-6 fatty acids, Ω-3 fatty acids and ketogenic diets reduce EAE by affecting splenic mononuclear cells (<xref ref-type="bibr" rid="B71">71</xref>) or T cells (<xref ref-type="bibr" rid="B73">73</xref>). (2) <italic>Vitamin D3</italic> has a broad effect on the immune system (<xref ref-type="bibr" rid="B108">108</xref>). In EAE, its effect is dependent on IL-10 (<xref ref-type="bibr" rid="B67">67</xref>). (3) <italic>Vitamin E</italic> has antioxidant properties (<xref ref-type="bibr" rid="B91">91</xref>), accelerates remyelination (<xref ref-type="bibr" rid="B107">107</xref>), and also affects splenocytes (<xref ref-type="bibr" rid="B91">91</xref>). (4) <italic>Vitamin A</italic> affects DC (<xref ref-type="bibr" rid="B94">94</xref>) and reduces T<sub>h1</sub> and T<sub>h17</sub> differentiation (<xref ref-type="bibr" rid="B95">95</xref>). (5) <italic>Zinc</italic> increases Foxp3<sup>+</sup> T cells (<xref ref-type="bibr" rid="B88">88</xref>), reduces T cell proliferation, and reduces their pro-inflammatory cytokine production (<xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>). (6) <italic>Selenium</italic> protects against oxidative damage and also affects T cells (<xref ref-type="bibr" rid="B90">90</xref>). (7) <italic>Caloric restriction/fasting</italic> reduces EAE, which is associated with changes in plasma levels of corticosterone, adiponectin, IL-6, and leptin (<xref ref-type="bibr" rid="B68">68</xref>). In addition, fasting reduces DC, T<sub>h1</sub>, Th17 cells and increases T<sub>reg</sub> cells as well as stimulates remyelination by oligodendrocytes (<xref ref-type="bibr" rid="B77">77</xref>). (8) A <italic>high-salt</italic> diet increases the T<sub>h17</sub> response, which is likely DC independent. Instead, salt induces SGK-1 signaling, leading to increased T<sub>h17</sub> differentiation. (9) <italic>Aryl hydrocarbon receptor ligands</italic> can have multiple effects on EAE. Cruciferous vegetables such as broccoli are rich in indole-3-carbinol, which upon contact with stomach acid, is converted into aryl hydrocarbon receptor ligands and can induce CD4<sup>+</sup> IEL. These cells can migrate into the CNS and are protective against EAE (<xref ref-type="bibr" rid="B62">62</xref>). 6-Formylindolo[3-2b]carbazole, a different aryl hydrocarbon receptor (AHR) ligand, increases the EAE disease score, while the tryptophan-derived AHR ligand ITE reduces EAE clinical signs. Tryptophan-derived AHR ligands limit astrocyte-mediated inflammation in the CNS (<xref ref-type="bibr" rid="B84">84</xref>). Aryl hydrocarbon receptor ligands may also act on type 3 ILC (<xref ref-type="bibr" rid="B17">17</xref>).</p>
</boxed-text>
</sec>
<sec id="S10">
<title>Gut Microbiota in MS Patients</title>
<sec id="S10-1">
<title>Comparing the Gut Microbiota of MS Patients with Healthy Controls</title>
<p>Colonization with bacteria and oral treatment with bacterial products and diet are all exogenous factors <italic>via</italic> which the clinical and/or pathological expression of EAE can be modified. It is therefore of considerable interest whether differences exist between the gut microbiota composition of MS patients compared to healthy individuals and to test whether treatment concepts developed in EAE can be translated to humans. Studies analyzing gut microbiota of MS patients are summarized in Table <xref ref-type="table" rid="T3">3</xref>. Of these studies, eight have investigated whether differences exist in the microbiota composition of MS patients compared to healthy individuals, for which collectively almost 250 MS samples were tested. A reduced abundance of SCFA producers such as <italic>Lachnospiraceae, Prevotella, Faecalibacterium prausnitzii</italic>, and <italic>Butyricimonas</italic> in the gut of MS patients has been repeatedly reported. As SCFA reduced the disease score in several EAE models, reduced SCFA production in the gut of MS patients may have an impact on MS pathology. Of note, <italic>F. prausnitzii</italic> produces a microbial anti-inflammatory molecule (MAM), which has anti-inflammatory effects in a mouse model of colitis. MAM displays an inhibitory effect on nuclear factor-κB activity in human epithelial cells. Moreover, administration of <italic>L. lactis</italic> delivering a MAM-encoding plasmid reduced morbidity in an animal colitis model, whereas wild-type <italic>L. lactis</italic> had no effect (<xref ref-type="bibr" rid="B111">111</xref>). By producing MAM, <italic>F. prausnitzii</italic> adds to an anti-inflammatory milieu in the gut. Additionally, the gut of MS patients harbors higher numbers of the archaea <italic>Methanobrevibacter</italic> compared to healthy individuals. As mentioned earlier, lipids from <italic>Methanobrevibacter</italic> are thought to elicit inflammatory reactions (<xref ref-type="bibr" rid="B112">112</xref>) and therefore possibly add to a pro-inflammatory milieu in the gut of MS patients. Two studies found that <italic>Enterobacteriaceae</italic> are increased in MS patients compared to healthy individuals. The <italic>Enterobacteriaceae</italic> family of gut bacteria includes pathogenic as well as non-pathogenic/opportunistic species. Increased <italic>Enterobacteriaceae</italic> abundance has been found in patients with inflammatory bowel disease (IBD). However, it is unclear if this dysbiosis is a cause or consequence of the IBD (<xref ref-type="bibr" rid="B3">3</xref>). Several <italic>Enterobacteriaceae</italic> members have a competitive growth advantage under inflammatory conditions in the gut of mice (<xref ref-type="bibr" rid="B113">113</xref>), and therefore, it is conceivable that <italic>Enterobacteriaceae</italic> abundance increases after IBD develops. Studies investigating the role of <italic>Enterobacteriaceae</italic> in EAE models were not found. Of note, children with autism and patients with Parkinson’s disease have increased <italic>Enterobacteriaceae</italic> abundance in their gut microbiota, indicating that <italic>Enterobacteriaceae</italic> could possibly play a role in CNS disorders (<xref ref-type="bibr" rid="B114">114</xref>). Only one study found that <italic>B. fragilis</italic> was reduced in a cohort of 18 pediatric MS patients compared to healthy individuals (<xref ref-type="bibr" rid="B115">115</xref>). <italic>In vitro</italic>, PSA induced expression of CD39 and Foxp3 on naïve human CD4<sup>+</sup> T cells and increased IL-10 production (<xref ref-type="bibr" rid="B116">116</xref>). Even though only one study found a difference in the abundance of <italic>B. fragilis</italic> (<xref ref-type="bibr" rid="B115">115</xref>), the beneficial effect of PSA on EAE may be translatable to corresponding human diseases, such as MS.</p>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p>Gut microbiota studies in MS patients.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Reference</th>
<th align="left" colspan="1" rowspan="1" valign="top">Number of subjects, type of MS</th>
<th align="left" colspan="1" rowspan="1" valign="top">Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tremlett et al. (<xref ref-type="bibr" rid="B115">115</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">18 RR pediatric, 17 HC</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in species richness. Increased <italic>Desulfovibrionaceae, Methanobrevibacter</italic><xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref>, <italic>Enterobacteriaceae</italic><xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref>. Reduced <italic>Lachnospiraceae</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>, <italic>Ruminococcaceae</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>, <italic>Faecalibacterium prausnitzii</italic><xref ref-type="table-fn" rid="tfn4"><sup>d</sup></xref>, and <italic>Butyricimonas</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>
<italic>Bacteroides fragilis</italic><xref ref-type="table-fn" rid="tfn3"><sup>c</sup></xref>. Functional prediction of microbial genes indicated increased glutathione metabolism in patients</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tremlett et al. (<xref ref-type="bibr" rid="B117">117</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">17 RR pediatric</td>
<td align="left" colspan="1" rowspan="1" valign="top">Depletion of Fusobacteria is associated with increased risk on earlier relapses. Higher abundance of Firmicutes and Euryarchaeota trended to be associated with increased risk on earlier relapses</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tremlett et al. (<xref ref-type="bibr" rid="B118">118</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">15 RR pediatric, 9 HC</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in blood Foxp3<sup>+</sup> T<sub>reg</sub> frequency and intracellular production of IFNγ, IL-17, IL-4, and IL-10 by CD4<sup>+</sup> T cells. IL-17<sup>+</sup> T cells correlated with gut microbiota richness in MS patients. IL-17<sup>+</sup> T cells inversely correlated with Bacteroidetes abundance in patients. T<sub>reg</sub> frequency correlated with Fusobacteria abundance in healthy controls</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Miyake et al. (<xref ref-type="bibr" rid="B119">119</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">20 RR, 40 HC, 18 HC</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in species richness. Reduced <italic>Faecalibacterium</italic><xref ref-type="table-fn" rid="tfn4"><sup>d</sup></xref>, <italic>Prevotella</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>, <italic>Anaerostipes</italic>, butyrate-producing bacterium A2-175<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>, and SL7/1<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>. Trends in increased <italic>Bifidobacterium, Streptococcus</italic></td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chen et al. (<xref ref-type="bibr" rid="B120">120</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">31 RR, 36 HC</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in species richness. Increased <italic>Pedobacter, Flavobacterium, Pseudomonas, Mycoplana, Blautia, Dorea</italic>, and <italic>Haemophilus</italic>. Reduced <italic>Parabacteroides, Adlercreutzia, Collinsella, Lactobacillus</italic>, and <italic>Prevotella</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>. Reduced fatty acids metabolism and increased phytoestrogen metabolism were predicted by functional analysis</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Jangi et al. (<xref ref-type="bibr" rid="B112">112</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">60 RR, 43 HC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased <italic>Methanobrevibacter</italic><xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref>, <italic>Akkermansia</italic>. Decreased <italic>Butyricimonas</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>. Untreated patients had reduced <italic>Prevotella</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>, <italic>Sutterella</italic>, increased <italic>Sarcina</italic>. Positive correlations between <italic>Methanobrevibacter</italic><xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref>, <italic>Akkermansia</italic>, and T-cell/monocyte gene expression implicated in MS pathology. Negative correlations for <italic>Butyricimonas</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref> with gene expressions implicated in MS pathology</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Jangi, et al., abstract (<xref ref-type="bibr" rid="B121">121</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">22 untreated, 13 GA, 18 IFN-β, 44 HC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased <italic>Methanobrevibacteriaceae</italic><xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref> in patients compared to HC. Reduced <italic>Butyricimonas</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref> in untreated patients compared to HC. Both treatment groups had increased <italic>Lachnospiraceae</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref> abundance compared to untreated MS patients</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Baum et al., abstract (<xref ref-type="bibr" rid="B122">122</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">54 MS patients vs healthy controls (the amount of controls is not stated in the abstract)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased <italic>Atopobium, Bifidobacteriae</italic>. Reduced <italic>Bacteroidaceae</italic> in MS patients</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantarel et al. (<xref ref-type="bibr" rid="B123">123</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">7 RR vitamin D-deficient, before and after vitamin D supplementation, 8 HC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced <italic>Bacteroidaceae, Faecalibacterium</italic><xref ref-type="table-fn" rid="tfn4"><sup>d</sup></xref>, increased <italic>Ruminococcus</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref> in patients. Vitamin D supplementation increased <italic>Faecalibacterium</italic><xref ref-type="table-fn" rid="tfn4"><sup>d</sup></xref>, <italic>Akkermansia</italic>, and C<italic>oprococcus</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>. GA treatment affected gut microbiota</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sand et al., abstract (<xref ref-type="bibr" rid="B124">124</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not specified in abstract</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased <italic>Enterobacteriaceae</italic><xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref> in female patients compared to HC. GA treatment affects gut microbiota</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tankou et al., abstract (<xref ref-type="bibr" rid="B125">125</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">43 untreated MS patients, disease subtype not specified</td>
<td align="left" colspan="1" rowspan="1" valign="top">Patients with &lt;40 ng/mL serum vitamin D concentration had lower <italic>Ruminococcaceae</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref> compared to patients with higher vitamin D levels</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Telesford et al. (<xref ref-type="bibr" rid="B116">116</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>In vitro</italic> cultures of patients and HC</td>
<td align="left" colspan="1" rowspan="1" valign="top">PSA from <italic>B. fragilis</italic><xref ref-type="table-fn" rid="tfn3"><sup>c</sup></xref> induced CD39<sup>+</sup> T<sub>reg</sub> cells <italic>in vitro</italic></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1">
<p><italic><sup>a</sup>SCFA producer</italic>.</p>
</fn>
<fn id="tfn2">
<p><italic><sup>b</sup>Likely pro-inflammatory</italic>.</p>
</fn>
<fn id="tfn3">
<p><italic><sup>c</sup>PSA producer</italic>.</p>
</fn>
<fn id="tfn4">
<p><italic><sup>d</sup>MAM producer</italic>.</p>
</fn>
<p><italic>MAM, microbial anti-inflammatory molecule; MS, multiple sclerosis; PSA, polysaccharide A; RR, relapsing remitting; SCFA, short-chain fatty acids</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Taken together, the gut microbiota composition of MS patients and healthy individuals likely differs, as reflected by a different abundance of SCFA producing bacteria, <italic>F. prausnitzii, Methanobrevibacter</italic>, and <italic>Enterobacteriaceae</italic> (see Figure <xref ref-type="fig" rid="F5">5</xref>). Not all studies reported the same differences between MS patients and healthy individuals. This may be explained by differences in sampling methods, molecular techniques, and differences in study populations such as their diet, received treatments, type of MS, or ethnicity. In addition, the populations of tested MS patients varied among studies. Differences in the gut microbiota of pediatric MS patients compared to adult MS patients may exist. Moreover, some studies divided patients in groups based on treatments, while others only separated patients from healthy individuals. Therefore, there is a great need of large controlled studies to determine which results from multiple small studies can be replicated in a bigger cohort. It is also not clear whether the dysbiosis in SCFA-producing bacteria, <italic>F. prausnitzii, Methanobrevibacter</italic>, and <italic>Enterobacteriaceae</italic> adds to the pathology of MS, or if it is a result of MS pathology or treatments.</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Similarities and differences in gut microbiota of MS patients and healthy controls. Eight studies investigating almost 250 patient fecal samples for differences in microbiota composition were analyzed. Many species were shown differently present. Only differences that have been reproduced by at least one other study are included in this figure. The gut microbiota of both MS patients and healthy controls are dominated by bacteria from the phyla <italic>Firmicutes</italic> and <italic>Bacteroidetes</italic> and their species richness does not differ. MS patients may have increased <italic>Methanobrevibacter</italic> and <italic>Enterobacteriaceae</italic>, but reduced <italic>Faecalibacterium prausnitzii</italic> and SCFA producing bacteria. SCFA, short-chain fatty acids; MS, multiple sclerosis.</p>
</caption>
<graphic xlink:href="fimmu-08-01081-g005"></graphic>
</fig>
</sec>
<sec id="S10-2">
<title>Prospective Microbiota Studies in MS Patients</title>
<p>Two relatively small studies have tried to link gut microbiota to clinical outcomes or changes in the immune system of MS patients. In a cohort of 17 pediatric MS patients, the absence of <italic>Fusobacteria</italic> was associated with increased risk on earlier relapses. Additionally, trends in increased abundance of <italic>Firmicutes</italic> and <italic>Euryarchaeota</italic> were observed which may be associated with increased risk of earlier relapses (<xref ref-type="bibr" rid="B117">117</xref>). In 15 pediatric MS patients, no difference was found in blood CD4<sup>+</sup> T<sub>reg</sub> cells compared to healthy individuals, but IL-17<sup>+</sup> T cells correlated with species richness and inversely correlated with <italic>Bacteroidetes</italic> in patient stools (<xref ref-type="bibr" rid="B118">118</xref>). These studies are an interesting indication that it may be possible to modulate the gut microbiota as a treatment of MS. However, studies performed thus far included far too few patients to be able to determine a causal relationship between the abundance of certain microbial species and symptoms or immune responses. The effect of MS treatments on gut microbiota has also only been investigated in relatively small studies thus far. Preliminary data suggest that both glatiramer acetate treatment and vitamin D supplementation affect gut microbiota (see Table <xref ref-type="table" rid="T3">3</xref>).</p>
<p>The aforementioned microbiota studies in MS patients are possibly biased as fecal/stool samples were used for characterization of gut microbiota. The composition of microbiota varies from the mucosal surface to the lumen, and fecal samples mostly detect luminal microbiota. Hence, differences in mucosa-associated species may be underappreciated (<xref ref-type="bibr" rid="B17">17</xref>). <italic>B. fragilis</italic> is one of the few species that can penetrate the tight inner mucus layer of the colon and can colonize the colonic crypts (<xref ref-type="bibr" rid="B15">15</xref>). It is, therefore, interesting to investigate whether mucosa-associated <italic>B. fragilis</italic> is differently present in patients. Moreover, as fecal samples more closely reflect microbiota composition of the colon than of the small intestines, differences in microbiota composition of the small intestines are undetected (<xref ref-type="bibr" rid="B16">16</xref>).</p>
</sec>
<sec id="S10-3">
<title>Potential Role of PGN in MS</title>
<p>Another way in which gut microbiota may influence MS is through PGN, a bacterial cell wall component. PGN is ubiquitously present in the gut and can be phagocytosed into APC (<xref ref-type="bibr" rid="B142">142</xref>). PGN is sensed through NOD-like and toll-like receptors, which induces pro-inflammatory mitogen-activated protein kinase and NF-κB (<xref ref-type="bibr" rid="B143">143</xref>). Microbiota-dependent NOD1 signaling increases the lifespan of circulating neutrophils and monocytes (<xref ref-type="bibr" rid="B144">144</xref>), and PGN has strong adjuvant properties, as mice injected with MOG<sub>35–55</sub> and incomplete Freund’s adjuvant did not develop EAE, while when PGN was added to the mixture mice did develop EAE (<xref ref-type="bibr" rid="B145">145</xref>). Mechanistically, PGN modulates DC, which leads to Th1 cell expansion (<xref ref-type="bibr" rid="B145">145</xref>). In the rhesus monkey and marmoset EAE model (<xref ref-type="bibr" rid="B146">146</xref>) as well as human MS (<xref ref-type="bibr" rid="B147">147</xref>), PGN is found in APC located in the brain. Another study in autopsied brain samples revealed that the expression of bacterial components in MS samples differed from non-MS samples. In both sample groups, the dominant phylum was Proteobacteria, but less diversity was observed in progressive MS samples. In addition, Actinobacteria were enriched in RRMS samples. The total amount of PGN in the brain did not distinguish MS samples from non-MS samples. But within MS lesions, PGN inversely correlated with myelin density and was associated with several genes of the immune system, including NF-κB (<xref ref-type="bibr" rid="B34">34</xref>). The presence of a TLR/NLR ligand in the brain, possibly originating from gut microbiota, may contribute to MS pathology by influencing inflammation, demyelination or remyelination, and therefore, more research is needed to elucidate the role of microbial compounds in MS brains.</p>
</sec>
</sec>
<sec id="S11">
<title>Dietary Studies in MS Patients</title>
<p>How different food components may affect MS has been reviewed comprehensively by Schmitz et al. (<xref ref-type="bibr" rid="B141">141</xref>) of which the most important ones are summarized in Table <xref ref-type="table" rid="T4">4</xref>. Multiple dietary intervention studies have been done in MS patients, but most were unsuccessful in reducing MS severity and have not examined the effects on microbiota. Vitamin D supplementation did show positive outcomes as it led to fewer relapses and reduced pro-inflammatory cytokines such as IFNγ and IL-4 in T-cells. Additionally, vitamin D supplementation increased peripheral IL-10<sup>+</sup>CD4<sup>+</sup> T cells, suppressed T-cell proliferation, and reduced the number of gadolinium-enhancing regions per patient (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B141">141</xref>). However, these results came from small studies and more randomized controlled trials investigating the effect of vitamin D for MS treatment are now taking place. The effect of vitamin D might in part be exerted <italic>via</italic> the gut microbiota, as in healthy individuals high vitamin D intake was associated with increased proportions of <italic>Prevotella</italic> and reduced proportions of <italic>Haemophilus</italic> and <italic>Veillonella</italic> (<xref ref-type="bibr" rid="B148">148</xref>). Vitamin D supplementation in vitamin D-deficient MS patients altered the relative proportions of different genera, but this study included very few subjects (<xref ref-type="bibr" rid="B123">123</xref>). In a study of 70 and a replication study of 59 RR MS patients, the influence of salt on MS was studied. As 80–90% of salt intake is excreted in urine, salt excretion rate in urine was measured as a proxy for salt intake. High salt excretion was associated with increased relapse rates, increased risk on developing a new lesion detected by MRI scans, and increased T2 lesion load. However, causality was not established. Patients with relapses are often treated with steroids, which influences salt excretion (<xref ref-type="bibr" rid="B137">137</xref>). Clinical trials with controlled salt intake are needed to assess the impact of increased salt intake on MS severity.</p>
<table-wrap id="T4" position="float">
<label>Table 4</label>
<caption>
<p>Dietary studies in MS patients.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Reference</th>
<th align="left" colspan="1" rowspan="1" valign="top">Number of subjects, type of MS</th>
<th align="left" colspan="1" rowspan="1" valign="top">Diet-groups</th>
<th align="left" colspan="1" rowspan="1" valign="top">Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bates et al. (<xref ref-type="bibr" rid="B126">126</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">292 RRMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ω-3 EPA and DHA vs oleic acid supplementation. Both groups also had vitamin E and antioxidant supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in relapse rate or EDSS</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Weinstock-Guttman et al. (<xref ref-type="bibr" rid="B127">127</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">27 RRMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low-fat diet (&lt;15% calories) with Ω-3 EPA and DHA supplements vs low fat (&lt;30% calories) with oleic acid supplements. Both groups received vitamin E, multivitamin, and calcium supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in relapse rate or EDSS between groups. Relapse rates, reduced compared to 1 year before the start of this study. EPA/DHA group had increased physical and mental parameters. Reduced fatigue score in the oleic acid group</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Torkildsen et al. (<xref ref-type="bibr" rid="B128">128</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">99 RRMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ω-3 EPA and DHA vs corn oil supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in relapse rate, EDSS, quality of life, and fatigue scores</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bates et al. (<xref ref-type="bibr" rid="B129">129</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">134 SPMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ω-6 Linoleic acid and γ-linolenic acid vs linoleic acid vs oleic acid supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in relapse rate or EDSS</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bates et al. (<xref ref-type="bibr" rid="B130">130</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">104 PPMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ω-6 Linoleic acid and γ-linolenic acid vs linoleic acid vs oleic acid supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">No difference in relapse rate or EDSS. High-dose linoleic acid group had less severe relapses</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Harbige and Sharief (<xref ref-type="bibr" rid="B131">131</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">28 RRMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ω-6 Linoleic acid supplementation vs placebo</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced relapse rate, improved EDSS</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Jafarirad et al. (<xref ref-type="bibr" rid="B132">132</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">35 RRMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vitamin A (retinyl palmitate) or placebo supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced T cell proliferation when incubated with MOG</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Wingerchuk et al. (<xref ref-type="bibr" rid="B133">133</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">15 RRMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vitamin D supplementation, uncontrolled</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced EDSS compared to baseline</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Mahon et al. (<xref ref-type="bibr" rid="B134">134</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">39 MS patients, subtype not specified</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vitamin D3 supplementation vs placebo. Both groups received calcium supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased TGF-β concentration in serum of vitamin D3 supplemented group. No differences in TNFα, IFNγ, and IL-13 concentrations</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Goldberg et al. (<xref ref-type="bibr" rid="B135">135</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">10 MS patients, subtype not specified</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vitamin D3, calcium, and magnesium supplementation, uncontrolled</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fewer relapses than expected</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Choi et al. (<xref ref-type="bibr" rid="B77">77</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">48 RRMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cycles of fasting vs ketogenic diet vs control</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fasting and diet group had improved health related quality of life, reduced disability scores. Fasting and ketogenic diet were well tolerated</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Haghikia et al. (<xref ref-type="bibr" rid="B136">136</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not specified in abstract</td>
<td align="left" colspan="1" rowspan="1" valign="top">Propionic acid treatment in patients and HC</td>
<td align="left" colspan="1" rowspan="1" valign="top">No side effects of PA. 25–30% increase of T<sub>reg</sub> and reduced Th17 cells in both groups</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Farez et al. (<xref ref-type="bibr" rid="B137">137</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">70 RRMS, replicated by a separate group of 52 patients</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">High salt excretion is associated with increased disease activity</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hadgkiss et al. (<xref ref-type="bibr" rid="B138">138</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">2,087 MS patients, subtype not specified</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">A general healthy diet, based on fruit, vegetable, fat, meat and dairy consumption was associated with better clinical scores</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rezapour-Firouzi et al. (<xref ref-type="bibr" rid="B139">139</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">65 RRMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Three groups: 1. hemp seed/evening primrose oil; 2. olive oil; and 3. cosupplemented oil vs baseline measurements. Subjects were advised to have a general healthy diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced relapse rates, EDSS in groups 1 and 3 compared to baseline</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nordvik et al. (<xref ref-type="bibr" rid="B140">140</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">16 RRMS</td>
<td align="left" colspan="1" rowspan="1" valign="top">General health lifestyle and A, B, D, E, Ω-3 fatty acid supplementation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced EDSS compared to baseline</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Dietary studies in MS patients have been extensively reviewed by Schmitz et al. (<xref ref-type="bibr" rid="B141">141</xref>)</italic>.</p>
<p><italic>AHR, aryl hydrocarbon receptor; CNS, central nervous system; DC, dendritic cells; DHA, docosahexaenoic acid; EDSS, expanded disability status scale; EAE, experimental autoimmune encephalomyelitis; EPA, eicosapentaenoic acid; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; SGK-1, serum/glucocorticoid kinase 1</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>In a cohort of 2,087 MS patients, a general healthy diet (based on fruit/vegetable, fat, meat, and dairy consumption) was associated with better clinical scores (<xref ref-type="bibr" rid="B138">138</xref>). Therapeutically, two studies have shown effect of a general healthy diet (low intake of saturated fatty acid, sugar, coffee, alcohol, and high intake of vegetables, fruits, fish and whole grain products) on MS clinical scores when combined with supplementation of oils rich in Ω-6 or Ω-3 fatty acids (<xref ref-type="bibr" rid="B139">139</xref>). Of note, one of these studies also supplemented multiple vitamins including vitamin A, B, D, and E (<xref ref-type="bibr" rid="B140">140</xref>). Since these studies used multiple dietary components as intervention, it is hard to determine which part of the intervention exerted the beneficial effects. A difference in fat consumption may be responsible, since a third study found that reduced fat intake supplemented with Ω-3 fatty acids reduces MS clinical scores (<xref ref-type="bibr" rid="B127">127</xref>). It is noteworthy that the abovementioned studies related results to baseline measurements instead of a control group. Because dietary studies in MS can hardly be blinded and patients in the control groups have little incentive to complete a study, control groups have high dropout rates. Efforts are now being made to develop study designs that increase the participation of patients in control groups and to test if an observation period prior to a test diet can serve as a control group (<xref ref-type="bibr" rid="B149">149</xref>). Multiple studies are currently listed on <uri xlink:href="http://www.clinicaltrials.gov" xlink:type="simple">www.clinicaltrials.gov</uri> as recruiting or ongoing, including studies testing diets such as ketogenic, low sodium, low saturated fat, caloric restriction, and a variation of Paleolithic diet (low grain, high vegetables). These studies should provide additional insight into which compounds may be responsible for the positive effects of a generally healthy diet. Preliminary results of oral treatment with propionic acid are promising. Healthy individuals and patients were treated with propionic acid, which increased T<sub>reg</sub> frequency and reduced T<sub>h17</sub> frequency in both groups without any side effects; only an abstract of this study is available (<xref ref-type="bibr" rid="B136">136</xref>).</p>
</sec>
<sec id="S12">
<title>Methods to Manipulate Gut Microbiota for Therapeutic Purposes</title>
<p>Current evidence suggests that MS patients may have a different gut microbiota composition compared to healthy individuals and that gut microbiota may affect the relapse rate (see Table <xref ref-type="table" rid="T3">3</xref>). If these results will be verified in larger studies, it would be interesting to test whether manipulation of the gut microbiota of MS patients induces immunosuppression. Multiple approaches can be used to manipulate the gut microbiota (see Box <xref ref-type="boxed-text" rid="BX3">3</xref>). Probiotics involve the treatment with live microorganisms that are absent or present in too low abundance in the host. In this way, bacteria that induce immunosuppression can be introduced in patients. Probiotics are already being used in intestinal diseases such as IBD or antibiotic-associated diarrhea (<xref ref-type="bibr" rid="B17">17</xref>). Prebiotics are food ingredients with which gut microbiota may be modified. Resistant starches, which can reach the colon before being metabolized, alter the gut microbiota and have been associated with increased butyrate production. Additionally, fibers can be fermented by gut microbiota that produce SCFA. However, the effect of prebiotics depends on microbial strains that are already present in the host. Therefore, high individual variation and a large number of non-responders are seen (<xref ref-type="bibr" rid="B150">150</xref>). Probiotics and prebiotics can also be used in conjunction, i.e., as synbiotic, to augment their individual effectiveness. The probiotics part introduces new strains, while the prebiotic part synergistically increases the efficacy of the introduced species due to increased survival, competition, or metabolic activity (<xref ref-type="bibr" rid="B150">150</xref>). Antibiotics can be used to remove or suppress unwanted, immunogenic strains from the gut microbiota. A downside of antibiotic treatment is that multiple strains are targeted and beneficial bacteria may also be depleted. This increases the risk of opportunistic infections. Moreover, in mice, vancomycin treatment disrupts complex carbohydrate fermentation and leads to reduced concentrations of SCFA, including butyrate and propionic acid (<xref ref-type="bibr" rid="B151">151</xref>). Phages may be employed for more specific targeting of immunogenic parts of the gut microbiota. In this way, beneficial bacteria remain untouched and immunosuppression may still occur. Phages may also be used to increase the competitiveness of strains that need to be introduced. However, phage therapy still requires more research before it can be implemented, as there is limited evidence of efficacy in human clinical trials (<xref ref-type="bibr" rid="B152">152</xref>). Fecal microbiota transplantation involves the administration of a liquid filtrate of a healthy person’s stool to a diseased recipient. In this way, the recipient gut microbiota can be modulated to resemble the gut microbiota of the donor. New strains may be introduced by the transplantation, and through competition and possibly cross talk between gut flora and the immune system, excessive strains may be reduced and dysbiosis could be normalized. Fecal microbiota transplantation has been effective in small randomized controlled trials for the treatment of recurrent <italic>Clostridium difficile</italic> infection. Based on these successes, clinical trials are now being done to investigate the efficacy of fecal microbiota transplantation in IBDs (<xref ref-type="bibr" rid="B153">153</xref>). Fecal microbiota transplantation may be a relatively safe option for restoration of a healthy microbiome in MS patients. Instead of manipulating microbiota, microbial products that induce immunosuppression may also be used for therapeutic purposes. Chemical alterations may have to be made to make sure that the compounds reach their site of action and act through their intended mechanism. SCFA are produced by bacteria in the colon, but when orally administered, a large proportion of SCFA are thought to be absorbed in the small intestine (<xref ref-type="bibr" rid="B100">100</xref>). Therefore, dosage and kinetic studies will have to point out how optimal use can be made of these products. The advantage of bacterial compounds over live bacterial species is that bacterial compounds can be dosed like any other drug, while live bacterial species are affected by colonization and may therefore lead to variable interindividual effects (<xref ref-type="bibr" rid="B37">37</xref>).</p>
<boxed-text id="BX3" position="float">
<label>Box 3</label>
<caption>
<title>Methods to alter or use microbiota as a therapeutic intervention.</title>
</caption>
<p><italic>Probiotics</italic> can be used to introduce strains that are missing in hosts. Since multiple sclerosis (MS) patients have reduced butyrate producing strains in their gut flora, these strains may be restored using probiotics.</p>
<p><italic>Prebiotics</italic> can be used to enrich strains that are deficiently present in the hosts. Resistant starches have been associated with increased butyrate production. Additionally, fibers can be fermented by gut microbiota which produce SCFA. The effect of prebiotics is dependent on microbial strains that are already present in the host. Therefore, high individual variation and a large number of non-responders are seen (<xref ref-type="bibr" rid="B150">150</xref>).</p>
<p><italic>Synbiotics</italic> contain a mixture of probiotics and prebiotics. This mixture introduces new strains while synergistically increasing their effectiveness due to increased survival, competition, or metabolic activity of the introduced strain (<xref ref-type="bibr" rid="B150">150</xref>).</p>
<p><italic>Antibiotics</italic> can be used to reduce unwanted strains in the gut microbiota. However, the effect of antibiotics is often very broad and targeting many strains at once also depletes beneficial bacteria, including short-chain fatty acids (SCFA)-producing bacteria (<xref ref-type="bibr" rid="B151">151</xref>).</p>
<p><italic>Phage therapy</italic> has the key advantage that it can be used to selectively reduce strains of bacteria, but is not yet in clinical use (<xref ref-type="bibr" rid="B152">152</xref>). In the future, phage therapy may specifically target pro-inflammatory bacteria that are increased in MS patients, while beneficial strains remain untouched.</p>
<p><italic>Fecal microbiota transplantation</italic> can be used in patients who have a dysbiosis to make their gut microbiota composition more closely resemble the composition of a healthy donor. Strains that are deficient in patients with a dysbiosis can be induced in the recipient using fecal microbiota transplantation, while excessive strains may be reduced through competition and possibly cross talk between gut flora and the immune system (<xref ref-type="bibr" rid="B153">153</xref>).</p>
<p><italic>Microbial products</italic> such as polysaccharide A (PSA) or SCFA may be administered to induce an anti-inflammatory response in the gut. Chemical alterations may be needed to promote therapeutic efficacy and dosage/kinetic studies will need to elucidate how to best use these products (<xref ref-type="bibr" rid="B100">100</xref>).</p>
<p><italic>Dietary</italic> interventions such as SCFA, Ω-3/6 fatty acid, vitamin, or trace element supplementation, reduced salt intake or caloric restriction may also be used to reduce MS.</p>
</boxed-text>
</sec>
<sec id="S13">
<title>Conclusion and Future Directions</title>
<p>This review shows that many different microbial species and dietary interventions affect EAE disease expression and differences in gut microbiota between MS patients and healthy individuals may exist. Therefore, altering the gut microbiota of MS patients, possibly through dietary interventions is a potential therapeutic aim. Thus far, multiple small studies found that SCFA producing bacteria are reduced in patients with MS, and the PSA producing bacterium <italic>B. fragilis</italic> may also be reduced although <italic>B. fragilis</italic> is only found differently present in the gut by one study. Potentially pro-inflammatory <italic>Methanobrevibacter</italic> and <italic>Enterobacteriaceae</italic> may be increased in patients with MS. In addition, small studies have tried to determine if a causal relationship exists between gut microbiota and MS severity or immune responses. To determine if the results found in small studies are true and to determine if a causal relationship exists, controlled, prospective studies are eagerly awaited. Because it is relatively easy to frequently collect stool samples, it is feasible to analyze a few 100 samples of MS patients. Of these patients, clinical data need to be gathered, such as which treatments they are on, when they have relapses, as well as immunological data such as the frequency of T cell subsets and their cytokine production. In this way, the effects of vitamin D, glatiramer acetate, and other treatments on gut microbiota can be assessed, and it will be possible to determine whether a causal relationship exists between microbiota of MS patients and their immune response in relation to disease progression.</p>
<p>We also propose to collect mucosa biopsies to investigate the contribution of mucosa-associated bacterial species in MS. Thus far, all studies on gut microbiota in MS patients used fecal samples, which focus on luminal microbiota. Therefore, differences in mucosa-associated species may have been left undetected. Comparing intestinal biopsies of MS patients with healthy individuals may show differences, which could be additional targets for treatment. Geva-Zatorsky et al. have recently monocolonized gnotobiotic mice with one of 53 different bacterial species and assessed their immunomodulatory effects. Even though the effects of bacteria may be different in SPF or conventionally housed mice, this does provide additional immunosuppressive species which may be combined to rationally develop probiotic mixtures (<xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>In the case that species that worsen or improve MS will be identified, the gut microbiota of MS patients may be modified for therapeutic benefit. This may be achieved by using probiotics, prebiotics, or a mixture of these two: synbiotics. The role of viruses in this process needs deeper investigation. As viruses can greatly influence the bacterial diversity, phage therapy may be used in conjunction with pre-, pro-, or symbiotic mixtures to reduce competitiveness of microbiota that are already present and increase colonization of introduced microbiota. These may also be used to reduce the abundance of unwanted microbial species. An already used and relatively safe option for altering the gut microbiota is fecal microbiota transplantation. The gut microbiota of MS patients may be restored with fecal microbiota transplantation to resemble the gut microbiota of healthy individuals.</p>
<p>An alternative for restoration of the gut microbiota of patients is treatment with bacterial products or dietary components that may dampen immune responses, such as purified PSA or SCFA. PSA is effective in EAE models through well-known mechanisms (<xref ref-type="bibr" rid="B99">99</xref>), and <italic>in vitro</italic> studies indicate that these results may translate well into humans (<xref ref-type="bibr" rid="B116">116</xref>). Therefore, it would be interesting to investigate if PSA would be equally effective in MS patients. Preliminary results of treatment with the dietary component propionic acid in MS patients are promising, as it shows immunological efficacy without safety concerns (<xref ref-type="bibr" rid="B136">136</xref>). This makes it a very promising therapeutic that needs to be tested in controlled clinical trials. The efficacy of vitamin D supplementation and reduced salt intake will also need to be tested in large randomized controlled trials.</p>
<p>In conclusion, gut microbiota and dietary interventions are promising treatments for MS, but there are still many questions that need to be investigated before we can conclude which bacterial species and which dietary components play a role in MS pathogenesis and before it will be possible to selectively target detrimental species as a treatment in MS patients.</p>
</sec>
<sec id="S14">
<title>Author Contributions</title>
<p>All the authors developed tables, boxes, and figures. WH prepared and revised the manuscript. BH wrote part of the EAE/MS paragraphs. JL and BH critically reviewed the different versions of the manuscript and provided comments and additional research articles.</p>
</sec>
<sec id="S15">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>The authors thank Mrs. Francesca van Hassel for the artwork and the Dutch MS Research Foundation for ongoing support, including a program grant to the MS Center Noord Nederland.</p>
</ack>
<sec id="S16">
<title>Abbreviations</title>
<p>ADCC, antibody-dependent cell-mediated cytotoxicity; AHR, aryl hydrocarbon receptor; APC, antigen presenting cells; ATP, adenosine 5′-triphosphate; CDC, complement-dependent cytotoxicity; CFA, complete Freund’s adjuvant; CNS, central nervous system; CRISPR, clustered regularly interspaced short palindromic repeats; DHA, docosahexaenoic acid; EAE, experimental autoimmune encephalomyelitis; EDSS, expanded disability status scale; EPA, eicosapentaenoic acid; FDC, follicular dendritic cells; FICZ, 6-formylindolo[3-2b]carbazole; GALT, gut-associated lymphoid tissue; GF, germfree; IBD, inflammatory bowel disease; IEL, intraepithelial lymphocytes; ILC, innate lymphoid cells; iNKT, invariant natural killer T cells; ITE 2-(1′H-indole-3′carbonyl)-thiazole-4-carboxylic acid methyl ester; KCV, kanamycin, colistin, and vancomycin; LCFA, long-chain fatty acids; MAIT, mucosa-associated invariant T; MAM, microbial anti-inflammatory molecule; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; MS, multiple sclerosis; ODC, oligodendrocyte; PGN, peptidoglycan; PLP, proteolipid protein; PP, primary progressive; PSA, polysaccharide A; RR, relapsing remitting; SCFA, short-chain fatty acids; SFB, segmented filamentous bacteria; SGK-1, serum/glucocorticoid kinase 1; SP, secondary progressive; SPF, specific pathogen-free; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TNF, tumor necrosis factor.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mielcarz</surname><given-names>DW</given-names></name><name><surname>Kasper</surname><given-names>LH</given-names></name></person-group>
<article-title>The gut microbiome in multiple sclerosis</article-title>.<source/>Curr Treat Options Neurol (<year>2015</year>) <volume>17</volume>:<fpage>4</fpage><pub-id pub-id-type="doi">10.1007/s11940-015-0344-7</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dendrou</surname><given-names>CA</given-names></name><name><surname>Fugger</surname><given-names>L</given-names></name><name><surname>Friese</surname><given-names>MA</given-names></name></person-group>. <article-title>Immunopathology of multiple sclerosis</article-title>. <source/>Nat Rev Immunol (<year>2015</year>) <volume>15</volume>:<fpage>545</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1038/nri3871</pub-id><pub-id pub-id-type="pmid">26250739</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carding</surname><given-names>S</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name><name><surname>Vipond</surname><given-names>DT</given-names></name><name><surname>Corfe</surname><given-names>BM</given-names></name><name><surname>Owen</surname><given-names>LJ</given-names></name></person-group>. <article-title>Dysbiosis of the gut microbiota in disease</article-title>. <source/>Microb Ecol Health Dis (<year>2015</year>) <volume>26</volume>:<fpage>26191</fpage>.<pub-id pub-id-type="doi">10.3402/mehd.v26.26191</pub-id><pub-id pub-id-type="pmid">25651997</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigoriadis</surname><given-names>N</given-names></name><name><surname>van Pesch</surname><given-names>V</given-names></name></person-group>
<article-title>A basic overview of multiple sclerosis immunopathology</article-title>. <source/>Eur J Neurol (<year>2015</year>) <volume>22</volume>:<fpage>S2</fpage><pub-id pub-id-type="doi">10.1111/ene.12798</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dusseaux</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Serriari</surname><given-names>N</given-names></name><name><surname>Peguillet</surname><given-names>I</given-names></name><name><surname>Premel</surname><given-names>V</given-names></name><name><surname>Louis</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Human MAIT cells are xenobiotic resistant, tissue-targeted, CD161hi IL-17 secreting T cells</article-title>. <source/>Blood (<year>2011</year>) <volume>117</volume>:<fpage>1250</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2010-08-303339</pub-id><pub-id pub-id-type="pmid">21084709</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Losy</surname><given-names>J</given-names></name><name><surname>Niezgoda</surname><given-names>A</given-names></name></person-group>. <article-title>IL-18 in patients with multiple sclerosis</article-title>. <source/>Acta Neurol Scand (<year>2001</year>) <volume>104</volume>:<fpage>171</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1034/j.1600-0404.2001.00356.x</pub-id><pub-id pub-id-type="pmid">11551238</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willing</surname><given-names>A</given-names></name><name><surname>Leach</surname><given-names>OA</given-names></name><name><surname>Ufer</surname><given-names>F</given-names></name><name><surname>Attfield</surname><given-names>KE</given-names></name><name><surname>Steinbach</surname><given-names>K</given-names></name><name><surname>Kursawe</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>CD8+ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis</article-title>. <source/>Eur J Immunol (<year>2014</year>) <volume>44</volume>:<fpage>3119</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201344160</pub-id><pub-id pub-id-type="pmid">25043505</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrahamsson</surname><given-names>SV</given-names></name><name><surname>Angelini</surname><given-names>DF</given-names></name><name><surname>Dubinsky</surname><given-names>AN</given-names></name><name><surname>Morel</surname><given-names>E</given-names></name><name><surname>Oh</surname><given-names>U</given-names></name><name><surname>Jones</surname><given-names>JL</given-names></name><etal></etal></person-group>
<article-title>Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis</article-title>. <source/>Brain (<year>2013</year>) <volume>136</volume>:<fpage>2888</fpage>–<lpage>903</lpage>.<pub-id pub-id-type="doi">10.1093/brain/awt182</pub-id><pub-id pub-id-type="pmid">23864273</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>JN</given-names></name><name><surname>Yaari</surname><given-names>G</given-names></name><name><surname>Vander Heiden</surname><given-names>JA</given-names></name><name><surname>Church</surname><given-names>G</given-names></name><name><surname>Donahue</surname><given-names>WF</given-names></name><name><surname>Hintzen</surname><given-names>RQ</given-names></name><etal></etal></person-group>
<article-title>B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes</article-title>. <source/>Sci Transl Med (<year>2014</year>) <volume>6</volume>:<fpage>248</fpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.3008879</pub-id><pub-id pub-id-type="pmid">25100741</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goverman</surname><given-names>J</given-names></name></person-group>. <article-title>Autoimmune T cell responses in the central nervous system</article-title>. <source/>Nat Rev Immunol (<year>2009</year>) <volume>9</volume>:<fpage>393</fpage>–<lpage>407</lpage>.<pub-id pub-id-type="doi">10.1038/nri2550</pub-id><pub-id pub-id-type="pmid">19444307</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhargava</surname><given-names>P</given-names></name><name><surname>Mowry</surname><given-names>EM</given-names></name></person-group>
<article-title>Gut microbiome and multiple sclerosis</article-title>. <source/>Curr Neurol Neurosci Rep (<year>2014</year>) <volume>14</volume>:<fpage>10</fpage><pub-id pub-id-type="doi">10.1007/s11910-014-0492-2</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>X</given-names></name><name><surname>Huttenhower</surname><given-names>C</given-names></name></person-group>
<article-title>Chapter 12: human microbiome analysis</article-title>.<source/>PLoS Comput Biol (<year>2012</year>) <volume>8</volume>:<fpage>12</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002808</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glenn</surname><given-names>JD</given-names></name><name><surname>Mowry</surname><given-names>EM</given-names></name></person-group>. <article-title>Emerging concepts on the gut microbiome and multiple sclerosis</article-title>. <source/>J Interferon Cytokine Res (<year>2016</year>) <volume>36</volume>:<fpage>347</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1089/jir.2015.0177</pub-id><pub-id pub-id-type="pmid">27145057</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>J</given-names></name></person-group>. <article-title>Murine gut microbiota – diet trumps genes</article-title>. <source/>Cell Host Microbe (<year>2015</year>) <volume>17</volume>:<fpage>3</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.chom.2014.12.004</pub-id><pub-id pub-id-type="pmid">25590753</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>GP</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Mazmanian</surname><given-names>SK</given-names></name></person-group>
<article-title>Gut biogeography of the bacterial microbiota</article-title>. <source/>Nat Rev Microbiol (<year>2015</year>) <volume>14</volume>:<fpage>20</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1038/nrmicro3552</pub-id><pub-id pub-id-type="pmid">26499895</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quigley</surname><given-names>EM</given-names></name></person-group>
<article-title>Gut bacteria in health and disease</article-title>. <source/>Gastroenterol Hepatol (<year>2013</year>) <volume>9</volume>:<fpage>560</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jandhyala</surname><given-names>SM</given-names></name><name><surname>Talukdar</surname><given-names>R</given-names></name><name><surname>Subramanyam</surname><given-names>C</given-names></name><name><surname>Vuyyuru</surname><given-names>H</given-names></name><name><surname>Sasikala</surname><given-names>M</given-names></name><name><surname>Negeshwar Reddy</surname><given-names>D</given-names></name></person-group>
<article-title>Role of the normal gut microbiota</article-title>. <source/>World J Gastroenterol (<year>2015</year>) <volume>21</volume>:<fpage>8836</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="doi">10.3748/wjg.v21.i29.8787</pub-id><pub-id pub-id-type="pmid">26269673</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubinak</surname><given-names>JL</given-names></name><name><surname>Round</surname><given-names>JL</given-names></name></person-group>. <article-title>Do antibodies select a healthy microbiota?</article-title>
<source/>Nat Rev Immunol (<year>2016</year>) <volume>16</volume>:<fpage>767</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1038/nri.2016.114</pub-id><pub-id pub-id-type="pmid">27818504</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>MEV</given-names></name><name><surname>Sjövall</surname><given-names>H</given-names></name><name><surname>Hansson</surname><given-names>GC</given-names></name></person-group>. <article-title>The gastrointestinal mucus system in health and disease</article-title>. <source/>Nat Rev Gastroenterol Hepatol (<year>2013</year>) <volume>10</volume>:<fpage>352</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1038/nrgastro.2013.35</pub-id><pub-id pub-id-type="pmid">23478383</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergström</surname><given-names>JH</given-names></name><name><surname>Birchenough</surname><given-names>GMH</given-names></name><name><surname>Katona</surname><given-names>G</given-names></name><name><surname>Schroeder</surname><given-names>BO</given-names></name><name><surname>Schütte</surname><given-names>A</given-names></name><name><surname>Ermund</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Gram-positive bacteria are held at a distance in the colon mucus by the lectin-like protein ZG16</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2016</year>) <volume>113</volume>:<fpage>13833</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1611400113</pub-id><pub-id pub-id-type="pmid">27849619</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>MS</given-names></name><name><surname>Seekatz</surname><given-names>AM</given-names></name><name><surname>Koropatkin</surname><given-names>NM</given-names></name><name><surname>Kamada</surname><given-names>N</given-names></name><name><surname>Hickey</surname><given-names>CA</given-names></name><name><surname>Wolter</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility</article-title>. <source/>Cell (<year>2016</year>) <volume>167</volume>:<fpage>1339</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2016.10.043</pub-id><pub-id pub-id-type="pmid">27863247</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matarazzo</surname><given-names>F</given-names></name><name><surname>Ribeiro</surname><given-names>AC</given-names></name><name><surname>Faveri</surname><given-names>M</given-names></name><name><surname>Taddei</surname><given-names>C</given-names></name><name><surname>Martinez</surname><given-names>MB</given-names></name><name><surname>Mayer</surname><given-names>MPA</given-names></name></person-group>. <article-title>The domain archaea in human mucosal surfaces</article-title>. <source/>Clin Microbiol Infect (<year>2012</year>) <volume>18</volume>:<fpage>834</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1111/j.1469-0691.2012.03958.x</pub-id><pub-id pub-id-type="pmid">22827611</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>L</given-names></name><name><surname>Sprott</surname><given-names>GD</given-names></name></person-group>. <article-title>Archaeosome adjuvants: immunological capabilities and mechanism(s) of action</article-title>. <source/>Vaccine (<year>2008</year>) <volume>26</volume>:<fpage>2043</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.02.026</pub-id><pub-id pub-id-type="pmid">18343538</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>C</given-names></name><name><surname>Weidenbach</surname><given-names>K</given-names></name><name><surname>Gutsmann</surname><given-names>T</given-names></name><name><surname>Heine</surname><given-names>H</given-names></name><name><surname>Schmitz</surname><given-names>RA</given-names></name></person-group>. <article-title>The intestinal archaea <italic>Methanosphaera stadtmanae</italic> and <italic>Methanobrevibacter smithii</italic> activate human dendritic cells</article-title>. <source/>PLoS One (<year>2014</year>) <volume>9</volume>:<fpage>6</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0099411</pub-id><pub-id pub-id-type="pmid">24915454</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manrique</surname><given-names>P</given-names></name><name><surname>Bolduc</surname><given-names>B</given-names></name><name><surname>Walk</surname><given-names>ST</given-names></name><name><surname>van der Oost</surname><given-names>J</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name><name><surname>Young</surname><given-names>MJ</given-names></name></person-group>
<article-title>Healthy human gut phageome</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2016</year>) <volume>113</volume>:<fpage>10400</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1601060113</pub-id><pub-id pub-id-type="pmid">27573828</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desbonnet</surname><given-names>L</given-names></name><name><surname>Clarke</surname><given-names>G</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name><name><surname>Dinan</surname><given-names>TG</given-names></name><name><surname>Cryan</surname><given-names>JF</given-names></name></person-group>
<article-title>Microbiota is essential for social development in the mouse</article-title>. <source/>Mol Psychiatry (<year>2014</year>) <volume>19</volume>:<fpage>2</fpage><pub-id pub-id-type="doi">10.1038/mp.2013.65</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaral</surname><given-names>FA</given-names></name><name><surname>Sachs</surname><given-names>D</given-names></name><name><surname>Costa</surname><given-names>VV</given-names></name><name><surname>Fagundes</surname><given-names>CT</given-names></name><name><surname>Cisalpino</surname><given-names>D</given-names></name><name><surname>Cunha</surname><given-names>TM</given-names></name><etal></etal></person-group>
<article-title>Commensal microbiota is fundamental for the development of inflammatory pain</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2008</year>) <volume>105</volume>:<fpage>2193</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0711891105</pub-id><pub-id pub-id-type="pmid">18268332</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desbonnet</surname><given-names>L</given-names></name><name><surname>Garrett</surname><given-names>L</given-names></name><name><surname>Clarke</surname><given-names>G</given-names></name><name><surname>Kiely</surname><given-names>B</given-names></name><name><surname>Cryan</surname><given-names>JF</given-names></name><name><surname>Dinan</surname><given-names>TG</given-names></name></person-group>. <article-title>Effects of the probiotic <italic>Bifidobacterium infantis</italic> in the maternal separation model of depression</article-title>. <source/>Neuroscience (<year>2010</year>) <volume>170</volume>:<fpage>1179</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.08.005</pub-id><pub-id pub-id-type="pmid">20696216</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neufeld</surname><given-names>K-AM</given-names></name><name><surname>Kang</surname><given-names>N</given-names></name><name><surname>Bienenstock</surname><given-names>J</given-names></name><name><surname>Foster</surname><given-names>JA</given-names></name></person-group>. <article-title>Effects of intestinal microbiota on anxiety-like behavior</article-title>. <source/>Commun Integr Biol (<year>2011</year>) <volume>4</volume>:<fpage>492</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.4161/cib.4.4.15702</pub-id><pub-id pub-id-type="pmid">21966581</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>TC</given-names></name><name><surname>Olson</surname><given-names>CA</given-names></name><name><surname>Hsiao</surname><given-names>EY</given-names></name></person-group>. <article-title>Interactions between the microbiota, immune and nervous systems in health and disease</article-title>. <source/>Nat Neurosci (<year>2017</year>) <volume>20</volume>:<fpage>145</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1038/nn.4476</pub-id><pub-id pub-id-type="pmid">28092661</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braniste</surname><given-names>V</given-names></name><name><surname>Al-Asmakh</surname><given-names>M</given-names></name><name><surname>Kowal</surname><given-names>C</given-names></name><name><surname>Anuar</surname><given-names>F</given-names></name><name><surname>Abbaspour</surname><given-names>A</given-names></name><name><surname>Tóth</surname><given-names>M</given-names></name></person-group>. <article-title>The gut microbiota influences blood-brain barrier permeability in mice</article-title>. <source/>Sci Transl Med (<year>2014</year>) <volume>19</volume>:<fpage>6</fpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.3009759</pub-id><pub-id pub-id-type="pmid">25411471</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erny</surname><given-names>D</given-names></name><name><surname>Hrabě de Angelis</surname><given-names>AL</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name></person-group>
<article-title>Communicating systems in the body: how microbiota and microglia cooperate</article-title>. <source/>Immunology (<year>2016</year>) <volume>150</volume>:<fpage>7</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1111/imm.12645</pub-id><pub-id pub-id-type="pmid">27392533</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolig</surname><given-names>AS</given-names></name><name><surname>Mittge</surname><given-names>EK</given-names></name><name><surname>Ganz</surname><given-names>J</given-names></name><name><surname>Troll</surname><given-names>JV</given-names></name><name><surname>Melancon</surname><given-names>E</given-names></name><name><surname>Wiles</surname><given-names>TJ</given-names></name><etal></etal></person-group>
<article-title>The enteric nervous system promotes intestinal health by constraining microbiota composition</article-title>. <source/>PLoS Biol (<year>2017</year>) <volume>15</volume>:<fpage>2</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.2000689</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branton</surname><given-names>WG</given-names></name><name><surname>Lu</surname><given-names>JQ</given-names></name><name><surname>Surette</surname><given-names>MG</given-names></name><name><surname>Holt</surname><given-names>RA</given-names></name><name><surname>Lind</surname><given-names>J</given-names></name><name><surname>Laman</surname><given-names>JD</given-names></name><etal></etal></person-group>
<article-title>Brain microbiota disruption within inflammatory demyelinating lesions in multiple sclerosis</article-title>. <source/>Sci Rep (<year>2016</year>) <volume>6</volume>:<fpage>37344</fpage>.<pub-id pub-id-type="doi">10.1038/srep37344</pub-id><pub-id pub-id-type="pmid">27892518</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arentsen</surname><given-names>T</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Gkotzis</surname><given-names>S</given-names></name><name><surname>Femenia</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Udekwu</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior</article-title>. <source/>Mol Psychiatry (<year>2017</year>) <volume>22</volume>:<fpage>257</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1038/mp.2016.182</pub-id><pub-id pub-id-type="pmid">27843150</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wekerle</surname><given-names>H</given-names></name><name><surname>Berer</surname><given-names>K</given-names></name><name><surname>Krishnamoorthy</surname><given-names>G</given-names></name></person-group>. <article-title>Remote control-triggering of brain autoimmune disease in the gut</article-title>. <source/>Curr Opin Immunol (<year>2013</year>) <volume>25</volume>:<fpage>683</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2013.09.009</pub-id><pub-id pub-id-type="pmid">24161654</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geva-Zatorsky</surname><given-names>N</given-names></name><name><surname>Sefik</surname><given-names>E</given-names></name><name><surname>Kua</surname><given-names>L</given-names></name><name><surname>Pasman</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>TG</given-names></name><name><surname>Ortiz-Lopez</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Mining the human gut microbiota for immunomodulatory organisms</article-title>. <source/>Cell (<year>2017</year>) <volume>168</volume>:<fpage>928</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2017.01.022</pub-id><pub-id pub-id-type="pmid">28215708</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>PJ</given-names></name><name><surname>Bending</surname><given-names>D</given-names></name><name><surname>Fouser</surname><given-names>LA</given-names></name><name><surname>Wright</surname><given-names>JF</given-names></name><name><surname>Stockinger</surname><given-names>B</given-names></name><name><surname>Cooke</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Th17 cell plasticity in <italic>Helicobacter hepaticus</italic>-induced intestinal inflammation</article-title>. <source/>Mucosal Immunol (<year>2013</year>) <volume>6</volume>:<fpage>6</fpage><pub-id pub-id-type="doi">10.1038/mi.2013.11</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pescovitz</surname><given-names>MD</given-names></name><name><surname>Torgerson</surname><given-names>TR</given-names></name><name><surname>Ochs</surname><given-names>HD</given-names></name><name><surname>Ocheltree</surname><given-names>E</given-names></name><name><surname>McGee</surname><given-names>P</given-names></name><name><surname>Krause-Steinrauf</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Effect of rituximab on human <italic>in vivo</italic> antibody immune responses</article-title>. <source/>J Allergy Clin Immunol (<year>2011</year>) <volume>128</volume>:<fpage>1295</fpage>–<lpage>302</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2011.08.008</pub-id><pub-id pub-id-type="pmid">21908031</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>AS</given-names></name><name><surname>Kaido</surname><given-names>S</given-names></name><name><surname>Carrier</surname><given-names>E</given-names></name></person-group>. <article-title>Immunological factors that affect the <italic>in vivo</italic> fate of T7 phage in the mouse</article-title>. <source/>J Virol Methods (<year>2004</year>) <volume>115</volume>:<fpage>99</fpage>–<lpage>104</lpage>.<pub-id pub-id-type="doi">10.1016/j.jviromet.2003.09.009</pub-id><pub-id pub-id-type="pmid">14656466</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Górski</surname><given-names>A</given-names></name><name><surname>Miedzybrodski</surname><given-names>R</given-names></name><name><surname>Borysowski</surname><given-names>J</given-names></name><name><surname>Dabrowska</surname><given-names>K</given-names></name><name><surname>Wierzbicki</surname><given-names>P</given-names></name><name><surname>Ohams</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Phage as a modulator of immune responses: practical implications for phage therapy</article-title>. <source/>Adv Virus Res (<year>2012</year>) <volume>83</volume>:<fpage>41</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1016/B978-0-12-394438-2.00002-5</pub-id><pub-id pub-id-type="pmid">22748808</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group>. <article-title>Animal models of multiple sclerosis: the good, the bad and the bottom line</article-title>. <source/>Nat Neurosci (<year>2012</year>) <volume>15</volume>:<fpage>1074</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nn.3168</pub-id><pub-id pub-id-type="pmid">22837037</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>SB</given-names></name><name><surname>Pierson</surname><given-names>ER</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Goverman</surname><given-names>JM</given-names></name></person-group>. <article-title>Modeling the heterogeneity of multiple sclerosis in animals</article-title>. <source/>Trends Immunol (<year>2013</year>) <volume>34</volume>:<fpage>410</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2013.04.006</pub-id><pub-id pub-id-type="pmid">23707039</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Procaccini</surname><given-names>C</given-names></name><name><surname>De Rosa</surname><given-names>V</given-names></name><name><surname>Pucino</surname><given-names>V</given-names></name><name><surname>Formisano</surname><given-names>L</given-names></name><name><surname>Matarese</surname><given-names>G</given-names></name></person-group>. <article-title>Animal models of multiple sclerosis</article-title>. <source/>Eur J Pharmacol (<year>2015</year>) <volume>759</volume>:<fpage>182</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejphar.2015.03.042</pub-id><pub-id pub-id-type="pmid">25823807</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>’t Hart</surname><given-names>BA</given-names></name><name><surname>van Kooyk</surname><given-names>Y</given-names></name><name><surname>Geurts</surname><given-names>JJG</given-names></name><name><surname>Gran</surname><given-names>B</given-names></name></person-group>
<article-title>The primate autoimmune encephalomyelitis model; a bridge between mouse and man</article-title>. <source/>Ann Clin Transl Neurol (<year>2015</year>) <volume>2</volume>:<fpage>581</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1002/acn3.194</pub-id><pub-id pub-id-type="pmid">26000330</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goverman</surname><given-names>J</given-names></name><name><surname>Woods</surname><given-names>A</given-names></name><name><surname>Larson</surname><given-names>L</given-names></name><name><surname>Weiner</surname><given-names>LP</given-names></name><name><surname>Hood</surname><given-names>L</given-names></name><name><surname>Zaller</surname><given-names>DM</given-names></name></person-group>. <article-title>Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity</article-title>. <source/>Cell (<year>1993</year>) <volume>72</volume>:<fpage>551</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1016/0092-8674(93)90074-Z</pub-id><pub-id pub-id-type="pmid">7679952</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berer</surname><given-names>K</given-names></name><name><surname>Mues</surname><given-names>M</given-names></name><name><surname>Koutrolos</surname><given-names>M</given-names></name><name><surname>Rasbi</surname><given-names>ZA</given-names></name><name><surname>Boziki</surname><given-names>M</given-names></name><name><surname>Johner</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination</article-title>. <source/>Nature (<year>2011</year>) <volume>479</volume>:<fpage>538</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1038/nature10554</pub-id><pub-id pub-id-type="pmid">22031325</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YK</given-names></name><name><surname>Menezes</surname><given-names>JS</given-names></name><name><surname>Umesaki</surname><given-names>Y</given-names></name><name><surname>Mazmanian</surname><given-names>SK</given-names></name></person-group>. <article-title>Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2011</year>) <volume>108</volume>:<fpage>4615</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1000082107</pub-id><pub-id pub-id-type="pmid">20660719</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokote</surname><given-names>H</given-names></name><name><surname>Miyake</surname><given-names>S</given-names></name><name><surname>Croxford</surname><given-names>JL</given-names></name><name><surname>Oki</surname><given-names>S</given-names></name><name><surname>Mizusawa</surname><given-names>H</given-names></name></person-group>
<article-title>NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora</article-title>. <source/>Am J Pathol (<year>2008</year>) <volume>173</volume>:<fpage>1714</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="doi">10.2353/ajpath.2008.080622</pub-id><pub-id pub-id-type="pmid">18974295</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa-Repáraz</surname><given-names>J</given-names></name><name><surname>Mielcarz</surname><given-names>DW</given-names></name><name><surname>Ditrio</surname><given-names>LE</given-names></name><name><surname>Burroughs</surname><given-names>AR</given-names></name><name><surname>Foureau</surname><given-names>DM</given-names></name><name><surname>Hague-Begum</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis</article-title>. <source/>J Immunol (<year>2009</year>) <volume>183</volume>:<fpage>6041</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0900747</pub-id><pub-id pub-id-type="pmid">19841183</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa-Repáraz</surname><given-names>J</given-names></name><name><surname>Mielcarz</surname><given-names>DW</given-names></name><name><surname>Haque-Begum</surname><given-names>S</given-names></name><name><surname>Kasper</surname><given-names>LH</given-names></name></person-group>. <article-title>Induction of a regulatory B cell population in experimental allergic encephalomyelitis by alteration of the gut commensal microflora</article-title>. <source/>Gut Microbes (<year>2010</year>) <volume>1</volume>:<fpage>103</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.4161/gmic.1.2.11515</pub-id><pub-id pub-id-type="pmid">21326918</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa-Repáraz</surname><given-names>J</given-names></name><name><surname>Mielcarz</surname><given-names>DW</given-names></name><name><surname>Ditrio</surname><given-names>LE</given-names></name><name><surname>Burroughs</surname><given-names>AR</given-names></name><name><surname>Begum-Haque</surname><given-names>S</given-names></name><name><surname>Dasgupta</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Central nervous system demyelinating disease protection by the human commensal <italic>Bacteroides fragilis</italic> depends on polysaccharide A expression</article-title>. <source/>J Immunol (<year>2010</year>) <volume>185</volume>:<fpage>4101</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1001443</pub-id><pub-id pub-id-type="pmid">20817872</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezendam</surname><given-names>J</given-names></name><name><surname>de Klerk</surname><given-names>A</given-names></name><name><surname>Gremmer</surname><given-names>ER</given-names></name><name><surname>Van Loveren</surname><given-names>H</given-names></name></person-group>. <article-title>Effects of <italic>Bifidobacterium animalis</italic> administered during lactation on allergic and autoimmune responses in rodents</article-title>. <source/>Clin Exp Immunol (<year>2008</year>) <volume>154</volume>:<fpage>424</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2249.2008.03788.x</pub-id><pub-id pub-id-type="pmid">19037925</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavasani</surname><given-names>S</given-names></name><name><surname>Dzhambazov</surname><given-names>B</given-names></name><name><surname>Nouri</surname><given-names>M</given-names></name><name><surname>Fåk</surname><given-names>F</given-names></name><name><surname>Buske</surname><given-names>S</given-names></name><name><surname>Molin</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells</article-title>. <source/>PLoS One (<year>2010</year>) <volume>5</volume>:<fpage>2</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0009009</pub-id><pub-id pub-id-type="pmid">20126401</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takata</surname><given-names>K</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name><name><surname>Okuno</surname><given-names>T</given-names></name><name><surname>Moriya</surname><given-names>M</given-names></name><name><surname>Kohda</surname><given-names>T</given-names></name><name><surname>Honorat</surname><given-names>JA</given-names></name><etal></etal></person-group>
<article-title>The lactic acid bacterium <italic>Pediococcus acidilactici</italic> suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells</article-title>. <source/>PLoS One (<year>2011</year>) <volume>6</volume>:<fpage>11</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0027644</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maassen</surname><given-names>CBM</given-names></name><name><surname>Claassen</surname><given-names>E</given-names></name></person-group>. <article-title>Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity</article-title>. <source/>Vaccine (<year>2008</year>) <volume>26</volume>:<fpage>2056</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.02.035</pub-id><pub-id pub-id-type="pmid">18378048</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>GC</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Hwang</surname><given-names>W</given-names></name><name><surname>Jash</surname><given-names>A</given-names></name><name><surname>Sahoo</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response</article-title>. <source/>Clin Immunol (<year>2013</year>) <volume>146</volume>:<fpage>217</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2013.01.001</pub-id><pub-id pub-id-type="pmid">23416238</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezende</surname><given-names>RM</given-names></name><name><surname>Oliveira</surname><given-names>RP</given-names></name><name><surname>Medeiros</surname><given-names>SR</given-names></name><name><surname>Gomes-Santos</surname><given-names>AC</given-names></name><name><surname>Alves</surname><given-names>AC</given-names></name><name><surname>Loli</surname><given-names>FG</given-names></name><etal></etal></person-group>
<article-title>Hsp65-producing <italic>Lactococcus lactis</italic> prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells</article-title>. <source/>J Autoimmun (<year>2013</year>) <volume>40</volume>:<fpage>45</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2012.07.012</pub-id><pub-id pub-id-type="pmid">22939403</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa-Repáraz</surname><given-names>J</given-names></name><name><surname>Mielcarz</surname><given-names>DW</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Begum-Haque</surname><given-names>S</given-names></name><name><surname>Dasgupta</surname><given-names>S</given-names></name><name><surname>Kasper</surname><given-names>DL</given-names></name><etal></etal></person-group>
<article-title>A polysaccharide from the human commensal <italic>Bacteroides fragilis</italic> protects against CNS demyelinating disease</article-title>. <source/>Mucosal Immunol (<year>2010</year>) <volume>3</volume>:<fpage>487</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1038/mi.2010.29</pub-id><pub-id pub-id-type="pmid">20531465</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Telesford</surname><given-names>KM</given-names></name><name><surname>Ochoa-Repáraz</surname><given-names>J</given-names></name><name><surname>Haque-Begum</surname><given-names>S</given-names></name><name><surname>Christy</surname><given-names>M</given-names></name><name><surname>Kasper</surname><given-names>EJ</given-names></name><etal></etal></person-group>
<article-title>An intestinal commensal symbiosis factor controls neuroinflammation via TLR2-mediated CD39 signalling</article-title>. <source/>Nat Commun (<year>2014</year>) <volume>5</volume>:<fpage>4432</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1038/ncomms5432</pub-id><pub-id pub-id-type="pmid">25043484</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Begum-Haque</surname><given-names>S</given-names></name><name><surname>Telesford</surname><given-names>KM</given-names></name><name><surname>Ochoa-Repáraz</surname><given-names>J</given-names></name><name><surname>Christy</surname><given-names>M</given-names></name><name><surname>Kasper</surname><given-names>EJ</given-names></name><etal></etal></person-group>
<article-title>A commensal bacterial product elicits and modulates migratory capacity of CD39+ CD4 T regulatory subsets in the suppression of neuroinflammation</article-title>. <source/>Gut Microbes (<year>2014</year>) <volume>5</volume>:<fpage>552</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.4161/gmic.29797</pub-id><pub-id pub-id-type="pmid">25006655</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>A</given-names></name><name><surname>Miyake</surname><given-names>S</given-names></name><name><surname>Saga</surname><given-names>R</given-names></name><name><surname>Chiba</surname><given-names>A</given-names></name><name><surname>Mochizuki</surname><given-names>H</given-names></name><name><surname>Yamamura</surname><given-names>T</given-names></name></person-group>. <article-title>Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3</article-title>. <source/>Nat Commun (<year>2016</year>) <volume>7</volume>:<fpage>11639</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms11639</pub-id><pub-id pub-id-type="pmid">27198196</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maassen</surname><given-names>CBM</given-names></name><name><surname>Laman</surname><given-names>JD</given-names></name><name><surname>van Holten-Neelen</surname><given-names>C</given-names></name><name><surname>Hoogteijling</surname><given-names>L</given-names></name><name><surname>Groenewegen</surname><given-names>L</given-names></name><name><surname>Visser</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Reduced experimental autoimmune encephalomyelitis after intranasal and oral administration of recombinant lactobacilli expressing myelin antigens</article-title>. <source/>Vaccine (<year>2003</year>) <volume>21</volume>:<fpage>4685</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1016/S0264-410X(03)00522-X</pub-id><pub-id pub-id-type="pmid">14585676</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haghikia</surname><given-names>A</given-names></name><name><surname>Jörg</surname><given-names>S</given-names></name><name><surname>Duscha</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>J</given-names></name><name><surname>Manzel</surname><given-names>A</given-names></name><name><surname>Waschbisch</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine</article-title>. <source/>Immunity (<year>2015</year>) <volume>43</volume>:<fpage>817</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2015.09.007</pub-id><pub-id pub-id-type="pmid">26488817</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemire</surname><given-names>JM</given-names></name><name><surname>Archer</surname><given-names>DC</given-names></name></person-group>. <article-title>1,25-Dihydroxyvitamin D3 prevents the <italic>in vivo</italic> induction of murine experimental autoimmune encephalomyelitis</article-title>. <source/>J Clin Invest (<year>1991</year>) <volume>87</volume>:<fpage>1103</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1172/JCI115072</pub-id><pub-id pub-id-type="pmid">1705564</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantorna</surname><given-names>MT</given-names></name><name><surname>Hayes</surname><given-names>CE</given-names></name><name><surname>Deluca</surname><given-names>HF</given-names></name></person-group>
<article-title>1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis</article-title>. <source/>Proc Nat Acad Sci U S A (<year>1996</year>) <volume>93</volume>:<fpage>7861</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.93.15.7861</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spach</surname><given-names>KM</given-names></name><name><surname>Nashold</surname><given-names>FE</given-names></name><name><surname>Dittel</surname><given-names>BN</given-names></name><name><surname>Hayes</surname><given-names>CE</given-names></name></person-group>. <article-title>IL-10 signaling is essential for 1,25-dihydroxyvitamin D 3-mediated inhibition of experimental autoimmune encephalomyelitis</article-title>. <source/>J Immunol (<year>2006</year>) <volume>177</volume>:<fpage>6030</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.177.9.6030</pub-id><pub-id pub-id-type="pmid">17056528</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccio</surname><given-names>L</given-names></name><name><surname>Stark</surname><given-names>JL</given-names></name><name><surname>Cross</surname><given-names>AH</given-names></name></person-group>. <article-title>Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis</article-title>. <source/>J Leukoc Biol (<year>2008</year>) <volume>84</volume>:<fpage>940</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.0208133</pub-id><pub-id pub-id-type="pmid">18678605</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esquifino</surname><given-names>AI</given-names></name><name><surname>Cano</surname><given-names>P</given-names></name><name><surname>Jimenez-Ortega</surname><given-names>V</given-names></name><name><surname>Fernández-Mateos</surname><given-names>MP</given-names></name><name><surname>Cardinali</surname><given-names>DP</given-names></name></person-group>. <article-title>Immune response after experimental allergic encephalomyelitis in rats subjected to calorie restriction</article-title>. <source/>J Neuroinflammation (<year>2007</year>) <volume>4</volume>:<fpage>6</fpage>.<pub-id pub-id-type="doi">10.1186/1742-2094-4-6</pub-id><pub-id pub-id-type="pmid">17254325</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kafami</surname><given-names>L</given-names></name><name><surname>Raza</surname><given-names>M</given-names></name><name><surname>Razavi</surname><given-names>A</given-names></name><name><surname>Mirshafiey</surname><given-names>A</given-names></name><name><surname>Movahedian</surname><given-names>M</given-names></name><name><surname>Khorramizadeh</surname><given-names>MR</given-names></name></person-group>. <article-title>Intermittent feeding attenuates clinical course of experimental autoimmune encephalomyelitis in C57Bl/6 mice</article-title>. <source/>Avicenna J Med Biotechnol (<year>2010</year>) <volume>2</volume>:<fpage>47</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">23407146</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbige</surname><given-names>LS</given-names></name><name><surname>Layward</surname><given-names>L</given-names></name><name><surname>Morris-Downes</surname><given-names>MM</given-names></name><name><surname>Dumonde</surname><given-names>DC</given-names></name><name><surname>Armor</surname><given-names>S</given-names></name></person-group>
<article-title>The protective effects of omega-6 fatty acids in experimental autoimune encephalomyelitis (EAE) in relatino to transforming grwoth factor-beta 1 (TGF-b1) upregulation and increased prostaglandin E2 (PGE2) production</article-title>. <source/>Clin Exp Immunol (<year>2000</year>) <volume>122</volume>:<fpage>445</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01399.x</pub-id><pub-id pub-id-type="pmid">11122253</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbige</surname><given-names>LS</given-names></name><name><surname>Yeatman</surname><given-names>N</given-names></name><name><surname>Amor</surname><given-names>S</given-names></name><name><surname>Crawford</surname><given-names>MA</given-names></name></person-group>
<article-title>Prevention of experimental autoimmune encephalomyelitis in Lewis rats by a noval fungal source of gamma-linolenic acid</article-title>. <source/>Br J Nutr (<year>1995</year>) <volume>74</volume>:<fpage>701</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1079/BJN19950173</pub-id><pub-id pub-id-type="pmid">8541276</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>Jui-Hung</surname><given-names>Y</given-names></name><name><surname>Ganea</surname><given-names>D</given-names></name></person-group>
<article-title>Ducosahexanoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentation and suppresses experimental autoimmune encephalomyelitis</article-title>. <source/>Brain Behav Immun (<year>2011</year>) <volume>25</volume>:<fpage>872</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbi.2010.09.012</pub-id><pub-id pub-id-type="pmid">20854895</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unoda</surname><given-names>K</given-names></name><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Yamane</surname><given-names>K</given-names></name><name><surname>Hosokawa</surname><given-names>T</given-names></name><name><surname>Ishida</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Eicasapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis</article-title>. <source/>J Neuroimmunol (<year>2013</year>) <volume>256</volume>:<fpage>7</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1016/j.jneuroim.2012.12.003</pub-id><pub-id pub-id-type="pmid">23276800</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvati</surname><given-names>S</given-names></name><name><surname>Di Biase</surname><given-names>A</given-names></name><name><surname>Attorri</surname><given-names>L</given-names></name><name><surname>Di Benedetto</surname><given-names>R</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Lorenzini</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Ethyleicosapentaenoic acid ameliorates the clinical course of experimental allergic encephalomyelitis induced in dark agouti rats</article-title>. <source/>J Nutr Biochem (<year>2013</year>) <volume>24</volume>:<fpage>1645</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1016/j.jnutbio.2013.02.005</pub-id><pub-id pub-id-type="pmid">23642735</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Turner</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>FD</given-names></name><name><surname>Rho</surname><given-names>JM</given-names></name></person-group>. <article-title>Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis</article-title>. <source/>PLoS One (<year>2012</year>) <volume>7</volume>:<fpage>5</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0035476</pub-id><pub-id pub-id-type="pmid">22567104</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>IY</given-names></name><name><surname>Piccio</surname><given-names>L</given-names></name><name><surname>Childress</surname><given-names>P</given-names></name><name><surname>Bollman</surname><given-names>B</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Brandhorst</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms</article-title>. <source/>Cell Rep (<year>2016</year>) <volume>15</volume>:<fpage>2136</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.009</pub-id><pub-id pub-id-type="pmid">27239035</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jörg</surname><given-names>S</given-names></name><name><surname>Kissel</surname><given-names>J</given-names></name><name><surname>Manzel</surname><given-names>A</given-names></name><name><surname>Kleinewietfeld</surname><given-names>M</given-names></name><name><surname>Haghikia</surname><given-names>A</given-names></name><name><surname>Gold</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>High salt drives Th17 responses in experimental autoimmune encephalomyelitis without impacting myeloid dendritic cells</article-title>. <source/>Exp Neurol (<year>2016</year>) <volume>279</volume>:<fpage>212</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1016/j.expneurol.2016.03.010</pub-id><pub-id pub-id-type="pmid">26976739</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krementsov</surname><given-names>DN</given-names></name><name><surname>Casse</surname><given-names>LK</given-names></name><name><surname>Hickey</surname><given-names>WF</given-names></name><name><surname>Teuscher</surname><given-names>C</given-names></name></person-group>. <article-title>Exacerbation of autoimmune neuroinflammation by dietary sodium is genetically controlled and sex specific</article-title>. <source/>FASEB J (<year>2015</year>) <volume>29</volume>:<fpage>3446</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1096/fj.15-272542</pub-id><pub-id pub-id-type="pmid">25917331</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Yosef</surname><given-names>N</given-names></name><name><surname>Thalhamer</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Kishi</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>Induction of pathogenic Th17 cells by inducible salt sensing kinase SGK1</article-title>. <source/>Nature (<year>2013</year>) <volume>496</volume>:<fpage>513</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nature11984</pub-id><pub-id pub-id-type="pmid">23467085</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinewietfeld</surname><given-names>M</given-names></name><name><surname>Manzel</surname><given-names>A</given-names></name><name><surname>Titze</surname><given-names>J</given-names></name><name><surname>Kvakan</surname><given-names>H</given-names></name><name><surname>Yosef</surname><given-names>N</given-names></name><name><surname>Linker</surname><given-names>RA</given-names></name><etal></etal></person-group>
<article-title>Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells</article-title>. <source/>Nature (<year>2013</year>) <volume>496</volume>:<fpage>518</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1038/nature11868</pub-id><pub-id pub-id-type="pmid">23467095</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhoen</surname><given-names>M</given-names></name><name><surname>Hirota</surname><given-names>K</given-names></name><name><surname>Westendorf</surname><given-names>AM</given-names></name><name><surname>Buer</surname><given-names>J</given-names></name><name><surname>Dumoutier</surname><given-names>L</given-names></name><name><surname>Renauld</surname><given-names>JC</given-names></name><etal></etal></person-group>
<article-title>The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins</article-title>. <source/>Nature (<year>2008</year>) <volume>453</volume>:<fpage>106</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/nature06881</pub-id><pub-id pub-id-type="pmid">18362914</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintana</surname><given-names>FJ</given-names></name><name><surname>Basso</surname><given-names>AS</given-names></name><name><surname>Iglesias</surname><given-names>AH</given-names></name><name><surname>Korn</surname><given-names>T</given-names></name><name><surname>Farez</surname><given-names>MF</given-names></name><name><surname>Bettelli</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Control of Treg and Th17 cell differentiation by the aryl hydrocarbon receptor</article-title>. <source/>Nature (<year>2008</year>) <volume>453</volume>:<fpage>65</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1038/nature06880</pub-id><pub-id pub-id-type="pmid">18362915</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothhammer</surname><given-names>V</given-names></name><name><surname>Mascanfroni</surname><given-names>I</given-names></name><name><surname>Bunse</surname><given-names>L</given-names></name><name><surname>Takenaka</surname><given-names>M</given-names></name><name><surname>Kenison</surname><given-names>JE</given-names></name><name><surname>Mayo</surname><given-names>L</given-names></name></person-group>
<article-title>Type I interferons and micorbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor</article-title>. <source/>Nat Med (<year>2016</year>) <volume>22</volume>:<fpage>586</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1038/nm.4106</pub-id><pub-id pub-id-type="pmid">27158906</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoye</surname><given-names>D</given-names></name><name><surname>Schubert</surname><given-names>C</given-names></name><name><surname>Goil</surname><given-names>A</given-names></name><name><surname>Guttek</surname><given-names>K</given-names></name><name><surname>Reinhold</surname><given-names>A</given-names></name><name><surname>Brocke</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Zinc aspartate suppresses T cell activation <italic>in vitro</italic> and relapsing experimental autoimmune encephalomyelitis in SJL/J mice</article-title>. <source/>Biometals (<year>2012</year>) <volume>25</volume>:<fpage>529</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1007/s10534-012-9532-z</pub-id><pub-id pub-id-type="pmid">22350510</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schubert</surname><given-names>C</given-names></name><name><surname>Guttek</surname><given-names>K</given-names></name><name><surname>Grüngreiff</surname><given-names>K</given-names></name><name><surname>Thielitz</surname><given-names>A</given-names></name><name><surname>Bühling</surname><given-names>F</given-names></name><name><surname>Reinhold</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Oral zinc aspartate treats experimental autoimmune encephalomyelitis</article-title>. <source/>Biometals (<year>2014</year>) <volume>27</volume>:<fpage>375</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1007/s10534-014-9786-8</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitabayashi</surname><given-names>C</given-names></name><name><surname>Fukada</surname><given-names>T</given-names></name><name><surname>Kanamoto</surname><given-names>M</given-names></name><name><surname>Ohashi</surname><given-names>W</given-names></name><name><surname>Hojyo</surname><given-names>S</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Zinc suppreses Th17 development via inhibition of STAT3 activation</article-title>. <source/>Int Immunol (<year>2010</year>) <volume>22</volume>:<fpage>375</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1093/intimm/dxq017</pub-id><pub-id pub-id-type="pmid">20215335</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenkranz</surname><given-names>E</given-names></name><name><surname>Maywald</surname><given-names>M</given-names></name><name><surname>Hilgers</surname><given-names>RD</given-names></name><name><surname>Brieger</surname><given-names>A</given-names></name><name><surname>Clarner</surname><given-names>T</given-names></name><name><surname>Kipp</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Induction of regulatory T cells in Th1-/Th17-driven experimental autoimmune encephalomyelitis by zinc administration</article-title>. <source/>J Nutr Biochem (<year>2016</year>) <volume>29</volume>:<fpage>116</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1016/j.jnutbio.2015.11.010</pub-id><pub-id pub-id-type="pmid">26895672</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scelsi</surname><given-names>R</given-names></name><name><surname>Savoldi</surname><given-names>F</given-names></name><name><surname>Ceroni</surname><given-names>M</given-names></name><name><surname>Allegrini</surname><given-names>M</given-names></name><name><surname>Poggi</surname><given-names>P</given-names></name></person-group>
<article-title>Selenium and experimental allergic encephalomyelitis</article-title>. <source/>J Neurol Sci (<year>1983</year>) <volume>61</volume>:<fpage>369</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1016/0022-510X(83)90170-3</pub-id><pub-id pub-id-type="pmid">6655488</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanaday</surname><given-names>NL</given-names></name><name><surname>De Bem</surname><given-names>AF</given-names></name><name><surname>Roth</surname><given-names>GA</given-names></name></person-group>. <article-title>Effect of diphenyl diselenide on the development of experimental autoimmune encephalomyelitis</article-title>. <source/>Neurochem Int (<year>2011</year>) <volume>59</volume>(<issue>1155</issue>):<fpage>62</fpage>.<pub-id pub-id-type="doi">10.1016/j.neuint.2011.10.004</pub-id><pub-id pub-id-type="pmid">22032971</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Alpha-tocopherol ameliorates experimental autoimmune encephalomyelitis through the regulation of Th1 cells</article-title>. <source/>Iran J Basic Med Sci (<year>2016</year>) <volume>19</volume>:<fpage>561</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">27403263</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>B</given-names></name><name><surname>Heurtaux</surname><given-names>T</given-names></name><name><surname>Garcia</surname><given-names>C</given-names></name><name><surname>Moll</surname><given-names>NM</given-names></name><name><surname>Caillava</surname><given-names>C</given-names></name><name><surname>Grandbarbe</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Tocopherol derivative TFA-12 promotes myelin repair in experimental models of multiple sclerosis</article-title>. <source/>J Neurosci (<year>2013</year>) <volume>33</volume>:<fpage>11633</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0774-13.2013</pub-id><pub-id pub-id-type="pmid">23843531</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Racke</surname><given-names>MK</given-names></name><name><surname>Burnett</surname><given-names>D</given-names></name><name><surname>Pak</surname><given-names>SH</given-names></name><name><surname>Albert</surname><given-names>PS</given-names></name><name><surname>Cannella</surname><given-names>B</given-names></name><name><surname>Raine</surname><given-names>CS</given-names></name><etal></etal></person-group>
<article-title>Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course</article-title>. <source/>J Immunol (<year>1995</year>) <volume>154</volume>:<fpage>450</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">7527821</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>XX</given-names></name><name><surname>Lui</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>JF</given-names></name><name><surname>Wang</surname><given-names>GY</given-names></name><name><surname>Mu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>TS</given-names></name><etal></etal></person-group>
<article-title>All-trans-retinoic acid ameliorates experimental allergic encephalomyelitis by affecting dendritic cell and monocyte development</article-title>. <source/>Immunology (<year>2013</year>) <volume>138</volume>:<fpage>333</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1111/imm.12040</pub-id><pub-id pub-id-type="pmid">23181351</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Korn</surname><given-names>T</given-names></name><name><surname>Lui</surname><given-names>SM</given-names></name><name><surname>Oukka</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-β-driven Smad3 signalling and inhibiting IL-6 and IL-23 receptor expression</article-title>. <source/>Immunology (<year>2008</year>) <volume>181</volume>:<fpage>2277</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.4.2277</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atarashi</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>J</given-names></name><name><surname>Shima</surname><given-names>T</given-names></name><name><surname>Umesaki</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Onoue</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>ATP drives lamina propria Th17 cell differentiation</article-title>. <source/>Nature (<year>2008</year>) <volume>455</volume>:<fpage>808</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1038/nature07240</pub-id><pub-id pub-id-type="pmid">18716618</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huizinga</surname><given-names>R</given-names></name><name><surname>Kreft</surname><given-names>KL</given-names></name><name><surname>Onderwater</surname><given-names>S</given-names></name><name><surname>Boonstra</surname><given-names>JG</given-names></name><name><surname>Brands</surname><given-names>R</given-names></name><name><surname>Hintzen</surname><given-names>RQ</given-names></name><etal></etal></person-group>
<article-title>Endotoxin- and ATP-neutralizing activity of alkaline phosphatase as a strategy to limit neuroinflammation</article-title>. <source/>J Neuroinflammation (<year>2012</year>) <volume>9</volume>:<fpage>266</fpage>.<pub-id pub-id-type="doi">10.1186/1742-2094-9-266</pub-id><pub-id pub-id-type="pmid">23231745</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Hamilton</surname><given-names>SE</given-names></name><name><surname>Bi</surname><given-names>K</given-names></name><name><surname>Schenkel</surname><given-names>JM</given-names></name><name><surname>Odumade</surname><given-names>OA</given-names></name><name><surname>Casey</surname><given-names>KA</given-names></name><etal></etal></person-group>
<article-title>Normalizing the environment recapitulates adult human immune traits in laboratory mice</article-title>. <source/>Nature (<year>2016</year>) <volume>532</volume>:<fpage>512</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/nature17655</pub-id><pub-id pub-id-type="pmid">27096360</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa-Repáraz</surname><given-names>J</given-names></name><name><surname>Kasper</surname><given-names>LH</given-names></name></person-group>. <article-title>The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease</article-title>. <source/>Transl Res (<year>2017</year>) <volume>179</volume>:<fpage>126</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="doi">10.1016/j.trsl.2016.07.016</pub-id><pub-id pub-id-type="pmid">27519147</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furusawa</surname><given-names>Y</given-names></name><name><surname>Obata</surname><given-names>Y</given-names></name><name><surname>Hase</surname><given-names>K</given-names></name></person-group>. <article-title>Commensal microbiota regulates T cell fate decision in the gut</article-title>. <source/>Semin Immunopathol (<year>2015</year>) <volume>37</volume>:<fpage>17</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1007/s00281-014-0455-3</pub-id><pub-id pub-id-type="pmid">25315350</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maassen</surname><given-names>CBM</given-names></name><name><surname>van Holten-Neelen</surname><given-names>C</given-names></name><name><surname>Balk</surname><given-names>F</given-names></name><name><surname>Heijne den Bak-Glashouwer</surname><given-names>M-J</given-names></name><name><surname>Leer</surname><given-names>RJ</given-names></name><name><surname>Laman</surname><given-names>JD</given-names></name><etal></etal></person-group>
<article-title>Strain-dependent induction of cytokine profiles in the gut by orally administered <italic>Lactobacillus</italic> strains</article-title>. <source/>Vaccine (<year>2000</year>) <volume>18</volume>:<fpage>2613</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1016/S0264-410X(99)00378-3</pub-id><pub-id pub-id-type="pmid">10775795</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maassen</surname><given-names>CBM</given-names></name><name><surname>Boersma</surname><given-names>WG</given-names></name><name><surname>van Holten-Neelen</surname><given-names>C</given-names></name><name><surname>Claassen</surname><given-names>E</given-names></name><name><surname>Laman</surname><given-names>JD</given-names></name></person-group>.<article-title>Growth phase of orally administered <italic>Lactobacillus</italic> strains differentially affects IgG1/IgG2a ratio for soluble antigens: implications for vaccine development</article-title>. <source/>Vaccine (<year>2003</year>) <volume>21</volume>:<fpage>2751</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/S0264-410X(03)00220-2</pub-id><pub-id pub-id-type="pmid">12798614</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancera</surname><given-names>P</given-names></name><name><surname>Wappenhans</surname><given-names>B</given-names></name><name><surname>Cordobilla</surname><given-names>B</given-names></name><name><surname>Virgili</surname><given-names>N</given-names></name><name><surname>Pugliese</surname><given-names>M</given-names></name><name><surname>Rueda</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Natural docosahexaenoic acid in the triglyceride form attenuates <italic>in vitro</italic> microglial activation and ameliorates autoimmune encephalomyelitis in mice</article-title>. <source/>Nutrients (<year>2017</year>) <volume>9</volume>:<fpage>681</fpage><pub-id pub-id-type="doi">10.3390/nu9070681</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>E</given-names></name><name><surname>O’Doherty</surname><given-names>RM</given-names></name><name><surname>Murtphy</surname><given-names>EF</given-names></name><name><surname>Wall</surname><given-names>R</given-names></name><name><surname>O’Sullivan</surname><given-names>O</given-names></name><name><surname>Nilaweera</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Impact of dietary fatty acids on metabolic activity and host intestinal microbiota composition in C57BL/6J mice</article-title>. <source/>Br J Nutr (<year>2014</year>) <volume>111</volume>:<fpage>1905</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1017/S0007114514000117</pub-id><pub-id pub-id-type="pmid">24555449</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>1,25-dihydroxyvitamin D3 induced dendritic cells suppress experimental autoimune encephalomyelitis by increasing proportions of regulatory lymphocytes and reducing Th1, Th17 cells</article-title>. <source/>Immunology (<year>2017</year>).<pub-id pub-id-type="doi">10.1111/imm.12776</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correale</surname><given-names>J</given-names></name><name><surname>Ysrraelit</surname><given-names>MC</given-names></name><name><surname>Gaitn</surname><given-names>MI</given-names></name></person-group>. <article-title>Immunomodulatory effects of Vitamin D in multiple sclerosis</article-title>. <source/>Brain (<year>2009</year>) <volume>132</volume>:<fpage>1146</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1093/brain/awp033</pub-id><pub-id pub-id-type="pmid">19321461</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goudarzvand</surname><given-names>M</given-names></name><name><surname>Javan</surname><given-names>M</given-names></name><name><surname>Mirnajafi-Zadeh</surname><given-names>J</given-names></name><name><surname>Mozafari</surname><given-names>S</given-names></name><name><surname>Tiraihi</surname><given-names>T</given-names></name></person-group>. <article-title>Vitamins E and D3 attenuate demyelination and potentiate remyelination processes of hippocampal formation of rats following local injection of ethidium bromide</article-title>. <source/>Cell Mol Neurobiol (<year>2010</year>) <volume>30</volume>:<fpage>289</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="doi">10.1007/s10571-009-9451-x</pub-id><pub-id pub-id-type="pmid">19768531</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Mach</surname><given-names>N</given-names></name></person-group>. <article-title>Role of vitamin D in the hygiene hypothesis: the interplay between vitamin D, vitamin D receptors, gut microbiota, and immune response</article-title>. <source/>Front Immunol (<year>2016</year>) <volume>7</volume>:<fpage>627</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2016.00627</pub-id><pub-id pub-id-type="pmid">28066436</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayneris-Perxachs</surname><given-names>J</given-names></name><name><surname>Bolick</surname><given-names>DT</given-names></name><name><surname>Leng</surname><given-names>J</given-names></name><name><surname>Medlock</surname><given-names>GL</given-names></name><name><surname>Kolling</surname><given-names>GL</given-names></name><name><surname>Papin</surname><given-names>JA</given-names></name><etal></etal></person-group>
<article-title>Protein- and zinc-deficient diets modulate the murine microbiome and metabolic phenotype</article-title>. <source/>Am J Clin Nutr (<year>2016</year>) <volume>104</volume>:<fpage>1253</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.3945/ajcn.116.131797</pub-id><pub-id pub-id-type="pmid">27733402</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Drew</surname><given-names>PD</given-names></name></person-group>. <article-title>9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes</article-title>. <source/>J Neuroimmunol (<year>2006</year>) <volume>171</volume>:<fpage>135</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.jneuroim.2005.10.004</pub-id><pub-id pub-id-type="pmid">16303184</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quévrain</surname><given-names>E</given-names></name><name><surname>Maubert</surname><given-names>MA</given-names></name><name><surname>Michon</surname><given-names>C</given-names></name><name><surname>Chain</surname><given-names>F</given-names></name><name><surname>Marquant</surname><given-names>R</given-names></name><name><surname>Tailhades</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Identification of an anti-inflammatory protein from <italic>Faecalibacterium prausnitzii</italic>, a commensal bacterium deficient in Crohn’s disease</article-title>. <source/>Gut (<year>2016</year>) <volume>65</volume>:<fpage>415</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1136/gutjnl-2014-307649</pub-id><pub-id pub-id-type="pmid">26045134</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jangi</surname><given-names>S</given-names></name><name><surname>Gandhi</surname><given-names>R</given-names></name><name><surname>Cox</surname><given-names>LM</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>von Glehn</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Alterations of the human gut microbiome in multiple sclerosis</article-title>. <source/>Nat Commun (<year>2016</year>) <volume>7</volume>:<fpage>12015</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms12015</pub-id><pub-id pub-id-type="pmid">27352007</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lupp</surname><given-names>C</given-names></name><name><surname>Robertson</surname><given-names>ML</given-names></name><name><surname>Wickham</surname><given-names>ME</given-names></name><name><surname>Sekirov</surname><given-names>I</given-names></name><name><surname>Champion</surname><given-names>OL</given-names></name><name><surname>Gaynor</surname><given-names>EC</given-names></name><etal></etal></person-group>
<article-title>Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae</article-title>. <source/>Cell Host Microbe (<year>2007</year>) <volume>2</volume>:<fpage>119</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1016/j.chom.2007.06.010</pub-id><pub-id pub-id-type="pmid">18005726</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheperjans</surname><given-names>F</given-names></name><name><surname>Aho</surname><given-names>V</given-names></name><name><surname>Pereira</surname><given-names>PA</given-names></name><name><surname>Koskinen</surname><given-names>K</given-names></name><name><surname>Paulin</surname><given-names>L</given-names></name><name><surname>Pekkonen</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Gut microbiota are related to Parkinson’s disease and clinical phenotype</article-title>. <source/>Mov Disord (<year>2015</year>) <volume>30</volume>:<fpage>350</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/mds.26069</pub-id><pub-id pub-id-type="pmid">25476529</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremlett</surname><given-names>H</given-names></name><name><surname>Fadrosh</surname><given-names>DW</given-names></name><name><surname>Faruqi</surname><given-names>AA</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Hart</surname><given-names>J</given-names></name><name><surname>Roalstad</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Gut microbiota in early pediatric multiple sclerosis: a case – control study</article-title>. <source/>Eur J Neurol (<year>2016</year>) <volume>23</volume>:<fpage>1308</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1111/ene.13026</pub-id><pub-id pub-id-type="pmid">27176462</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Telesford</surname><given-names>KM</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Ochoa-Reparaz</surname><given-names>J</given-names></name><name><surname>Pant</surname><given-names>A</given-names></name><name><surname>Kircher</surname><given-names>C</given-names></name><name><surname>Christy</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>A commensal symbiotic factor derived from <italic>Bacteroides fragilis</italic> promotes human CD39 <sup>+</sup> Foxp3 <sup>+</sup> T cells and T <sub>reg</sub> function</article-title>. <source/>Gut Microbes (<year>2015</year>) <volume>6</volume>:<fpage>234</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1080/19490976.2015.1056973</pub-id><pub-id pub-id-type="pmid">26230152</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremlett</surname><given-names>H</given-names></name><name><surname>Fadrosh</surname><given-names>DW</given-names></name><name><surname>Faruqi</surname><given-names>AA</given-names></name><name><surname>Hart</surname><given-names>J</given-names></name><name><surname>Roalstad</surname><given-names>S</given-names></name><name><surname>Graves</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Gut microbiota composition and relapse risk in pediatric MS: a pilot study</article-title>. <source/>J Neurol Sci (<year>2016</year>) <volume>363</volume>:<fpage>153</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.jns.2016.02.042</pub-id><pub-id pub-id-type="pmid">27000242</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremlett</surname><given-names>H</given-names></name><name><surname>Fadrosh</surname><given-names>DW</given-names></name><name><surname>Faruqui</surname><given-names>AA</given-names></name><name><surname>Hart</surname><given-names>J</given-names></name><name><surname>Roalstad</surname><given-names>S</given-names></name><name><surname>Graves</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Associations between immune markers and gut microbiota in pediatric multiple sclerosis and controls</article-title>. <source/>Neurology (<year>2016</year>) <volume>16</volume>:<fpage>182</fpage><pub-id pub-id-type="doi">10.1186/s12883-016-0703-3</pub-id><pub-id pub-id-type="pmid">27652609</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Suda</surname><given-names>W</given-names></name><name><surname>Oshima</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Matsuoka</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters</article-title>. <source/>PLoS One (<year>2015</year>) <volume>10</volume>:<fpage>9</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0137429</pub-id><pub-id pub-id-type="pmid">26367776</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chia</surname><given-names>N</given-names></name><name><surname>Kalari</surname><given-names>KR</given-names></name><name><surname>Yao</surname><given-names>JZ</given-names></name><name><surname>Novotna</surname><given-names>M</given-names></name><name><surname>Soldan</surname><given-names>MMP</given-names></name><etal></etal></person-group>
<article-title>Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls</article-title>. <source/>Nat Sci Rep (<year>2016</year>) <volume>6</volume>:<fpage>28484</fpage>.<pub-id pub-id-type="doi">10.1038/srep28484</pub-id><pub-id pub-id-type="pmid">27346372</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jangi</surname><given-names>S</given-names></name><name><surname>Gandhi</surname><given-names>R</given-names></name><name><surname>Glanz</surname><given-names>B</given-names></name><name><surname>Cook</surname><given-names>S</given-names></name><name><surname>Nejad</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Increased archaea species and changes with therapy in gut microbiome of multiple sclerosis subjects</article-title>. <source/>Neurology (<year>2014</year>) <volume>82</volume>:<fpage>Suppl.24.001</fpage>.</mixed-citation>
</ref>
<ref id="B122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>K</given-names></name><name><surname>Rejmus</surname><given-names>R</given-names></name><name><surname>Dörffel</surname><given-names>Y</given-names></name></person-group>
<article-title>Commensal gut flora in MS: spatial organization and composition</article-title>. <source/>Mult Scler (<year>2015</year>) <volume>21</volume>(<issue>Suppl 11</issue>):<fpage>458</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="B123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantarel</surname><given-names>BL</given-names></name><name><surname>Waubrant</surname><given-names>E</given-names></name><name><surname>Chehoud</surname><given-names>C</given-names></name><name><surname>Kuczynski</surname><given-names>J</given-names></name><name><surname>DeSantis</surname><given-names>TZ</given-names></name><name><surname>Warrington</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Gut microbiota in MS: possible influence of immunomodulators</article-title>. <source/>J Investig Med (<year>2015</year>) <volume>63</volume>:<fpage>729</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1097/JIM.0000000000000192</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sand</surname><given-names>IK</given-names></name><name><surname>Baranzini</surname><given-names>S</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name><name><surname>Farber</surname><given-names>RS</given-names></name><name><surname>Bencosme</surname><given-names>Y</given-names></name><name><surname>Kanner</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>The MS microbiome consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS</article-title>. <source/>Neurology (<year>2015</year>) <volume>84</volume>(<issue>14 Suppl</issue>):<fpage>2.205</fpage>.</mixed-citation>
</ref>
<ref id="B125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tankou</surname><given-names>S</given-names></name><name><surname>Bry</surname><given-names>L</given-names></name><name><surname>Gerber</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>N</given-names></name><name><surname>Glanz</surname><given-names>B</given-names></name><name><surname>Cook</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Effect of vitamin D level in the gut microbiome of MS patients</article-title>. <source/>Neurology (<year>2015</year>) <volume>84</volume>(<issue>14 Suppl</issue>):<fpage>2.206</fpage>.</mixed-citation>
</ref>
<ref id="B126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>D</given-names></name><name><surname>Cartlidge</surname><given-names>NE</given-names></name><name><surname>French</surname><given-names>JM</given-names></name><name><surname>Jackson</surname><given-names>MJ</given-names></name><name><surname>Nightingale</surname><given-names>S</given-names></name><name><surname>Shaw</surname><given-names>DA</given-names></name><etal></etal></person-group>
<article-title>A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis</article-title>. <source/>J Neurol Neurosurg Psychiatry (<year>1989</year>) <volume>52</volume>:<fpage>18</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1136/jnnp.52.1.18</pub-id><pub-id pub-id-type="pmid">2540285</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name><name><surname>Baier</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Feichter</surname><given-names>J</given-names></name><name><surname>Lee-Kwen</surname><given-names>P</given-names></name><name><surname>Gallagher</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients</article-title>. <source/>Prostaglandins Leukot Essent Fatty Acids (<year>2005</year>) <volume>73</volume>:<fpage>397</fpage>–<lpage>404</lpage>.<pub-id pub-id-type="doi">10.1016/j.plefa.2005.05.024</pub-id><pub-id pub-id-type="pmid">16099630</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torkildsen</surname><given-names>Ø</given-names></name><name><surname>Wergeland</surname><given-names>S</given-names></name><name><surname>Bakke</surname><given-names>S</given-names></name><name><surname>Beiske</surname><given-names>AG</given-names></name><name><surname>Bjerve</surname><given-names>KS</given-names></name><name><surname>Hovdal</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>ω-3 fatty acid treatment in multiple sclerosis (OFAMS study)</article-title>. <source/>Arch Neurol (<year>2012</year>) <volume>69</volume>:<fpage>1044</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1001/archneurol.2012.283</pub-id><pub-id pub-id-type="pmid">22507886</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>D</given-names></name><name><surname>Fawcett</surname><given-names>PR</given-names></name><name><surname>Shaw</surname><given-names>DA</given-names></name><name><surname>Weightman</surname><given-names>D</given-names></name></person-group>
<article-title>Trials of polyunsaturated fatty acids in non-relapsing multiple sclerosis</article-title>. <source/>Br Med J (<year>1977</year>) <volume>2</volume>:<fpage>932</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1136/bmj.2.6096.1217-a</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>D</given-names></name><name><surname>Fawcett</surname><given-names>PR</given-names></name><name><surname>Shaw</surname><given-names>DA</given-names></name><name><surname>Weightman</surname><given-names>D</given-names></name></person-group>. <article-title>Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis</article-title>. <source/>Br Med J (<year>1978</year>) <volume>2</volume>:<fpage>1390</fpage>–<lpage>1</lpage>.<pub-id pub-id-type="doi">10.1136/bmj.2.6149.1390</pub-id><pub-id pub-id-type="pmid">363236</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbige</surname><given-names>LS</given-names></name><name><surname>Sharief</surname><given-names>MK</given-names></name></person-group>. <article-title>Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis</article-title>. <source/>Br J Nutr (<year>2007</year>) <volume>98</volume>:<fpage>46</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1017/S0007114507833010</pub-id><pub-id pub-id-type="pmid">17922959</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafarirad</surname><given-names>S</given-names></name><name><surname>Siassi</surname><given-names>F</given-names></name><name><surname>Harirchian</surname><given-names>M-H</given-names></name><name><surname>Sahraian</surname><given-names>M-A</given-names></name><name><surname>Eshraghian</surname><given-names>M-R</given-names></name><name><surname>Shokri</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis</article-title>. <source/>J Neurosci Rural Pract (<year>2012</year>) <volume>3</volume>:<fpage>294</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.4103/0976-3147.102609</pub-id><pub-id pub-id-type="pmid">23188981</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wingerschuk</surname><given-names>DM</given-names></name></person-group>
<article-title>A pilot study of oral calcitrol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis</article-title>. <source/>J Neurol Neurosurg Psychiatry (<year>2005</year>) <volume>76</volume>:<fpage>1294</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1136/jnnp.2004.056499</pub-id><pub-id pub-id-type="pmid">16107372</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahon</surname><given-names>B</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Cruz</surname><given-names>J</given-names></name><name><surname>Cosman</surname><given-names>F</given-names></name><name><surname>Cantorna</surname><given-names>M</given-names></name></person-group>. <article-title>Cytokine profile in patients with multiple sclerosis following vitamin D supplementation</article-title>. <source/>J Neuroimmunol (<year>2003</year>) <volume>134</volume>:<fpage>128</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1016/S0165-5728(02)00396-X</pub-id><pub-id pub-id-type="pmid">12507780</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>P</given-names></name><name><surname>Fleming</surname><given-names>MC</given-names></name><name><surname>Picard</surname><given-names>EH</given-names></name></person-group>
<article-title>Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D</article-title>. <source/>Med Hypotheses (<year>1986</year>) <volume>21</volume>:<fpage>193</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="doi">10.1016/0306-9877(86)90010-1</pub-id><pub-id pub-id-type="pmid">3537648</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haghikia</surname><given-names>A</given-names></name><name><surname>Duscha</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>J</given-names></name><name><surname>Jörg</surname><given-names>S</given-names></name><name><surname>Wilck</surname><given-names>N</given-names></name><name><surname>Müller</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Role of fatty acids in multipe sclerosis: therapeutic potential of propionic acid</article-title>. <source/>Neurology (<year>2016</year>) <volume>86</volume>(<issue>16</issue>):<fpage>Suppl.1.374</fpage>.</mixed-citation>
</ref>
<ref id="B137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farez</surname><given-names>MF</given-names></name><name><surname>Fiol</surname><given-names>MP</given-names></name><name><surname>Gaitán</surname><given-names>M</given-names></name><name><surname>Quintana</surname><given-names>FJ</given-names></name><name><surname>Correale</surname><given-names>J</given-names></name></person-group>. <article-title>Sodium intake is associated with increased disease activity in multiple sclerosis</article-title>. <source/>J Neurol Neurosurg Psychiatry (<year>2015</year>) <volume>86</volume>:<fpage>26</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1136/jnnp-2014-307928</pub-id><pub-id pub-id-type="pmid">25168393</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadgkiss</surname><given-names>EJ</given-names></name><name><surname>Jelinek</surname><given-names>GA</given-names></name><name><surname>Weiland</surname><given-names>TJ</given-names></name><name><surname>Pereira</surname><given-names>NG</given-names></name><name><surname>Marck</surname><given-names>CH</given-names></name><name><surname>van der Meer</surname><given-names>DM</given-names></name></person-group>. <article-title>The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis</article-title>. <source/>Nutr Neurosci (<year>2015</year>) <volume>18</volume>:<fpage>125</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1179/1476830514Y.0000000117</pub-id><pub-id pub-id-type="pmid">24628020</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezapour-Firouzi</surname><given-names>S</given-names></name><name><surname>Arefhosseini</surname><given-names>SR</given-names></name><name><surname>Mehdi</surname><given-names>F</given-names></name><name><surname>Mehrangiz</surname><given-names>EM</given-names></name><name><surname>Baradaran</surname><given-names>B</given-names></name><name><surname>Sadeghihokmabad</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Immunomodulatory and therapeutic effects of hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients</article-title>. <source/>Complement Ther Med (<year>2013</year>) <volume>7</volume>:<fpage>2891</fpage>–<lpage>901</lpage>.<pub-id pub-id-type="doi">10.1016/j.ctim.2013.06.006</pub-id><pub-id pub-id-type="pmid">24050582</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordvik</surname><given-names>I</given-names></name><name><surname>Myhr</surname><given-names>KM</given-names></name><name><surname>Nyland</surname><given-names>H</given-names></name><name><surname>Bjerve</surname><given-names>KS</given-names></name></person-group>. <article-title>Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients</article-title>. <source/>Acta Neurol Scand (<year>2000</year>) <volume>102</volume>:<fpage>143</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1034/j.1600-0404.2000.102003143.x</pub-id><pub-id pub-id-type="pmid">10987373</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>K</given-names></name><name><surname>Barthelmes</surname><given-names>J</given-names></name><name><surname>Stolz</surname><given-names>L</given-names></name><name><surname>Beyer</surname><given-names>S</given-names></name><name><surname>Diehl</surname><given-names>O</given-names></name><name><surname>Tegeder</surname><given-names>I</given-names></name></person-group>
<article-title>“Disease modifying nutricials” for multiple sclerosis</article-title>. <source/>Pharmacol Ther (<year>2015</year>) <volume>148</volume>:<fpage>85</fpage>–<lpage>113</lpage>.<pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.11.015</pub-id><pub-id pub-id-type="pmid">25435020</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>JJ</given-names></name><name><surname>Thomas-McKay</surname><given-names>E</given-names></name><name><surname>Thoree</surname><given-names>V</given-names></name><name><surname>Robertson</surname><given-names>J</given-names></name><name><surname>Hewitt</surname><given-names>RE</given-names></name><name><surname>Skepper</surname><given-names>JN</given-names></name><etal></etal></person-group>
<article-title>An endogenous nanomineral chaperones luminal antigen and peptidoglycan to intestinal immune cells</article-title>. <source/>Nat Nanotechnol (<year>2015</year>) <volume>10</volume>:<fpage>361</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/nnano.2015.19</pub-id><pub-id pub-id-type="pmid">25751305</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanneganti</surname><given-names>TD</given-names></name><name><surname>Lamkanfi</surname><given-names>M</given-names></name><name><surname>Núñez</surname><given-names>G</given-names></name></person-group>. <article-title>Intracellular NOD-like receptors in host defense and disease</article-title>. <source/>Immunity (<year>2007</year>) <volume>27</volume>:<fpage>549</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2007.10.002</pub-id><pub-id pub-id-type="pmid">17967410</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hergot</surname><given-names>CB</given-names></name><name><surname>Roche</surname><given-names>AM</given-names></name><name><surname>Tamashiro</surname><given-names>E</given-names></name><name><surname>Clarke</surname><given-names>TB</given-names></name><name><surname>Bailey</surname><given-names>AG</given-names></name><name><surname>Laughlin</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Peptidoglycan from the gut microbiota governs the lifespan of circulating phagocytes at homeostasis</article-title>. <source/>Blood (<year>2016</year>) <volume>127</volume>:<fpage>2460</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2015-10-675173</pub-id><pub-id pub-id-type="pmid">26989200</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>L</given-names></name><name><surname>Jan de Heer</surname><given-names>H</given-names></name><name><surname>Boven</surname><given-names>LA</given-names></name><name><surname>van Riel</surname><given-names>D</given-names></name><name><surname>van Meurs</surname><given-names>M</given-names></name><name><surname>Melief</surname><given-names>MJ</given-names></name><etal></etal></person-group>
<article-title>Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease</article-title>. <source/>J Immunol (<year>2005</year>) <volume>174</volume>:<fpage>808</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.174.2.808</pub-id><pub-id pub-id-type="pmid">15634902</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>L</given-names></name><name><surname>Melief</surname><given-names>MJ</given-names></name><name><surname>van Riel</surname><given-names>D</given-names></name><name><surname>van Meurs</surname><given-names>M</given-names></name><name><surname>Sick</surname><given-names>EA</given-names></name><name><surname>Inamura</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates</article-title>. <source/>Am J Pathol (<year>2006</year>) <volume>169</volume>:<fpage>1671</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.2353/ajpath.2006.060143</pub-id><pub-id pub-id-type="pmid">17071591</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrijver</surname><given-names>IA</given-names></name><name><surname>van Meurs</surname><given-names>M</given-names></name><name><surname>Melief</surname><given-names>MJ</given-names></name><name><surname>Wim Ang</surname><given-names>C</given-names></name><name><surname>Buljevac</surname><given-names>D</given-names></name><name><surname>Ravid</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis</article-title>. <source/>Brain (<year>2001</year>) <volume>124</volume>:<fpage>1544</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1093/brain/124.8.1544</pub-id><pub-id pub-id-type="pmid">11459746</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luthold</surname><given-names>RV</given-names></name><name><surname>Fernandes</surname><given-names>GR</given-names></name><name><surname>Franco-de-Moraes</surname><given-names>AC</given-names></name><name><surname>Folchetti</surname><given-names>LGD</given-names></name><name><surname>Ferreira</surname><given-names>SRG</given-names></name></person-group>. <article-title>Gut microbiota interactions with the immunomodulatory role of vitamin D in normal individuals</article-title>. <source/>Metabolism (<year>2017</year>) <volume>69</volume>:<fpage>76</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1016/j.metabol.2017.01.007</pub-id><pub-id pub-id-type="pmid">28285654</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name></person-group>
<article-title>Diet: changing the recipe</article-title>. <source/>Nature (<year>2016</year>) <volume>540</volume>:<fpage>S13</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/540S13a</pub-id><pub-id pub-id-type="pmid">27902680</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krumbeck</surname><given-names>JA</given-names></name><name><surname>Maldonado-Gomez</surname><given-names>MX</given-names></name><name><surname>Ramer-Tait</surname><given-names>AE</given-names></name><name><surname>Hutkins</surname><given-names>RW</given-names></name></person-group>
<article-title>Prebiotics and synbiotics: dietary strategies for improvign gut health</article-title>. <source/>Curr Opin Gastroenterol (<year>2016</year>) <volume>32</volume>:<fpage>110</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1097/MOG.0000000000000249</pub-id><pub-id pub-id-type="pmid">26825589</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preidis</surname><given-names>GA</given-names></name><name><surname>Versalovic</surname><given-names>J</given-names></name></person-group>. <article-title>Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era</article-title>. <source/>Gastroenterology (<year>2009</year>) <volume>136</volume>:<fpage>2015</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2009.01.072</pub-id><pub-id pub-id-type="pmid">19462507</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>BK</given-names></name><name><surname>Abedon</surname><given-names>ST</given-names></name><name><surname>Loc-Carrillo</surname><given-names>C</given-names></name></person-group>. <article-title>Phage cocktails and the future of phage therapy</article-title>. <source/>Future Microbiol (<year>2013</year>) <volume>8</volume>:<fpage>769</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="doi">10.2217/fmb.13.47</pub-id><pub-id pub-id-type="pmid">23701332</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>HH</given-names></name><name><surname>Cho</surname><given-names>Y-S</given-names></name></person-group>. <article-title>Fecal microbiota transplantation: current applications, effectiveness, and future perspectives</article-title>. <source/>Clin Endosc (<year>2016</year>) <volume>49</volume>:<fpage>257</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="doi">10.5946/ce.2015.117</pub-id><pub-id pub-id-type="pmid">26956193</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>R</given-names></name></person-group>
<article-title>Probiotics in human medicine</article-title>. <source/>Gut (<year>1991</year>) <volume>32</volume>:<fpage>439</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1136/gut.32.4.439</pub-id><pub-id pub-id-type="pmid">1902810</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Roberfroid</surname><given-names>MB</given-names></name></person-group>. <article-title>Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics</article-title>. <source/>J Nutr (<year>1995</year>) <volume>125</volume>:<fpage>1401</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">7782892</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>